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Persons with heart failure are at risk for frequent hospitalization, diminished 
quality of life, reduced life expectancy, and are susceptible to environmental and 
contextual effects related to unconventional natural gas development (UNGD) activity. 
We assessed whether four UNGD activity metrics by phase were separately associated 
with hospitalization for heart failure or B-natriuretic peptide (BNP) levels in blood among 
subjects with heart failure, and we evaluated effect modification by heart failure with 
preserved (HFpEF) or reduced (HFrEF) ejection fraction on these associations. We 
obtained electronic health records for subjects with heart failure who were seen at a 
Geisinger facility in Pennsylvania between 2008-2015. We utilized multilevel logistic 
regression and generalized estimating equations (GEE) to evaluate associations of 30-
day metrics of UNGD activity with odds of hospitalization for heart failure and odds of 
BNP concentration  400 pg/mL. Comparing subjects in the fourth to the first quartile of 
UNGD activity, adjusted associations (OR [95% confidence interval]) with hospitalization 
were 1.70 (1.35–2.13), 1.80 (1.35–2.40), and 1.62 (1.07–2.45) for the pad preparation, 
well stimulation, and production metrics, respectively; each metric evidenced exposure-
effect relations. Only the production metric was associated (OR [95% confidence 
interval]) with BNP and evidenced exposure-effect relations of increasing magnitude of 
association across quartiles, of 1.36 (1.08–1.71), 1.42 (1.05–1.93), and 1.52 (1.07–2.17) 
for the second, third, and fourth (vs. first) quartiles. In the effect modification analysis of 
hospitalization, we did not find evidence in favor of our hypothesized moderation, but did 
observe stronger associations of UNGD activity metrics with heart failure hospitalization 
among those who were phenotyped (subjects with HFpEF and HFrEF) vs. those who 
could not be phenotyped (p for global significance = 0.03 for pad; 0.009 for spud; 0.4 for 
stimulation; and 0.08 for production metrics). In the BNP analysis, there was a strong 
 iii 
independent effect of HFrEF phenotype with greater BNP concentrations and some 
evidence of effect modification of UNGD and BNP associations by HFrEF phenotype. 
However, these associations were difficult to interpret given overlapping confidence 
intervals. These results suggest that UNGD activity could exacerbate existing conditions 
in exposed heart failure subjects. 
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Chapter 1: Introduction  
1.0  RATIONALE 
This dissertation work was borne from increasingly convincing environmental and 
epidemiologic evidence indicative of the negative environmental, societal, and health 
impacts of unconventional natural gas development (UNGD). UNGD has been 
colloquially referred to as “fracking,” but this term was designed by the industry’s 
opponents to have negative connotations, only refers to a brief phase of the entirety of 
UNGD, and will not be used herein. UNGD involves obtaining natural gas from shale 
resources below the earth’s surface and consequently has resulted in areas of 
concentrated development and activity, with adverse environmental (i.e., air pollution, 
groundwater contamination, noise) [1-5] and contextual (community changes, crime, and 
traffic) impacts [6-8]. UNGD has been associated with a number of adverse health 
outcomes (low birth weight, small for gestational age [9, 10]; preterm birth [11-13]; 
congenital defects [14]; three types of asthma exacerbations [15, 16]; migraine, fatigue, 
nasal and sinus symptoms [17]; and depression symptoms [18]) in environmental 
epidemiologic studies, however all of these studies have evaluated outcomes that 
concern early and mid-life populations; none have evaluated biological markers 
informing candidate exposure pathways, and none have evaluated any biologically 
important effect modification. 
To date, no environmental epidemiology studies have evaluated UNGD activity in 
relation to heart failure, a prevalent, severe, and costly disease that typically affects 
older individuals [19-21]. Individuals with heart failure are prone to frequent 
hospitalization, which can be exacerbated by air pollution [22-26] and other community 
impacts of UNGD [27]. This research therefore evaluated associations between UNGD 
activity and hospitalization for heart failure. Further, this dissertation evaluated 
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associations between UNGD activity and both inpatient and outpatient laboratory 
measures of B-type natriuretic peptide (BNP), a clinical biomarker of heart failure 
diagnosis and prognosis [28-32]. We also evaluated effect modification of these 
associations by heart failure phenotypes (i.e., heart failure with preserved [HFpEF] or 
reduced [HFrEF] ejection fraction), two distinct presentations of heart failure with 
differing pathophysiology, which allowed us to understand biologic mechanisms 
underlying associations between UNGD activity and hospitalization and between UNGD 
activity and BNP levels. Understanding the associations between UNGD activity and 
heart failure would fill a gap in the epidemiologic literature regarding potential health 
impacts of UNGD in older populations, whom we would expect to be most susceptible to 
the environmental and community impacts associated with UNGD. Further, this work 
advanced the environmental epidemiology of heart failure, particularly with respect to 
heart failure phenotypes and understanding differential environmental associations with 
BNP. 
1.1 UNGD: AN OVERVIEW 
Unconventional natural gas development (UNGD) has increased rapidly in the 
United States in the past ten years and is expected to continue to grow [33, 34]. In 
contrast to conventional natural gas, which is procured from geological resources that do 
not require advanced technologies to obtain, unconventional natural gas requires the 
tapping of shale resources that can sit at least a mile below the ground’s surface [35] 
and involves hydraulic fracturing and/or horizontal drilling. UNGD wells are typically 
between 5000-10,000 feet deep and can extend up to two horizontal miles from the drill 
site [36]. The UNGD process involves, in order, well pad preparation (e.g., clearing of 
land), well drilling (both vertical and horizontal), well stimulation (i.e., hydraulic 
fracturing), gas extraction, storage and transport. A distinguishing feature of UNGD is 
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well stimulation, which involves the injection of fracking fluid (a mixture of water, 
chemical lubricants, and proppants [e.g., sand or ceramic materials to keep fractures 
open]) into the well to force shale rock to fracture, releasing natural gas into the well for 
extraction. Consequently, UNGD wells require the use and transport of substantive 
equipment, and compared to conventional natural gas development, UNGD produces 
vastly more natural gas and waste byproducts (e.g., wastewater, drilling lubricants, sand, 
and radionuclides) [35, 37].  
The process of UNGD has been associated with adverse environmental impacts 
that are relevant to public health. First, UNGD has been associated with increases in air 
pollutants (particulate matter less than 2.5 microns in diameter [PM2.5], volatile organic 
compounds [VOCs], oxides of nitrogen [NOx], oxides of sulfur [SOx], and ozone [O3]) 
through a variety of sources and phases within the UNGD process [38-41]. Some of 
these air pollutants are regional (e.g., PM2.5, NOx, O3) [39], whereas VOCs are more local 
and are characterized by episodic release into the environment from the UNGD process 
[41]. Phases of UNGD activity that have been specifically linked to these emissions 
include drilling, hydraulic fracturing, production, compressor stations, and transport [39, 
40]. In addition to the direct release of air pollutants into the environment, air pollutants 
can vaporize from injected fracking fluid, subsurface water, and storage pits and tanks 
used to store “flow back” wastewater, which is water that is recovered from wells after 
being used to hydraulically fracture shale [37, 42-44]. Because of the chemicals used in 
the hydraulic fracturing process, and because of natural gas (methane) itself is a water 
contaminant, groundwater and drinking water contamination near UNGD activity has 
been documented [2, 5, 45], although the extent of groundwater and drinking water 
contamination is highly variable due to geologic factors [46, 47]. Additionally, due to the 
necessity of transporting equipment, personnel, and natural gas, UNGD operations have 
been associated with increased truck traffic and traffic accidents [6, 48]. Traffic, and 
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truck traffic in particular, has been associated with increased noise and higher air 
pollution levels [22-24, 49], suggesting that there could be secondary environmental 
impacts from the volume of traffic associated with UNGD. Figure 1.1 provides a visual 
representation of how negative environmental impacts can occur as a result of 
unconventional natural gas development at various stages.  
FIGURE  1.1. DIAGRAM OF UNCONVENTIONAL NATURAL GAS PROCESS [43] 
Adding to the intensity of its environmental impacts, horizontal drilling allows for multiple 
wells on one well pad, meaning that a lot of natural gas is extracted from a very small 
area, and thus activities are very concentrated [22, 27]. This does not, however, negate 
the fact that UNGD results in the loss of natural vegetation and undeveloped land; a 
2010 study by the Nature Conservancy estimated that UNGD requires the development 
of, on average, 8.8 acres of forest land for well pad development and the building of 
associated roads and infrastructure [34], which has relevance to heart failure because 
greenness has been associated with improved cardiovascular outcomes [50-52]. In 
addition to the loss of natural habitat, the influx of necessary personnel, machinery, and 
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equipment for UNGD results in secondary and contextual impacts, and several studies 
have documented increases in community stressors, such as crime and traffic, due to 
UNGD [9, 22, 53, 54]. Additionally, UNGD can have negative impacts on housing and 
property values in areas of heavy development [7, 55]. Compared to conventional 
natural gas development, UNGD may pose additional stress risks stemming from these 
secondary impacts and community changes [27, 54]. 
 
FIGURE 1.2. SHALE GAS PLAYS IN THE UNITED STATES [56] 
1.1.2 UNGD IN PENNSYLVANIA 
 Shale gas deposits are located throughout the US (Figure 1.2), and the UNGD 
industry has been established in at least 16 states [57, 58]. In particular, shale gas 
resources in Colorado, Texas and Pennsylvania have seen intensive development, 
eliciting mixed responses from communities and environmental advocates [59, 60]. Of 
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these states, Pennsylvania has experienced some of the most rapid development where 
over 9000 wells have been drilled in the Marcellus shale since 2004, but mainly since 
2009, according to regulatory data (Figure 1.3) [61], making Pennsylvania the second-
largest natural gas producing state in the US [43].  
1.1.3 UNGD AND HEALTH: EPIDEMIOLOGICAL EVIDENCE AND EXPOSURE PATHWAYS 
Epidemiologic studies to date have attempted to characterize and quantify UNGD 
activity through the use of UNGD activity metrics and [9, 12, 15, 62]. Growing 
epidemiologic evidence supports associations between UNGD activity metrics and 
population health impacts (e.g., pregnancy outcomes [low birth weight, small for 
gestational age, preterm birth, congenital defects], asthma exacerbations, symptoms of 
chronic rhinosinusitis, migraine headaches, fatigue, self-reported stress, and depression 
symptoms [9, 13, 17, 18, 57, 63]). An advantage of the use of UNGD activity metrics in 
epidemiologic studies is that they likely reflect multiple exposure pathways, including the 
FIGURE 1.3.  TIME SERIES OF NEWLY SPUDDED (DRILLED) NATURAL GAS WELLS IN PENNSYLVANIA 
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contextual effects of UNGD activity. UNGD is suspected to exacerbate stress through its 
secondary impacts (i.e., land use changes, increases in traffic, and negative impacts on 
property values [27, 55], so GIS-based UNGD activity metrics will likely reflect these 
secondary impacts as well. A disadvantage to using UNGD activity metrics in 
epidemiologic studies, however, is that it is not known whether the associations between 
UNGD activity metrics and health outcomes observed in epidemiologic studies are due 
to specific chemical (e.g., air pollution) or physical (i.e., noise, light, vibration) agents, or 
to stress-related exposure pathways [1, 64], each of which should be captured by the 
GIS-based UNGD activity metrics employed to date. Despite these limitations, a growing 
body of epidemiologic evidence has found associations between UNGD activity and 
biologically plausible adverse health outcomes. No prior epidemiological studies have 
isolated specific exposure pathways underlying observed associations between UNGD 
activity metrics and any health outcomes [9, 11, 13, 15, 65]. While we did not address 
this limitation of previous studies through improved exposure assessment, we utilized 
UNGD activity metrics to evaluate associations between UNGD and heart failure 
outcomes. Importantly, we had retrospective health data, so retrospective assessment of 
UNGD activity was necessary, and therefore UNGD activity metrics were helpful. 
To date, no epidemiologic studies have evaluated UNGD activity in relation to 
heart failure outcomes, a common and severe end-stage cardiovascular disease. 
However, rationale for epidemiologic studies of UNGD and heart failure are supported by 
other epidemiologic studies of UNGD and health [66]. A 2018 study in Colorado, for 
example, has linked oil and gas activity to slightly higher levels of plasma concentrations 
of interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-), two inflammatory 
markers [66]. Although the sample size of this study included only 97 individuals living 
near oil and gas activity (i.e., not only UNGD activity), both of these inflammatory 
markers have been specifically implicated in endothelial dysfunction and the progression 
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of heart disease [67-70] in older adults [71, 72], which lends support to the biologic 
rationale for studying heart failure in relation to UNGD.  
1.2 EPIDEMIOLOGY OF HEART FAILURE 
1.2.1 OVERVIEW 
Heart failure refers to a condition in which the heart is unable to pump blood 
effectively, causing a cascade of symptoms that impact patient quality of life, morbidity, 
and mortality. The Centers for Disease Control and Prevention (CDC) estimate that 5.7 
million Americans have heart failure [73]. Prevalence of heart failure is projected to 
increase by 46% from 2012 to 2030; at this rate, there will be more than 8 million 
Americans with heart failure by the year 2030 [74, 75]. Risk factors for heart failure 
include classic cardiovascular disease risk factors such as coronary artery disease, high 
blood pressure, diabetes, tobacco smoking, lack of physical activity, poor diet, and 
obesity [73]. Although not all heart failure cases result in immediate death, it is estimated 
that in 2009, 1 in 9 deaths in the United States were in some way due to heart failure 
(i.e., heart failure was mentioned on the death certificate); the average duration of 
survival after diagnosis is only five years, and 10-year survival rates are estimated to be 
as low as 10% [76, 77].  
Symptoms of heart failure include shortness of breath, fatigue, and swelling of 
the legs due to fluid buildup (edema) [75].  Because heart failure can make physical 
activity difficult and results in a number of physical symptoms, living with heart failure 
can have negative impacts on quality of life, and mental health comorbidities such as 
depression often accompany the condition [78-80]. Furthermore, the disease is costly; 
CDC estimates that heart failure results in over $30 billion in direct and indirect health 
care costs, including missed work days, medication costs, and health care services, 
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annually [21, 73]. By 2030, costs of heart failure treatment are projected to increase to 
$53 billion (direct) and $70 billion (total) [74]. 
1.2.2 HEART FAILURE PHYSIOLOGY, PHENOTYPES, AND THE HEART FAILURE 
SPECTRUM 
Traditionally, heart failure includes two phenotypes: heart failure with preserved 
ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) [81]. 
The ejection fraction is a measure of the proportion of blood that the left ventricle is able 
to effectively pump out of the heart relative to the quantity that is pumped into the left 
ventricle from the left atrium.  In HFrEF or systolic heart failure, the heart muscles cannot 
contract to efficiently pump blood, and thus the total volume of blood that is pumped out 
of the heart is substantially reduced [82]. In HFpEF or diastolic heart failure, the heart 
muscle stiffens or does not adequately fill with blood, but the relative volume of blood 
pumped out of the heart remains preserved [82]. Presentation of symptoms is similar for 
HFpEF and HFrEF (i.e., shortness of breath, fatigue, fluid retention), and each accounts 
for roughly 50% of heart failure cases [83]. Epidemiological literature has found common 
risk factors among phenotypes for both developing heart failure and for heart failure 
hospitalization, including age, race/ethnicity, sex, obesity, tobacco smoking, physical 
inactivity, diabetes, stress, hypertension, and previous myocardial infarction and 
coronary artery disease diagnoses [73, 77, 81, 84].  
However, there is evidence that some risk factors differ between HFpEF and 
HFrEF, which has implications for epidemiologic study [81, 82, 85]. Studies of the 
precipitating factors in HF hospitalization, for example, have found that patients with 
HFpEF were more likely to be female, obese, have poor blood pressure control, lower 
hemoglobin levels, higher exposures to NO2, have had a previous episode of atrial 
fibrillation, and more commonly had respiratory infections than patients who were 
admitted for HFrEF [86-88]. There is also evidence that the prevalence of HFpEF is 
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increasing relative to HFrEF, possibly due to increases in HFpEF-associated 
comorbidities such as obesity and diabetes [77, 89-91]. 
In recent years, there has been evolved thinking regarding the pathology of heart 
failure which focuses more on the intracardiac (e.g., cardiomyopathy, hypertrophy, 
ventricular remodeling) and extracardiac abnormalities (e.g., diabetes, obesity, 
hypertension) shared between HFpEF and HFrEF patients, rather than on the 
differences between the two phenotype groups [92-96]. Some researchers have even 
argued that the two phenotypes should be viewed less as distinctive conditions but 
rather as differing, yet overlapping, presentations of the same disease along a spectrum 
[92, 97]. For these reasons, we chose to evaluate heart failure outcomes with 
differentiation between HFpEF and HFrEF subjects. 
1.3 B-TYPE NATRIURETIC PEPTIDE (BNP) 
Natriuretic peptides are a family of vasoactive neuroendocrine proteins and 
include atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type 
natriuretic peptide (CNP) [98, 99]. ANP is expressed in the atria, ventricles, kidney, 
adipose tissue, and in the brain; BNP is primarily expressed by the ventricles, but also 
by atria and the brain; lastly, CNP can be expressed in the bone, brain, endothelial 
tissues, and throughout the heart [98]. In recent years, BNP in particular, has shown 
promise for the diagnosis and management of heart failure [28, 100, 101]. Epidemiologic 
studies increasingly also measure NT-pro-BNP, which is a biologically inert byproduct of 
BNP synthesis but has a longer half-life, and find similar clinical interpretations as do 
studies of BNP [100-103]. Serum concentrations of both BNP and NT-pro-BNP are 




1.3.1 BNP SYNTHESIS 
 The most common source of BNP synthesis is from the ventricles in response to 
intracardiac pressures, such as volume overload which occurs in heart failure patients 
[98, 105, 106]. Under these pressures, de novo synthesis of BNP occurs in the 
ventricular myocardium due to rapid gene expression [105]. BNP is synthesized as a 
108-amino acid prohormone (proBNP), and, when secreted, is cleaved into two 
byproducts: NT-proBNP (biologically inert, 76 amino acids) and BNP (biologically active, 
32 amino acids) [105, 107]. Figure 1.4 provides a visual schematic of BNP synthesis 
and secretion into systemic circulation from the ventricular myocardium. Once in 
systemic circulation, BNP is cleared by receptor mediated mechanisms (e.g., natriuretic 
peptide receptor-A [NRP-A], natriuretic peptide receptor-C [NRP-C]) and excreted by the 
kidneys [98, 107, 108]. Of note, the gene that codes for BNP synthesis, Nppb, has been 
identified in humans on chromosome 1 at 1p36.2 [98, 109]. Several single nucleotide 
polymorphisms (SNPs) have been identified in the Nppb gene, although these SNPs 
seem to only affect proBNP, but not the circulating 32 amino acid form of BNP which is 
found in circulation [98]. This implies that BNP might be more appropriate than NT-
proBNP in epidemiologic studies, since there could be more inter-individual variability in 
measures of NT-proBNP than for BNP. 
1.3.2 BNP BIOLOGY 
Circulating BNP has a number of biologic functions that include decreasing blood 
pressure, increasing sodium excretion and water excretion (natriuresis and diuresis); 
regulating sympathetic nervous system activity; inhibiting the renin-angiotensin-
aldosterone system; modulating vasopressin, endothelin, and cytokine activity, and 
involvement in cardiac remodeling [110, 111]. Interestingly, BNP seems to be a natural 
defense mechanism in response to high intracardiac pressures; its circulation is involved 
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in neuroendocrine signaling between the heart, kidneys, and brain to maintain 
homeostasis (Figure 1.5) [111].  
 
 
FIGURE 1.4. SCHEMATIC OF BNP SYNTHESIS [105] 
 
There is some evidence that BNP can interface with the HPA axis [112, 113], 
although the mechanisms that link BNP with HPA and psychosocial stress are not very 
well understood. Some studies show decreases in BNP in relation to psychosocial stress 
[114], while others have illustrated that psychosocial stress leads to increases in BNP 
[115], and others have shown that BNP increases were associated with greater reports 
of emotional anger [116]. Yet, as BNP was first isolated from a porcine brain in 1988 




FIGURE 1.5. PHYSIOLOGIC ACTIONS OF CIRCULATING NATRIURETIC PEPTIDES, INCLUDING BNP [106] 
 
1.3.3 BNP EPIDEMIOLOGY AND ENVIRONMENTAL EPIDEMIOLOGY 
 What is well understood at this point is that BNP is an important diagnostic and 
prognostic marker in heart failure patients [28, 119]. Beyond diagnosis, BNP is 
increasingly linked to survival in epidemiologic studies of patients with and without 
cardiovascular disease [32, 120-122]. This association can exist even in asymptomatic 
patients, indicating that BNP can be a subclinical marker of intracardiac pressure and of 
the complex cascade of biological processes that follow [31, 123]. Although 
epidemiologic associations between BNP levels and survival are fairly well established, 
there are very few epidemiologic studies that evaluate BNP with respect to 
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environmental factors [124-126]. Of these studies, associations between environmental 
factors (e.g., air pollution) and BNP are inconsistent, and are likely due to the fact that 
these studies had very small sample sizes (i.e., n = 28 – 45). Epidemiologic evaluation of 
environmental factors in relation to BNP is thus a very fruitful area of research, because 
it is a molecule with important prognostic significance in heart failure; it might shed light 
on mechanistic pathways; it is commonly and regularly measured in subjects with heart 
failure, and thus may minimize misclassification issues associated with the identification 
of heart failure exacerbation by hospitalization alone; and few studies of environmental 
exposures in relation to BNP have been completed to date. 
1.4 ENVIRONMENTAL EPIDEMIOLOGY OF HEART FAILURE 
1.4.1 ENVIRONMENTAL EXPOSURE PATHWAYS RELEVANT TO HEART FAILURE 
HOSPITALIZATIONS 
 Exposure to air pollution, and to particulate matter specifically, has been associated 
with adverse cardiovascular outcomes, as reviewed in Rajagopalan et al. [127, 128]. The 
associations between air pollution and cardiovascular disease exist in the short-term (i.e., 
exacerbations and hospitalizations) [129, 130] as well as in the long term (i.e., contributing to 
the progression of cardiac disease and mortality) [131-133]. Mechanisms underlying these 
associations include: systemic inflammation [134, 135], endothelial dysfunction [136, 137], 
blood coagulation [138, 139], and consequential cardiac remodeling [140, 141]. 
Observational studies that elucidate these mechanisms, however, are limited by the inability 
to fully characterize the effects of comorbidities that could mediate or modify the associations 
between environmental factors and cardiovascular outcomes.  
1.4.2 ENVIRONMENTAL EPIDEMIOLOGY OF HEART FAILURE HOSPITALIZATIONS 
Heart failure is an excellent health outcome for study in relation to UNGD 
because prior studies suggest that heart failure can be exacerbated by toxicants in air 
pollution [142] and stress [143], two primary sets of UNGD impacts. There is consistent 
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epidemiologic evidence that supports links between air pollution and heart failure; a 
recent review by Shah et al., found increases in heart failure hospital admissions and 
mortality on the day of and the day following increases in PM2.5, SOx, NOx, and CO [142]. 
Studies of the short-term effects of air pollution find similar associations for both 
cardiovascular and respiratory outcomes [144, 145], and both cardiovascular and 
respiratory exacerbations are influenced by stress [146-148]. Because no studies have 
yet evaluated associations between UNGD activity and any health outcome in older 
adults, and because persons living with heart failure might be susceptible to the air 
pollution and community impacts associated with UNGD, we evaluated associations 
between UNGD activity and heart failure outcomes. In the next sections, I describe the 
environmental epidemiology and rationale for also considering additional environmental 
and community variables in this research. 
1.4.3 GREENNESS 
A growing body of epidemiological evidence reports that greenness is associated 
with beneficial health effects [50, 51, 149, 150]. These studies find that the normalized 
difference vegetative index (NDVI), a common measure of greenness, is associated with 
decreased risk of adverse birth outcomes (e.g., preterm birth, birth weight, small for 
gestational age [SGA]), diabetes, hypertension and hyperlipidemia, cardiovascular 
disease, mental health conditions, and mortality [50, 51, 57, 149, 151, 152]. Proposed 
mechanisms for NDVI-health associations include: reducing air and noise pollution, 
providing opportunities for physical activity, providing opportunities for social interaction, 
and through direct improvements in mental health conditions such as stress and 
depression [149, 151], particularly from the perspective of providing mental restoration 
and stress reduction [153, 154]. Other studies that measured salivary cortisol, heart rate, 
and cognitive function before and after individuals’ exposure to natural environments 
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with higher levels of greenness documented acute health benefits (i.e., reduced salivary 
cortisol and heart rate, and improved cognitive function) in response to spending as little 
as 30 minutes in these environments [153, 155]. Similarly, a recent longitudinal study of 
NDVI and mortality in the Nurses’ Health Study cohort (women only) found that NDVI, 
calculated at a 250m buffer around a participants’ residence, was independently 
associated with reduced non-accidental mortality and this association was, in part, 
mediated by measures of physical activity, depression, PM2.5, and social engagement 
[51], and the authors estimated that physician-diagnosed depression or anti-depressive 
medication use explained 30.6% (95% CI: 15.5%, 51.4%) of the association between 
NDVI and non-accidental mortality [51]. Another study utilized the natural experiment of  
the emerald ash borer, an invasive pest which killed over 100 million ash trees between 
the years 2002-2010 in the Midwestern US, and its associations with increased risk of 
cardiovascular disease in women [156]. This study documented increased hazard 
(hazard ratio: 1.2, 95% CI: 1.20-1.31) for cardiovascular disease development, 
comparing women living in counties that were infested with the emerald ash borer to 
those living in counties that were not infested [156]. NDVI was thus included in this 
research because we suspected that it could be associated with heart failure 
hospitalization and levels of BNP in heart failure subjects.  
1.4.4 COMMUNITY SOCIOECONOMIC DEPRIVATION 
Epidemiologic studies demonstrate that community socioeconomic deprivation 
(CSD) is independently associated with cardiovascular diseases, diabetes, body mass 
index (BMI), cognitive function, and overall morbidity and mortality [157-161]. 
Understanding the mechanisms responsible for these associations is difficult because 
CSD is likely confounded by a number of individual- (e.g., race/ethnicity, socioeconomic 
status [SES], economic disadvantage, fear of crime) and community-level exposures 
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(i.e., racial segregation, lack of community resources) that can work through a variety of 
biological pathways to cause these adverse health outcomes [162, 163]. These 
stressors can act to impact physical activity and social engagement, exacerbating the 
effects of CSD on health [164-166], either through epidemiologic mediation or effect 
modification. In addition, many of these factors are associated with mental health 
comorbidities (e.g., depression [167, 168]) and could therefore be associated with heart 
failure etiology and susceptibility to heart failure hospitalization. This is consistent with 
studies that, although unable to disentangle mechanisms, provide growing evidence that 
deprivation measures are independently associated with heart failure hospitalization and 
mortality [169, 170]. For these reasons, we evaluated CSD in relation to all of the heart 
failure outcomes considered in this research, and in relation to UNGD activity and NDVI 
to assess the extent to which CSD could moderate or mediate associations between 
UNGD activity, NDVI, and heart failure outcomes. 
1.4.5 PROXIMITY TO ROADWAYS 
A substantial body of epidemiologic literature has examined residential proximity 
to major and minor roadways in relation to adverse health outcomes, including 
hypertension [171], low birth weight [172], type 2 diabetes [173],  and markers of 
inflammation [174]. Often, proximity to roadways is used as a proxy for air pollution and 
noise exposure due to traffic, although wind and atmospheric conditions can lead to 
differential dispersion of noise and air pollution from these sources [175]. Despite the 
uncertainty in etiological agent, residential proximity to roadways can be a good indicator 
of both air pollution and noise for use in epidemiologic studies of cardiovascular 
outcomes [176, 177].  Although this was not the main environmental exposure 
considered in this research, we evaluated the associations between proximity to major 
and minor roadways in analyses of heart failure hospitalization and with BNP levels 
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because it could confound associations between UNGD and heart failure outcomes; 
community deprivation and heart failure outcomes; and NDVI and heart failure 
outcomes.  
1.5 PUBLIC HEALTH RELEVANCE 
This study is the first epidemiologic study to examine associations between 
UNGD activity and heart failure hospitalization – the first evaluation of any health 
outcome in relation to UNGD activity that primarily affects older adults. Given growing 
evidence that UNGD is associated with several health impacts in the Marcellus shale 
(e.g., asthma exacerbation [15], migraine headaches and fatigue [17], birth outcomes [9-
11, 13, 64], reports of stress [63], depressive symptoms, and disordered sleep [18]), we 
suspected that older adults, and particularly those with heart failure, would likely be most 
susceptible to adverse environmental exposures and contextual effects of UNGD 
activity. Importantly, this study is the first to evaluate associations between UNGD 
activity and any biological marker in a large, representative population of subjects with 
heart failure. Adding to the epidemiologic literature regarding UNGD and health impacts, 
the evaluation of BNP in relation to UNGD activity is the first study to evaluate 
environmental factors of any kind in relation to BNP levels in a large population. 
To the best of our knowledge, this study is first epidemiologic study to examine 
effect modification of environmental associations with heart failure hospitalization and 
with BNP levels by HFpEF and HFrEF phenotype status of the associations between 
UNGD and hospitalization and the association between UNGD activity and BNP. Being 
able to systematically distinguish heart failure phenotypes has been a limitation in 
previous large scale epidemiology studies of heart failure, but advances in data science 
have made extracting heart failure phenotype information from EHRs a novel possibility 
[178, 179]. This study evaluated whether heart failure phenotype modified the 
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associations between UNGD activity and hospitalization and UNGD activity and BNP 
levels because HFpEF and HFrEF are two distinct phenotypes of heart failure with 
differing pathophysiology. We suspected that understanding effect modification of these 
two associations by phenotypes would provide insights to biologic mechanisms 
underlying these associations.  
We hypothesized that environmental associations would be stronger among 
HFpEF subjects than among HFrEF subjects because heart failure, and HFpEF in 
particular, is increasing in prevalence and is more commonly associated with non-
cardiac comorbidities that are related to the built and natural environment than HFrEF. 
This possibility has been posited by several studies of differential responses to stressors 
(chemical and non-chemical) in heart failure exacerbation (e.g., mortality, hospitalization) 
by phenotype [180, 181]. Greater susceptibility to environmental factors related to 
exacerbation by phenotype would provide insights beneficial to understanding the 
etiology and treatment of heart failure and could help explain recent trends in increasing 
HFpEF prevalence relative to HFrEF. 
 
1.6 SPECIFIC AIMS 
Given the aforementioned considerations, the specific aims of this dissertation 
research were to:   
 SA1 (Chapter 3): Evaluate associations of four phases of UNGD activity with 
heart failure hospitalizations in a case-control analysis (i.e., comparing heart 
failure patients with and without heart failure hospitalizations) using multilevel 
logistic regression. 
 SA2 (Chapter 4): Evaluate associations of four phases of UNGD activity with 
BNP levels in blood among subjects with heart failure, using generalized 
estimating equations (GEE). 
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 SA3 (Chapter 5): Evaluate whether heart failure phenotype (HFpEF and HFrEF) 
status modified associations of UNGD activity with heart failure hospitalization 
and BNP levels in separate analyses: 
o SA3a (Chapter 5a): Evaluate effect modification by phenotype status of 
the association between UNGD activity and heart failure hospitalization. 
o SA3b (Chapter 5b): Evaluate effect modification by phenotype status of 
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Chapter 2: Detailed Methods 
2.0 CHAPTER OVERVIEW 
The methods underlying this dissertation research center around two main study 
designs: a nested case-control study of heart failure hospitalization in the cohort of 
subjects with heart failure in the Geisinger health system (Chapter 3) and a cross-
sectional study of B-type natriuretic peptide (BNP) levels in blood (Chapter 4). Next, I 
evaluated effect modification by heart failure phenotype (preserved vs. reduced ejection 
fraction) for both of these analyses (Chapter 5). In this chapter, I describe the methods 
for Chapters 3 to 5, including study design, study population, study sample, and analytic 
variable creation (unconventional natural gas development [UNGD] activity, 
comorbidities, medication use, environmental variables), with detailed information on 
preliminary analysis of UNGD activity metrics including evaluation of duration. Only 
methods that are not explicitly described in Chapters 3 to 5 are described here. 
2.1 STUDY POPULATION 
 
2.1.1 GEISINGER ELECTRONIC HEALTH RECORD (EHR) 
Electronic health record (EHR) data were obtained from Geisinger in 
Pennsylvania. Geisinger is an integrated health system serving over 450,000 primary 
care patients from over 38 counties in central and Northeastern Pennsylvania who 
represent the general population in the region [182]. These EHR data are useful for 
epidemiologic study because they are longitudinal, provide extensive information on a 
patient’s medical history, and are detailed in that they include dates of all encounters for 
patients within the health care system, including medications, procedures, and 
laboratory measures [182]. Additionally, the EHR provides accurate and systematic 
documentation of individual-level factors and comorbidities that are important for 
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analyses, including age, sex, residential address, race/ethnicity, a measure of poverty 
(Medical Assistance, a needs-based program, for health insurance), and related risk 
factors (e.g., BMI, diabetes, chronic obstructive pulmonary disease, cardiovascular 
conditions such as previous myocardial infarction or coronary artery disease, and other 
diagnoses) [182].  
2.1.2 SELECTION OF STUDY SAMPLE 
The sole criterion for the EHRs we obtained from Geisinger was that the subject 
had to have at least one International Classification of Disease (ICD-9) code for “428.x” 
for heart failure from any type of encounter. We obtained EHRs for 16,098 subjects who 
fit these criteria and were seen at a Geisinger facility between 2005-2015. From these 
16,098 subjects, we excluded a total of 2915 subjects according to the following: 435 
subjects who had either an ICD-9 diagnosis code for congenital heart anomalies (746.x) 
or endocardial fibroelastosis (425.3); 321 subjects who did not have a residential 
address in Pennsylvania, or who were unable to be geocoded; two subjects without 
demographic information; 2071 subjects who were not observed in the EHR between 
2008-2015, a time period that coincided with UNGD activity; and 86 subjects who were 
not at least 18 years old at the start of the study period, January 1, 2008. The remaining 
13,183 subjects were eligible for selection into either the hospitalization or BNP 
analyses.  
In Figure 2.1, I outline the steps for selecting subjects into the analyses 
presented in Chapters 3 to 5. The rationale and processes through which I selected 
subjects for the hospitalization analysis and the BNP analysis are described in greater 
detail in Chapters 3 and 4. The study samples for Chapter 5a and Chapter 5b are the 
same samples as used in Chapter 3 and Chapter 4, respectively. In Chapter 5, I 
evaluate effect modification of the hospitalization and BNP outcomes by heart failure 
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phenotypes (comparing subjects with heart failure with preserved [HFpEF] vs. reduced 
ejection fraction [HFrEF]) using classifications obtained from the Electronic Medical 
Records and Genomics Network (eMERGE) phenotype algorithm (explained in next 
paragraph) [179]. A total of 9639 subjects were selected for either the hospitalization 
analysis or the BNP analysis, with 9054 of these subjects comprising the study 
population for the hospitalization analysis (Chapter 3) and 3938 subjects included in the 
BNP analysis (Chapter 4). Further detail and rationale for the exclusion criteria and 
study selection processes can be found in each of the respective chapters. Comparing 
across these two populations, there were 3353 subjects that were included in both the 
hospitalization and BNP analyses; 5701 subjects included in the hospitalization analysis 
that were not included in the BNP analysis; and 585 subjects in the BNP analysis that 
were not included in the hospitalization analysis. A major reason for the differences in 
subjects between these two analyses is due to low numbers of BNP orders in later years 
of the analysis (i.e., 2013-2015), illustrated in Table 2.1 in section 2.2.2.1 of this chapter. 
Additional comparisons of the subjects in each of the analyses are described in section 
2.7 of this chapter. 
After completion of the analyses of the main effects associations of the phase-
specific UNGD metrics with heart failure hospitalization status or BNP levels, effect 
modification by heart failure phenotype on these relations was next evaluated. This 
required that we use a method to identify heart failure phenotype. Because Geisinger is 
a member of the eMERGE network, a National Institutes of Health (NIH)-funded 
consortium of institutions that utilize EHRs and DNA biobanks to develop novel research 
approaches [183, 184], we decided to use the eMERGE heart failure phenotype method 
[179]. This method is described in Chapters 5a and 5b, with additional detail in 
Appendix A, but here we describe how application of the phenotype method influenced 
the samples in the two primary analyses. As Figure 2.1 outlines, only 5446 of the 13,183 
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eligible subject records had the eMERGE algorithm successfully applied; this relatively 
small proportion was due to the abundance of information needed in the EHR to 
accurately phenotype HF patients with eMERGE, which is detailed in section 2.2.3 of 
this chapter. Because application of the eMERGE heart failure phenotyping algorithm 
required additional information, subjects who had the eMERGE algorithm applied had a 
higher proportion of comorbidities, medications, and had a greater average duration of 
heart failure (i.e., the time between a subject’s first heart failure diagnosis and the date 
of the case event, control encounter, or laboratory date for BNP) compared to subjects 
who did not have the algorithm applied (Tables 2.9-2.13; further comparisons between 
study subjects across our analytic samples are detailed in  section 2.7 of this chapter). 
Therefore, findings from Chapters 5a and 5b should be interpreted with caution, since 
subjects with the eMERGE algorithm applied were likely sicker and certainly had more 
information in the EHR compared to subjects who did not have the algorithm applied and 
could therefore bias the findings from Chapter 5a and 5b away from the null.
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FIGURE 2.2. ALGORITHM FOR STUDY SELECTION 
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2.2 STUDY DESIGNS 
2.2.1 HOSPITALIZATION ANALYSIS 
In Chapter 3 and in Chapter 5a, the outcome was hospitalization for heart failure 
among the previously identified subjects with heart failure.  
2.2.1.1 CASE SELECTION 
We identified hospitalizations by searching the EHR for a ICD-9 diagnosis code 
of ‘428.x’ for heart failure associated with two types of encounters, specifically an 
inpatient encounter and also what the health system refers to as an ED to IPT 
encounter, in which the subject was first evaluated in the emergency department (ED) 
and then hospitalized for heart failure. Because some subjects had a number of frequent 
and recurring hospitalizations, we considered only the subjects’ first heart failure 
hospitalization within the years 2008-2015 as our case events (n = 5839). 
2.2.1.2 CONTROL SELECTION 
In Chapter 3, I describe in detail the process for control selection. Briefly, we 
used a 1:1 frequency matching strategy based on the age, sex, and year of the 5839 
heart failure subjects’ case events. We randomly selected 5839 control encounters, 
since we needed to assign time-varying covariates and UNGD activity metrics to a date 
for controls. Control encounters could be any outpatient encounter or medication order, 
excluding those with a diagnosis code of “428.x” for heart failure. Because of our 
frequency matching strategy, some subjects were selected for control encounters more 
than once, leaving us with 3215 control subjects with 5839 control events and a total of 
11,678 control encounters and case events for the hospitalization analysis. 
2.2.2 BNP ANALYSIS 
In Chapter 4 and in Chapter 5b, the outcome evaluated was BNP levels in 
blood. We identified these laboratory orders and results by searching the EHR laboratory 
records for procedure codes of ‘83880.01’ and ‘83880.03’ for ‘natriuretic peptide’ and 
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‘BNP’, respectively. We evaluated laboratory BNP values obtained from both inpatient 
and outpatient settings. 
2.2.2.1 NT-PRO-BNP AND BNP: RATIONALE FOR CHOOSING BNP 
Increasingly, epidemiologic studies of BNP also evaluate N-terminal pro B-type 
natriuretic peptide (NT-pro-BNP), which is a non-active prohormone associated with 
BNP. NT-pro-BNP has a longer half-life than BNP,  with NT-pro-BNP having a half-life of 
approximately 120 minutes compared to a half-life of 20 minutes for BNP [105]. Studies 
of BNP and NT-pro-BNP show similar prognostic and diagnostic value [100, 105], so we 
evaluated frequencies of both of these relevant laboratory orders by year and by 
laboratory setting (Table 2.1). Prior to 2012, procedure codes for 83880.01 “Natriuretic 
peptide” were more prevalent in this population of heart failure patients than procedure 
codes for 83880.02 “Pro BNP,” which became more prevalent in later years in this study. 
Beginning in 2012, Geisinger began using the procedure code of 83880.03 for “BNP” 
instead of the previously used procedure code of 83880.01 for “natriuretic peptide.” 
Because of these differences in procedure codes by year, we did not feel it was 
appropriate to pool the laboratory results from measures of BNP and NT-pro-BNP in a 
single statistical analysis, we limited our analysis for Chapter 4 and Chapter 5b to 
laboratory orders for procedure codes of 83880.01 and 83880.03 for measures of BNP. 
The years of these orders coincided more closely with UNGD activity in the region and 
were thus more relevant for our evaluation of associations between UNGD activity and 
BNP values. However, we included measures of BNP after 2012 because clinicians still 
ordered BNP laboratory tests in later years. To evaluate if the inclusion of BNP beyond 
2011 biased our results, we conducted a sensitivity analysis using only 2008-2011 data. 
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Table 2.1 Summary of all BNP orders, by year, procedure code, and laboratory 
setting 
  Number of laboratory measures (n) 
Mean concentration (pg/mL) (Standard deviation) 
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2.2.3 HEART FAILURE PHENOTYPE ANALYSIS  
Analysis for Chapter 5a and Chapter 5b classification of heart failure subjects 
into the categories of heart failure with preserved vs. reduced ejection fraction (HFpEF 
or HFrEF) was determined using the Electronic Medical Records and Genomics 
(eMERGE) network algorithm for heart failure. This algorithm was developed with 
funding from the National Human Genome Research Institute, where electronic medical 
record systems were combined with genetic data from DNA repositories for validation 
and classification [185]. Briefly, the algorithm for differentiating between HFpEF and 
HFrEF phenotypes relies on a collection of diagnoses and procedure codes from the 
EHR, including physician-interpreted ejection fraction data (both qualitative and 
quantitative), obtained from echocardiogram records. Necessary information includes: 
patient demographics, encounter history, ICD-9 diagnosis codes, structured or 
unstructured problem list, echocardiography measurements, and medications. Because 
the eMERGE algorithm had these strict case criteria, not all of the subjects in both the 
case-control study and the BNP study were able to be phenotyped with this algorithm. 
Figure 2.2 illustrates directly how the algorithm uses EHR data to differentiate between 
subjects with HFpEF and HFrEF, using a cutpoint of an ejection fraction of 50% [185], 
while also including exclusion criteria, and is also included in Appendix A. Heart failure 
algorithm, which includes detailed information on how the eMERGE algorithm is applied 
to EHR data for phenotype differentiation. Of note, Figure 2.2 illustrates that, in order for 
the phenotyping algorithm to designate a subject as a case, a “HF date assigned per 
algorithm”; this date is the first date of a heart failure mention in the subject’s problem list 
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or the first heart failure diagnosis code.  One major difference between the criteria for the 
eMERGE algorithm and the criteria used for selection into the hospitalization or BNP 
study is that the eMERGE algorithm requires a mention of heart failure in the subject’s 
problem list, whereas we did not consider the problem list for selection of subjects into 
the hospitalization or BNP study. This is because our sample selection was primarily 
driven by the presence of a hospitalization for heart failure or a BNP laboratory order, 
not having heart failure mentioned in the problem list at a previous date. Although we 
required at least two ICD-9 codes to indicate the presence of comorbidities, we required 
only a single ICD-9 code for heart failure diagnosis because the positive predictive value 
and sensitivity of the heart failure ICD-9 diagnosis code 428.x are quite high, with 
specificity estimated at  95% [186, 187] and estimated positive predictive value ranging 
from 83.5% to 100% [187, 188]. In the hospitalization analysis, 68.1 % of the 9054 
subjects had heart failure mentioned in their problem list; in the BNP analysis, 74.0 % of 
the 3938 subjects had heart failure mentioned in their problem list. For these reasons 
and for reasons described in section 2.7 and in Chapters 5a and 5b, we considered 
both the application of the eMERGE algorithm and the presence of a phenotype for 
HFpEF or HFrEF as an indication of more severe disease. 
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FIGURE 2.3. SCHEMATIC OF THE EMERGE ALGORITHM [185] 
  
 42 
2.3 GEOCODING  
2.3.1 Patient addresses 
Patient addresses were geocoded from address fields located in the EHR. 
Joseph DeWalle, a geographic information systems (GIS) analyst at Geisinger’s 
Environmental Health Institute, obtained patient address fields from the EHR and 
processed them for geocoding. Processing of the address fields involved removing 
extraneous text information and ensuring that address fields were in a correct format 
(i.e., not a PO box). After processing patient addresses for errors and formatting, 
addresses were geocoded using ArcGIS v.10. Several basemaps obtained from ESRI 
(the company that produces ArcGIS software) and the United States Census Bureau’s 
TIGER line shapefiles were used to geocode patient addresses. Latitude and longitude 
coordinates were obtained using 3-point matching (requiring street address, city, and zip 
code) and, if city information was unavailable, 2-point matching (requiring street address 
and zip code), as was previously done in studies in this geography [57, 161, 189]. We 
ensured that subjects included in this study were able to be geocoded to a street 
address in Pennsylvania. Of the 16,098 subjects with a diagnosis code of 428.x for heart 
failure, 16,056 (99.7%) were able to be successfully geocoded. Of the 16,056 geocoded 
subjects, 15,765 (98.2%) had a residence in Pennsylvania.  
2.4.1 EXPOSURE DATA 
2.4.1.1 GENERATION OF UNGD ACTIVITY METRICS 
Unconventional natural gas development (UNGD) well data were obtained from 
the Pennsylvania Department of Environmental Protection (PA DEP) for the years 2005-
2015. These data included the dates and locations of natural gas wells drilled during this 
time period. Each natural gas well had its own unique identifier for the well itself and for 
the well pad on which it was drilled. Data also included the dates when a well was 
stimulated, and the total volume of natural gas produced over the course of a year. In 
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2012, the PA DEP began reporting the volume of natural gas produced from a single 
well in six-month increments instead of in annual increments, as was reported 
previously. To obtain the total daily volume of natural gas produced by each well, we 
divided the reported volume by the appropriate number of days for the reporting 
timeframe. We used these data to identify UNGD activity in four phases: well pad 
preparation (e.g., clearing of site, delivery of equipment and personnel), beginning of 
drilling of well (i.e., spud date), stimulation (hydraulic fracturing) of well, and production 
of natural gas [15]. 
We generated quantitative estimates of UNGD activity based on the distance of 
the patient’s residential address and the dates of each of the four UNGD phases, as in 
prior studies of UNGD activity in this region that examined UNGD activity in relation to 
asthma hospitalizations [15], pregnancy outcomes [13], and nasal and sinus, migraine 
headache, and fatigue symptoms [17]. We assigned UNGD activity metric values for 
subjects at a 1-day lag prior to the heart failure hospitalization. For estimating a subject’s 
UNGD activity for the well pad preparation (pad) and spud metrics, we used the 
following equation developed by Rasmussen et al. [15], where j is the subject, n is the 
number of wells and d2ij is the squared distance (m
2) between j and well i. subject j’s 
activity metric is estimated by Equation 1: 
(Equation 1) 

















where ti is the total well depth (vertical plus horizontal) and is used as a surrogate for 
such activities as truck traffic, volume of water brought to site, volume of stimulation 
chemicals injected into well, volatilization of these chemicals from flowback water into 
air, drilling engine emissions, and compressor engine emissions (as fluids are injected 
under high pressure) [15, 190]. The production metric, instead of using total well depth, 
incorporates the total daily volume of natural gas (m3) produced for well i (vi), which is 
used as a surrogate for production activity, compressor engine activity emissions, and 
fugitive emissions [15, 190]. Equation 3 was used for the generation of the production 
(prod) activity metric: 
(Equation 3) 






In addition to the four phase-specific activity metrics, a composite metric was created as 
the z-transformed (mean of zero, standard deviation of 1) sum of the four phase-specific 
metrics for each subject. We evaluated correlations between the composite metric and 
the phase-specific metrics in section 2.6 of this chapter. 
2.5.3 INDIVIDUAL-LEVEL COVARIATES 
2.5.3.1 ASSIGNMENT OF COVARIATES FROM THE EHR 
In Chapters 3-5, we assigned a number of time-varying covariates at the 
individual level to account for comorbid conditions and relevant medications among 
subjects with heart failure. For comorbidities, we identified these when subjects had 
least two diagnosis codes in the EHR for each respective comorbid condition prior to the 
date of the case event or control encounter (Chapters 3 and 5a) or prior to the 
laboratory order date (Chapters 4 and 5b). These ICD-9 diagnosis codes could be 
obtained from any combination of inpatient, outpatient, or emergency department 
encounters, as well as medication orders, but not from the EHR's problem list. Table 2.2 
lists the ICD-9 codes used to define these key covariates.  
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Table 2.2. Diagnosis codes used for EHR covariate assignment 
Condition ICD-9 diagnoses codes used 
Chronic kidney disease 585.x 
Chronic obstructive pulmonary disease 496.x 
Coronary artery disease 414.01 
Hypertension 401.9 
Myocardial infarction 410.x 
Type 2 diabetes 250.x 
Valve disorders V43.3, 424.x, 396.9, 391.1, 392.0, 390, 395.9, 
or 421.9 
Relevant medications were assigned in a similar time-varying manner. Medication use 
was defined as a binary variable (yes vs. no) to indicate whether or not a medication 
order (which had a defined start and end point) encompassed the date of the case event 
or control encounter (Chapters 3 and 5a) or the laboratory order date (Chapters 4 and 
5b). Medications were identified using the Medi-Span Generic Product Identified 
Therapeutic Classification System [191] to sort medications into the following classes: 
anti-hypertensive, anti-hyperlipidemic, and anticoagulant medications. Table 2.3 lists the 
medication subclasses identified by these broader medication class categories. 
Table 2.3. Medication classes and subclasses used for covariate assignment 
Medication class Medication subclasses represented 
Antihypertensive Angiotensin converting enzyme (ACE) inhibitors 
Agents for pheochromocytoma 
Angiotensin II receptor antagonists 
Antiadrenergic antihypertensives 
Antihypertensive combinations 
Direct renin inhibitors 
Selective aldosterone receptor antagonists 
Vasodilators 
Antihyperlipidemic Antihyperlipidemic combinations 
Bile acid sequestrants 
Fibric acid derivatives 
HMG-CoA reductase inhibitors (statins) 
Intestinal cholesterol absorption inhibitors 
Miscellaneous antihyperlipidemics 
Nicotinic acid derivatives 
Anticoagulant Coumarin anticoagulants 
Direct factor XA inhibitors 




We calculated a number of other individual level covariates relevant to analyses in 
Chapters 3-5. These included smoking status, receipt of Medical Assistance, body mass 
index (BMI), Charlson index, duration of contact with the health care system, and 
duration of heart failure. Smoking status was calculated from the EHR's social history file 
and was classified as ‘current’, ‘former’, or ‘never’ at the time of the case or control event 
or the laboratory order date. Receipt of Medical Assistance was categorized as ‘ever’ or 
‘never’ having received Medical Assistance based on the presence of insurers listed in 
Table 2.4. Medical Assistance was used as a surrogate for family socioeconomic status 
as in previous studies [192-194]. 
Table 2.4. List of insurers considered for receipt of Medical Assistance 
Name of insurer 
PENNA M A PROGRAM D01 
PA MEDICAID PRESUMPTIVE D02 
GHP MA G09 
CBHNP PA HEALTH CHOICES D04 
COVENTRY CARES D06 
ACCESS PLUS D15 
MEDICAID OF NEW YORK D43 
MEDICAID OF OHIO D45 
MEDICAID OF MARYLAND D46 
MEDICAID OF VIRGINIA D47 
MEDICAID SSU D74 
MA PENDING D99 
MA OUT OF STATE Z43 
GATEWAY MDC ASSURD MDC HMO M17 
GATEWAY 995 
GHP PPO HEALTHCHOICES G22 
CHIP UHC COMM PL KIDS H64 
GHP CHILD HLTH INS PROG (CHIP) 
BLUE CHIP S18 
CHIP FIRST PRIORITY HEALTH H31 
CHIP CAPITAL BLUE CROSS H20 
CHIP HIGHMARK BC AND BS H51 
CHIP HIGHMARK BS CENTL PA H53 
CHIP KEYSTONE HLTH PL E IBC H55 
CHIP FIRST PRIORITY HEALTH H31 
CHIP UPMC FOR KIDS I07 
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BMI was calculated by obtaining the height and weight data for individuals in Chapters 3 
to 5 from the EHR at the closest date prior to, but not on the day of or after, either the 
control encounter, case event, or laboratory order date. The formula used for calculating 
this BMI was: 
(Equation 4) 
BMI (kg / m2) = weight (lbs) X 703  height (in2)  
For individuals without complete height and weight data, we used multiple imputation to 
estimate BMI based on age at time of case event, control encounter (Chapters 3 and 
5a), or laboratory date (Chapters 4 and 5b), sex, race/ethnicity, smoking status, and 
receipt of Medical Assistance. To have a composite measure of overall morbidity, we 
also calculated the Charlson index of comorbidity using 17 items. The 17 items included 
the following conditions: myocardial infarction, congestive heart failure, peripheral 
vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, 
connective tissue disease, peptic ulcer disease, liver disease (mild and moderate to 
severe), diabetes (and diabetes with end organ damage), hemiplegia, moderate or 
severe renal disease, any tumor, leukemia, lymphoma, metastatic tumors, and HIV/AIDS 
[195, 196]. The Charlson index was calculated at the date of the case event or control 
encounter (Chapters 3 and 5b) or at the laboratory date (Chapters 4 and 5b). For 
individuals without a Charlson index score (some individuals did not have enough 
contact time with the EHR preceding their event and thus were unable to be assigned a 
Charlson index score), we imputed Charlson index scores using multiple imputation 
based on: age, sex, race/ethnicity, smoking status, and receipt of Medical Assistance. 
Lastly, because we recognized that the duration of contact with the health care system 
as well as the duration of care for heart failure could affect both outcomes evaluated in 
Chapter 3 and Chapter 4 as either confounding variables or as surrogates for 
measurement error in variables obtained from the EHR, we created two additional 
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variables. Duration of contact with the health care system was defined as the elapsed 
time between an individual’s first contact with the health care system (for any condition) 
and the date of the case event or control encounter (Chapters 3 and 5b) or the 
laboratory date (Chapters 4 and 5b). Duration of heart failure was defined as the 
elapsed time between an individual’s first ICD-9 code of ‘428.x’ for heart failure and the 
date of the case event or control encounter (Chapters 3 and 5b) or the laboratory date 
(Chapters 4 and 5b). 
2.5.3.2 INDIVIDUAL-LEVEL MEASURES OF ENVIRONMENTAL VARIABLES 
2.5.3.2.1 Distance to major roads, minor roads, and nearest hospital or clinic  
We obtained the 2011 and 2013 shapefiles for highways in Pennsylvania and 
New York from the Federal Highway Administration. These data distinguished roads by 
the Federal Aid System codes 1-7. These codes were used to designate roads as major 
roads and minor roads. Major roads included interstates, principal arterial for freeways 
and expressways, and other principal arterial roads. Minor roads included minor 
arterials. Other roads that were not used in the major and minor roads designation were 
major collector roads, urban minor collector roads, and other highways designated as 
part of the National Highway System. Using ArcGIS and the ‘generate near table’ 
function, we calculated the Euclidian distance to major and minor roads from a subject’s 
residential address in meters. Similarly, we calculated the distance to the nearest 
Geisinger hospital or clinic from a subject’s residential address. Geocoded locations of 
outpatient clinics and hospitals were obtained from the health care system. 
 
2.5.3.2.2 ASSIGNMENT OF THE NORMALIZED DIFFERENCE VEGETATION INDEX (NDVI)  
We obtained satellite imagery files from the National Aeronautics and Space 
Administration’s (NASA)’s moderate resolution imaging spectroradiometer (MODIS) 
satellites. NASA operates two MODIS satellites that circulate the globe every 1-2 days: 
MODIS Terra and MODIS Aqua. These two satellites provide images of the same 
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surface of the Earth approximately 3 hours apart from each other [197]. NASA derives 
data in 36 spectral bands (i.e., wavelength groupings) from these two satellites in 16-day 
increments and in 250m x 250m grids. From these 36 spectral bands, NASA uses the 
red, near-infrared, and blue wavelengths to derive the normalized difference vegetation 
index (NDVI), an indicator of green vegetation ranging from 0 to 1, in the 250m x 250m 
grid [197]. 
We assigned NDVI to individuals based on the peak greenness (i.e., two-week 
period with highest NDVI values [maximal greenness]) of each calendar year for the date 
of the case event or control encounter (Chapters 3 and 5b) or the laboratory date 
(Chapters 4 and 5b). Since we used NDVI measures as a proxy for the beneficial 
effects of greenness exposure, we deemed it appropriate to use the time period where 
greenness was best captured by satellite imagery, i.e., during the period of peak annual 
greenness. Subjects were assigned a NDVI value as done previously in this region, by 
calculating the average NDVI value for an area delineated by a 1250m x 1250m grid that 
encompasses a patient’s residential address [57]. Each subject was assigned a value 
from 0 to 1, with greater values indicating greater residential greenness. 
2.5.4 COMMUNITY-LEVEL COVARIATES 
We obtained data from the United States Census Bureau’s American Community 
Survey for the years 2010-2014. Specifically, we used the 2010-2014 ACS 5-year 
estimates of several community variables at defined geographies (i.e., census tracts). 
The variables obtained from the ACS were used for the generation of community 
socioeconomic deprivation (CSD) as previously reported [161, 189, 190, 192, 198]: the 
percentage of the population with educational attainment less than high school, the 
percentage of the population not in the labor force, the percentage of the population 
living below the federal poverty level, the percentage of the population who were 
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unemployed, the percentage of the population without a car, and the percentage of the 
population that received public assistance.. Each variable was standardized for direction 
such that higher values represented more deprivation and was in standard deviation 
units (after z-transformation) and then summed to create a CSD index value.  
Of importance to Chapters 3-5 is the assignment of community types using a 
mixed definition of place that is appropriate for the geography of our study area, which 
encompasses both urban and rural areas. We assigned CSD index values to the 
community level (i.e., census tracts and minor civil divisions) that encompassed a 
subject’s residential address, with higher values indicating higher levels of deprivation. In 
cities, we used census tracts; elsewhere within the study area, we used minor civil 
divisions (MCD, i.e., township, borough, or city) as the spatial unit of analysis for CSD 
[15, 199]. The mixed definition of place means that we used census tract boundaries for 
some (i.e., census tracts in cities) and MCD boundaries for others (i.e., townships, 
boroughs). These methods were consistent for both the case-control and BNP studies 
(Chapters 3 and 4). 
2.6 CREATION OF AND RATIONALE FOR UNGD ACTIVITY METRICS 
2.6.1 EVALUATION OF CORRELATION BETWEEN METRICS  
In the case-control study population (Chapter 3), we created three different 
durations of UNGD activity metrics (i.e., 30-day, 60-day, and 90-day durations) with a 
one-day lag and compared correlations between each of these metrics at the three 
specified durations. We used a one-day lag for the generation of these UNGD activity 
metrics because previous studies of the short-term effects of ambient air pollution (one 
of the suspected mechanisms of UNGD effects on health) and hospitalization for 
cardiovascular diseases suggest that there is a short latency between exposure and 
hospitalization [200-203]. In addition to the four phase-specific UNGD activity metrics, 
 51 
we also generated a ‘composite’ metric, which was the sum of the z-transformed UNGD 
activity phases (i.e., pad, spud, stim, and prod) for these three specified durations. We 
calculated Spearman correlation matrices for each of these metrics for the three 
specified durations, and we determined that the composite metric did not accurately 
reflect each of the four phase-specific metrics for any of the durations evaluated. 
Because the correlations among the four phase-specific metrics using the 30-day 
duration were in the low to moderate correlation range for some metrics but higher for 
others, we decided to evaluate each phase-specific metric separately in analyses for 
Chapters 3-5. 
2.6.1 EVALUATION OF DIFFERENT DURATIONS FOR UNGD ACTIVITY METRICS 
After deciding that we would use individual, phase-specific UNGD activity 
metrics, we examined various durations of exposure metrics (i.e., 30-day, 60-day, and 
90-day durations) with a one-day lag to determine if differences in duration of the UNGD 
activity metrics would impact the hospitalization and BNP analyses. We calculated the 
Spearman correlation coefficients between these different durations for each metric 
assigned to case events or control encounters in Chapter 3. These correlation matrices, 
displayed in Tables 2.5-2.8, showed that the correlations among phase-specific metrics 
of different durations were highly correlated, with rs ranging from 0.88 to 1.0. Because of 
these very high correlations among the various durations, we decided to simplify our 
approach and use just the 30-day duration phase-specific UNGD activity metrics in the 
analysis.  










1.00   
60-day duration, one-
day lag 
0.92 1.00  
90-day duration, one-
day lag 
0.91 0.99 1.00 
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1.00   
60-day duration, one-
day lag 
0.90 1.00  
90 day duration, one-day 
lag 
0.88 0.98 1.00 
 










1.00   
60-day duration, one-
day lag 
0.96 1.00  
90-day duration, one-
day lag 
0.95 0.99 1.00 
 
Table 2.8. Spearman correlation matrix for prod metrics at 30-, 60-, and 90- day durations (n = 11,678) 








1.00   
60-day duration, one-
day lag 
0.9950 1.00  
90-day duration, one-
day lag 
0.9948 0.9998 1.00 
2.7 COMPARISON OF STUDY SUBJECTS BY PHENOTYPE STATUS AND BY STUDY SAMPLE 
Because not all subjects in the case control study and in the BNP study were 
able to have an assigned phenotype from the eMERGE algorithm, I have included 
several tables comparing subjects who had the eMERGE algorithm applied compared to 
those who have not. First, Table 2.9 compares subject characteristics, community type 
represented, and the mean number of ICD-9 codes for heart failure received for subject 
across several categories: all of the available 16,098 records, subjects in the 
hospitalization analysis, subjects in the BNP analysis, subjects in both analyses who had 
the eMERGE algorithm applied, and, among these, the subjects who had a confirmed 
HFpEF or HFrEF phenotype by the eMERGE algorithm. Across all subject categories, 
the distribution of sex, race/ethnicity, and age was similar, although subjects in the BNP 
analysis had a mean age of 69.1 years (standard deviation: 12.1 years) and all subjects 
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in the hospitalization analysis had a mean age of 67.1 years (standard deviation: 12.7 
years).  The subjects who had the eMERGE algorithm applied and who had a confirmed 
HFpEF or HFrEF phenotype had a greater mean number of ICD-9 codes for heart failure 
from the problem list than did subjects in the hospitalization or BNP analyses.  However, 
subjects in the BNP analysis had a greater mean number of ICD-9 codes for heart failure 
medications than did subjects in the other groups (mean of 62.8 heart failure ICD-9 
codes among the BNP subjects, compared to a mean of 38.6 heart failure medications 
among subjects in the hospitalization study and a mean of 53.6 heart failure medications 
among subjects with a HFpEF or HFrEF phenotype). There was also a greater 
proportion of subjects who had died in the BNP analysis (48.8% deceased) compared to 
subjects in the hospitalization analysis (33.7%); the subjects with the eMERGE algorithm 
applied (35.3%); and the subjects with a HFpEF or HFrEF phenotype. 
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Table 2.9. Comparison of subject characteristics across study samples in the hospitalization and BNP analyses and 
by eMERGE algorithm status 
















HFpEF or HFrEF 
phenotype 
Total subjects, n = 16098 n = 16098 n = 9054 n = 3938 n = 5446 n = 4141 
Sex, n (%) 
    Male 
    Female 





















Race/ethnicity, n (%) 
    White 
    Black 
    Hispanic 
    Other 































Age*, years, mean (SD) 











Community type, n (%) 
    Borough 
    Township 
    Census tract (city) 


























Patient status at end of study, n 
(%) 
   Alive 
   Deceased 


























Number of heart failure ICD-9 
codes per subject, mean (SD) 
    Problem list 
    Inpatient visits 



























Within the context of the hospitalization analysis, Tables 2.10 and 2.11 illustrate 
differences in the case control study subjects by whether or not the eMERGE algorithm 
was able to be applied to these subjects’ records. Because the hospitalization analysis 
utilized time-varying covariates based on the dates of case events and control 
encounters, these tables are based on a total of 11,678 events rather than the 9054 
individual subjects, since some subjects served as a control and then later became a 
case. In Table 2.10, we observed that a greater proportion of subjects who had the 
eMERGE algorithm applied were male; lived in townships and boroughs compared to 
census tracts; were deceased by the end of the study period (January 31, 2015); and 
were former smokers. We also observed that the mean age for subjects with the 
eMERGE algorithm applied was 72.6 years compared to 70.3 years for those who did 
not have the algorithm applied and that the mean duration, in days, from a case event or 
control encounter to the subject’s first diagnosis of heart failure was slightly greater for 
those who had the algorithm applied compared to those who did not (1149 days vs. 
1056 days). In Table 2.11, we display the proportion of subject events in the 
hospitalization analysis with relevant medications and comorbidities by whether or not 
the subjects had the eMERGE algorithm applied. Medication use was greater in subjects 
that had the eMERGE algorithm applied compared to those who did not. Similarly, there 
was a greater proportion of subjects with the following comorbid diagnoses among 
subjects with the eMERGE algorithm applied compared to those who did not: chronic 
obstructive pulmonary disease, coronary artery disease, hypertension, myocardial 
infarction, valve disorder, type 2 diabetes, chronic kidney disease. Similarly, the mean 
value for the Charlson index of morbidity was greater (9.23 vs. 8.26) in those with the 
eMERGE algorithm applied compared to those without. 
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Table 2.10. Selected subject characteristics, at time of case or control event, among persons in 
hospitalization analysis, by whether or not the eMERGE algorithm was applied, n = 11,678 events among 
9054 persons 
 
Total events n = 11,678 
eMERGE not applied 
n = 5988 
eMERGE applied 
n = 5690 
Sex, n (%) 
    Male 







Race/ethnicity, n (%) 
    White 
    Black 
    Hispanic 
    Other 













Age at hospitalization or at control 





Age category at first event, n (%) years 
   > 18-30 
   > 30-40 
   > 40-50 
   > 50-60 
   > 60-70 
   > 70-80 
   > 80-90 



















Community type, n (%) 
    Borough 
    Township 









Community socioeconomic deprivation 
(CSD),* SD units, quartiles 
     1 
     2 
     3 











Total events n = 11,678 
eMERGE not applied 
n = 5988 
eMERGE applied 
n = 5690 
Patient status at end of study, n (%) 
   Alive 

























Smoking status at event, n (%) 
    Current 
    Former 









Receipt of Medical Assistance† n (%) 





Body mass index (BMI) at event, kg/m2, 













* Community socioeconomic deprivation (CSD) was calculated based on US Census indicators; further information 
is detailed in the text 
**Major & minor roads were identified from the Federal Highway Administration databases; distance from subject’s 
residential address to these roads was calculated in meters 
†Medical Assistance, a surrogate for family socioeconomic status, was calculated based on health insurance status 
at the time of encounters 
‡ Days from first HF diagnosis to the date of case or control event  
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Table 2.11. Selected diagnoses and medication use, at time of case or control event, among persons in 
hospitalization analysis, by whether or not the eMERGE algorithm was applied, n = 11,678 events among 
9054 persons 
 
Total events n = 11678 
eMERGE not applied 
n = 5988 
eMERGE applied 
n = 5690 
Medication use, by class, n (%)* 
    Antihypertensive 
    Antihyperlipidemic 







 3120 (54.8) 
1424 (25.0) 
Chronic obstructive pulmonary 




1402 (24.6)  




Hypertension, n (%) 4495 (75.1) 4711 (82.8) 
Myocardial infarction, n (%) 690 (11.5) 878 (15.4) 
Valve disorder, n (%) 1075 (18.0) 1681 (29.5) 
Type 2 diabetes, n (%) 2477 (40.9) 2769 (48.7) 
Chronic kidney disease, n (%) 1580 (26.4) 2021 (35.5) 






* Relevant medication classes were identified based on the dates of physician orders 
** A composite measure of overall morbidity; definition described in text
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 Similar to our evaluation of differences in subject characteristics by whether or 
not the eMERGE algorithm was applied to subjects in the hospitalization analysis, we 
also evaluated these differences among subjects in the BNP analysis. To best illustrate 
these differences by subject, we selected the first BNP measurement per person and 
displayed characteristics by whether or not the eMERGE algorithm was able to be 
applied to the subject (Tables 2.12 and 2.13). In Table 2.12, a slightly higher proportion 
of subjects with the eMERGE algorithm applied were men, compared to those who did 
not have the algorithm applied (54.7% vs. 51.5%, p = 0.04). Similar to the subjects in the 
hospitalization analysis, a greater proportion of subjects in the BNP analysis who had 
the eMERGE algorithm applied lived in Townships and Boroughs compared to census 
tracts (p < 0.001) and had a greater mean duration, in days, from the time of their first 
diagnosis of heart failure to their laboratory date (921 days vs. 702 days, p < 0.0001). 
However, we did not see as many differences between smoking status, body mass 
index, receipt of Medical Assistance, or in the proportion of subjects who had died by the 
end of the study period. Table 2.13 shows that, a greater proportion of subjects in the 
BNP analysis who had the eMERGE algorithm applied had used antihypertensive, 
antihyperlipidemic, and anticoagulant medications (p < 0.001, p < 0.001, and p = 0.05, 
respectively) compared to those who did not have the algorithm applied. Similar to the 
subjects in the hospitalization analysis, a greater proportion of subjects in the BNP 
analysis with the eMERGE algorithm applied had the following comorbidities: chronic 
obstructive pulmonary disease, coronary artery disease, hypertension, myocardial 
infarction, valve disorders, type 2 diabetes, and chronic kidney disease (p < 0.001 for all 
of these except for chronic obstructive pulmonary disease, p = 0.05). The mean 
Charlson index of morbidity value was also greater in those with the eMERGE algorithm 
applied compared to those without (p = 0.0006).  
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Table 2.12. Selected subject characteristics, at the time of each subject’s first B-type natriuretic peptide 
(BNP) laboratory measurement, by whether or not the eMERGE algorithm was applied 
 
Total subjects n = 3938 
eMERGE not applied 
n = 1780 
eMERGE applied 
n = 2158 
 
p-value* 
Sex, n (%) 
    Male 










Race/ethnicity, n (%) 
    White 
    Black 
    Hispanic 
    Other 

























Community type, n (%) 
    Borough 
    Township 














deprivation (CSD),* SD units, 
quartiles 
     1 
     2 
     3 














Patient status at end of study, n (%) 
   Alive 




































Total subjects n = 3938 
eMERGE not applied 
n = 1780 
eMERGE applied 
n = 2158 
 
p-value* 
Smoking status at event, n (%) 
    Current 
    Former 





















Body mass index (BMI) at event, 















 < 0.0001 
*p-value calculated by chi2 for categorical variables and analysis of variance (ANOVA) F-test for continuous 
variables 
* Community socioeconomic deprivation (CSD) was calculated based on US Census indicators; further information 
is detailed in the text 
†Major & minor roads were identified from the Federal Highway Administration databases; distance from subject’s 
residential address to these roads was calculated in meters 
‡ Medical Assistance, a surrogate for family socioeconomic status, was calculated based on health insurance 
status at the time of encounters 
§ Days from first heart failure diagnosis to the date of case or control event 
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Table 2.13. Selected diagnoses and medication use at time of first B-type natriuretic peptide (BNP) 
laboratory order, by heart failure phenotype status 
 
Total subjects n = 3938 
eMERGE not applied 
n = 1780 
eMERGE applied 
n = 2158 
 
p-value* 
Medication use, by class, n (%) 
    Antihypertensive 
    Antihyperlipidemic 













Chronic obstructive pulmonary 




474 (22.0)  
 
0.5 
Coronary artery disease (CAD), n (%) 272 (15.3) 532 (24.7) < 0.001 
Hypertension, n (%) 1090 (61.2) 1481 (68.6) < 0.001 
Myocardial infarction, n (%) 126 (7.1) 234 (10.8) < 0.001 
Valve disorder, n (%) 254 (14.3) 497 (23.0) < 0.001 
Type 2 diabetes, n (%) 655 (36.8) 922 (42.7) < 0.001 
Chronic kidney disease, n (%) 706 (39.7) 975 (45.2) < 0.001 








* p-value obtained from either chi2 tests (for categorical variables) or analysis of variance (ANOVA) F-test (for 
continuous variables), comparing subjects who had the phenotyping algorithm (eMERGE) applied vs. those who 
did not have the necessary information to have this algorithm applied 
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In both the hospitalization and BNP analyses, it is clear that subjects who had the 
eMERGE algorithm applied tended to have more comorbidities, medications, and a 
longer duration of heart failure (as calculated from the EHR) (Tables 2.10-2.13). In both 
of these analyses, a smaller proportion of subjects who had the eMERGE algorithm 
applied were female and lived in census tracts (cities). It is possible that analyses reliant 
on the eMERGE algorithm (i.e., Chapter 5a and Chapter 5b analyses) could be biased 
away from the null because of these differences, which suggested that those who had 
the eMERGE algorithm applied had more frequent utilization of health care services. 
However, in Chapter 5, I explore these differences in greater detail and by subjects who 
had a confirmed HFpEF or HFrEF phenotype, within the context of the hospitalization 
and the BNP analyses. Additionally, I evaluated all of the variables (e.g., comorbidities, 
sex, duration of heart failure) that differed between subjects who had the eMERGE 
algorithm applied and subjects who did not have the eMERGE algorithm applied in 
Chapters 5a and 5b.  
2.8 DATA ANALYSIS 
The primary descriptions of the statistical analyses are in the relevant specific 
chapters. Here I describe additional details not included in those chapters. 
2.8.1 UNIVARIATE ANALYSIS AND BIVARIATE ASSOCIATIONS 
For all variables considered in Chapters 3-5, we examined distributions and 
measures of central tendency, range, and dispersion across all available data; across 
study subjects (often using one randomly selected observation per person to evaluate 
the distributions of time-varying variables across study subjects); and within individual 
subjects over time, where longitudinal data were available. We used scatterplots and 
Spearman’s correlation coefficients to examine bivariate associations for continuous 
variables; stratified histogram plots for examining bivariate associations between 
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categorical and continuous variables; and frequency tables with chi2 tests for evaluating 
bivariate associations between categorical variables.  
2.8.2 INVERSE PROBABILITY WEIGHTING TO ACCOUNT FOR SELECTION BIAS IN 
HOSPITALIZATION AND BNP STUDY 
In Figure 2.1, I note that 13,183 individuals were “eligible for selection” into the 
analyses presented in Chapters 3-5. To account for any potential selection bias in 
analyses presented in Chapter 4 compared to Chapter 3, I generated inverse 
probability weights from logistic regression models that predicted the probability of being 
selected in the BNP analysis (Chapter 4). These logistic regression models adjusted for 
smoking status (ever vs. never), total contact time with the EHR (centered and centered-
squared), Charlson index (centered and centered-squared), age at end of study 
(centered), diagnoses of: myocardial infarction, coronary artery disease, valve disorder, 
chronic kidney disease, and ever receiving anticoagulant medication. The Pearson’s 
goodness of fit test for this model yielded a p-value of 0.33 and the Hosmer-Lemeshow 
goodneww of fit test, using 10 groups, yielded a p-value of 0.75, indicating that the 
model adequately fit these data. We calculated the predicted probabilities of inclusion in 
the BNP analysis from this model (described in greater detail in Chapter 4), and we 
used the inverse of these probabilities in a weighted analysis accounting for the 
probability of inclusion. The results of sensitivity analyses that account for these inverse-





1. Casey, J.A., et al., Using Electronic Health Records for Population Health 
Research: A Review of Methods and Applications. Annual Review of Public 
Health, 2016. 37(1): p. 61-81. 
2. Bielinski, S.J., et al., A Robust e-Epidemiology Tool in Phenotyping Heart Failure 
with Differentiation for Preserved and Reduced Ejection Fraction: the Electronic 
Medical Records and Genomics (eMERGE) Network. 2015(1937-5395 
(Electronic)). 
3. Institute, G.M. eMERGE Electronic Medical Records and Genomics Network. 
2019  [cited 2019; Available from: 
https://www.geisinger.edu/research/departments-and-centers/gmi/emerge-
electronic-medical-records-and-genomics-network. 
4. Health;, N.I.o. Electronic Medical Records and Genomics Network (eMERGE). 
2019; Available from: https://www.genome.gov/Funded-Programs-
Projects/Electronic-Medical-Records-and-Genomics-Network-eMERGE. 
5. Weber, M., C. Mitrovic V Fau - Hamm, and C. Hamm, B-type natriuretic peptide 
and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary 
artery disease. (1205-6626 (Print)). 
6. Maries, L. and I. Manitiu, Diagnostic and prognostic values of B-type natriuretic 
peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). 
(1680-0745 (Electronic)). 
7. Bielinski;, S.J., Heart Failure (HF) with Differentiation between Preserved and 
Reduced Ejection Fraction, in PheKB, M. Clinic., Editor. 2013. 
8. Rosamond Wayne, D., et al., Classification of Heart Failure in the Atherosclerosis 
Risk in Communities (ARIC) Study. Circulation: Heart Failure, 2012. 5(2): p. 152-
159. 
9. Goff, D.C., Jr., et al., Congestive Heart Failure in the United States: Is There 
More Than Meets the I(CD Code)? The Corpus Christi Heart Project. JAMA 
Internal Medicine, 2000. 160(2): p. 197-202. 
10. Grijalva, C.G., et al., Computerized definitions showed high positive predictive 
values for identifying hospitalizations for congestive heart failure and selected 
infections in Medicaid enrollees with rheumatoid arthritis. Pharmacoepidemiology 
and drug safety, 2008. 17(9): p. 890-895. 
11. Casey, J.A., et al., Greenness and Birth Outcomes in a Range of Pennsylvania 
Communities. International Journal of Environmental Research and Public 
Health, 2016. 13(3). 
12. Schwartz, B.S., et al., Body Mass Index and the Built and Social Environments in 
Children and Adolescents Using Electronic Health Records. American Journal of 
Preventive Medicine, 2011. 41(4): p. e17-e28. 
13. Liu, A.Y., et al., The contextual influence of coal abandoned mine lands in 
communities and type 2 diabetes in Pennsylvania. Health & Place, 2013. 22: p. 
115-122. 
14. Rasmussen, S.G., et al., Association Between Unconventional Natural Gas 
Development in the Marcellus Shale and Asthma Exacerbations. . JAMA Internal 
Medicine, 2016(2168-6114). 
15. Casey, J.A., et al., Unconventional Natural Gas Development and Birth 
Outcomes in Pennsylvania, USA. Epidemiology, 2015. 
16. Tustin, A.W., et al., Associations between Unconventional Natural Gas 
Development and Nasal and Sinus, Migraine Headache, and Fatigue Symptoms 
in Pennsylvania. Environ Health Perspect, 2016. 
 66 
17. Koehler, K., et al., Exposure Assessment Using Secondary Data Sources in 
Unconventional Natural Gas Development and Health Studies. Environmental 
Science & Technology, 2018. 52(10): p. 6061-6069. 
18. Medi-Span, Master Drug Data Base Documentation Manual. 2007, Indianapolis, 
Indiana. 
19. Casey, J.A., et al., Measures of SES for Electronic Health Record-based 
Research. American Journal of Preventive Medicine, 2018. 54(3): p. 430-439. 
20. Hirsch, A.G., et al., Early-life antibiotic use and subsequent diagnosis of food 
allergy and allergic diseases. Clinical and experimental allergy : journal of the 
British Society for Allergy and Clinical Immunology, 2017. 47(2): p. 236-244. 
21. Schwartz, B.S., et al., Attention deficit disorder, stimulant use, and childhood 
body mass index trajectory. Pediatrics, 2014. 133(4): p. 668-676. 
22. Charlson, M., et al., A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. (0021-9681 (Print)). 
23. Chuang, J.H., C. Friedman, and G. Hripcsak, A comparison of the Charlson 
comorbidities derived from medical language processing and administrative data, 
in Proc AMIA Symp. 2002. 
24. NASA;. NASA Distributed Active Archive Center (DAAC); MODIS Data: Terra vs. 
Aqua. 2019; Available from: https://nsidc.org/data/modis/terra_aqua_differences. 
25. American Community Survey. 2010, United States Census Bureau. 
26. Schwartz, B.S., et al., Body mass index and the built and social environments in 
children and adolescents using electronic health records. (1873-2607 
(Electronic)). 
27. Martins, L.C., et al., The effects of air pollution on cardiovascular diseases: lag 
structures. (0034-8910 (Print)). 
28. Braga, A.L., J. Zanobetti A Fau - Schwartz, and J. Schwartz, The lag structure 
between particulate air pollution and respiratory and cardiovascular deaths in 10 
US cities. (1076-2752 (Print)). 
29. Guo, B., et al., Using spatio-temporal lagged association pattern to unravel the 
acute effect of air pollution on mortality. (1879-1026 (Electronic)). 
30. de Paula Santos, U., et al., Effects of air pollution on blood pressure and heart 
rate variability: a panel study of vehicular traffic controllers in the city of Sao 




Chapter 3: Association between unconventional natural gas 
development activity and hospitalization among patients with 
heart failure in Pennsylvania, 2008-2015. 
 
Authors: Tara P. McAlexander, MPH1, Karen Bandeen-Roche, PhD, MS2,3, Jessie P. 
Buckley, PhD, MPH1,4, Jonathan Pollak, MS1, Erin D. Michos, MD, MHS3, John William 
McEvoy, MBBCh, MHS3,5, Brian S. Schwartz, MD, MS1,3,4 
 
Affiliations 
1 Department of Environmental Health and Engineering, Johns Hopkins Bloomberg 
School of Public Health, Baltimore, Maryland, United States 
2 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, 
Baltimore, Maryland, United States 
3 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, 
Maryland, United States 
4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
Baltimore, Maryland, United States 
5 National Institute for Preventive Cardiology, National University of Ireland, Galway, 
Ireland 
 
Corresponding Author: Brian S. Schwartz, Johns Hopkins Bloomberg School of Public 
Health, 615 N. Wolfe Street, Room W7041, Baltimore, Maryland 21205, email 
bschwar1@jhu.edu 




This research was supported by funding from the National Institute of Environmental 
Health Sciences (NIEHS) training grant # 5T32ES007141-32 (T McAlexander) and 
NIEHS grant ES023675-01 (PI: B Schwartz). Additional support was provided by the 
Degenstein foundation for the compiling of well data. The authors would like to thank 
Joseph DeWalle, Dione Mercer, and staff of the Geisinger Environmental Health Institute 
for their assistance in obtaining data essential for this study.  
 
Competing financial interest disclosure: The authors declare that they have no 




Background: A growing number of epidemiologic studies report associations between 
unconventional natural gas development (UNGD) activity and several health outcomes; 
hypothesized underlying pathways include air pollution, noise and stress. Heart failure 
subjects are susceptible to environmental stressors and hospitalization for 
exacerbations, making it a logical outcome for investigation. 
Objectives: To evaluate the association between measures of UNGD activity and the 
odds of hospitalization among heart failure subjects living in Pennsylvania, a state with 
active UNGD in the Marcellus shale.  
Methods: We conducted a nested case-control study of hospitalization among persons 
with heart failure seen at Geisinger from 2008 to 2015 using electronic health record 
(EHR) data. We frequency-matched persons with heart failure and hospitalizations to 
randomly selected control encounters among heart failure subjects without 
hospitalizations, by age, sex, and year. We assigned metrics of UNGD activity by phase 
in the 30 days prior to hospitalization or control encounter and compared the odds of 
hospitalization by quartile, adjusting for confounding variables with particular attention to 
potential spatial and temporal confounding. 
Results: We identified 9,054 heart failure subjects, 47.7% (n = 4,321) of whom were 
female, with a mean (SD) age of 71.1 (SD) years and 5,839 hospitalizations for heart 
failure. Comparing the 4th to 1st quartiles of UNGD activity, we found associations with 
hospitalization (OR [95% CI]) of 1.70 (1.35 - 2.13), 0.97 (0.75-1.27), 1.80 (1.35-2.40), 
and 1.62 (1.07-2.45) for the phases of pad preparation, well drilling, well stimulation, and 
natural gas production, respectively. Several metrics evidenced exposure-effect relations 
across UNGD quartiles.  
Conclusions: This is the first study to directly assess hospitalization among heart failure 
subjects in relation to UNGD in a large patient population. Most prior studies of UNGD 
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and health focused on health conditions that mainly affected young and middle-aged 
persons; heart failure is a condition that mainly affects older persons, who should be 
more susceptible to the exposures that arise from UNGD, Three of four phases of UNGD 
activity were associated with increased odds of hospitalization, findings which are both 
biologically plausible and consistent with a growing body of epidemiological evidence 
suggesting negative health effects are associated with UNGD activity. 
 
3.2 INTRODUCTION 
Heart failure is a common chronic condition which effects over 5.7 million 
Americans and 25 million persons globally [73-75, 204]. Known risk factors for heart 
failure include coronary artery disease, hypertension, ischemic heart disease, atrial 
fibrillation, diabetes [86, 89], chronic obstructive pulmonary disease [205], depression 
and anxiety [143, 206, 207], and lifestyle factors that both directly and indirectly worsen 
heart failure including tobacco smoking, lack of physical activity, and poor diet [73, 208]. 
Collectively, heart failure costs the US health care system over $30 billion in direct (e.g., 
pharmaceuticals, health care services) and indirect (e.g., missed work days) costs 
annually [20, 21, 73].  
Clinically, there are two main phenotypes of heart failure: heart failure with 
reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction 
(HFpEF) [209, 210].  In both phenotypes, heart failure subjects have impairment of the 
left ventricle’s pump capacity, resulting in reduced blood flow to critical organs (e.g., 
kidneys, lungs, brain) [211]. Symptoms of acute heart failure include but are not limited 
to: dyspnea, fatigue, irregular heartbeat, persistent cough, and fluid retention, swelling of 
the legs, and rapid weight gain due to reduced blood flow to these vital organs [212]. 
Given these symptoms, subjects with heart failure are at risk for frequent hospitalizations 
and mortality due to worsening of left ventricular pump function and the co-occurrence of 
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related conditions (e.g., hypertension, diabetes, coronary artery disease) [89]. 
Understanding the full spectrum of risk factors associated with these severe and acute 
symptoms is thus vitally important for improved patient outcomes and quality of life. 
Persons living with heart failure are also susceptible to environmental exposures 
[213]. A growing number of epidemiologic studies have found associations between 
environmental factors, particularly air pollution (i.e., PM2.5), and hospital admissions for 
heart failure [26, 130, 214, 215]. Suspected biologic mechanisms underlying these 
associations include systemic inflammation, direct tissue injury, ischemia, arrhythmias, 
and thrombosis [213, 216]. There is also a growing body of literature linking 
environmental noise exposure to the worsening of hypertension, coronary artery 
disease, and heart rate variability [217, 218]. Psychosocial stress has also been linked to 
coronary artery disease and hypertension [143, 219], two important risk factors for heart 
failure. 
Unconventional natural gas development (UNGD) is a growing industry 
worldwide, and Pennsylvania, US has seen substantial growth, where over 9000 wells 
have been drilled in the Marcellus shale since 2004 [61]. UNGD has a number of 
environmental impacts such as increased noise and air pollution levels (e.g., PM2.5, 
oxides of nitrogen [NOx], oxides of sulfur [SOx], volatile organic compounds [VOCs], 
polycyclic aromatic hydrocarbons [PAHs]) associated with its several stages [22-25]. A 
growing literature has identified associations between metrics of UNGD activity and 
health outcomes including low birth weight, small for gestational age [9, 10]; preterm 
birth [11-13]; congenital defects [14]; three types of asthma exacerbations [15, 16]; and 
migraine, fatigue, nasal and sinus symptoms (Tustin, Hirsch et al. 2016), and depression 
symptoms [18]. None of these studies have concurrently measured exposure elements 
to identify the likely impact pathways, but the existing health literature clearly documents 
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the biological plausibility of these health impacts through several candidate mechanisms 
[18, 27, 66]. 
The purpose of this study was to evaluate associations between UNGD activity 
metrics, by phase of development, and hospitalization among subjects with heart failure. 
To the best of our knowledge, no prior epidemiologic studies have examined 
associations between measures of UNGD activity and heart failure outcomes in a large 
subject population.  
 
3.3 METHODS AND MEASURES 
3.3.1 STUDY POPULATION AND STUDY DESIGN 
We conducted a case-control study, comparing persons with heart failure with 
and without hospitalizations, using electronic health record (EHR) data from Geisinger, 
an integrated health system with multiple inpatient and outpatient centers in 
Pennsylvania, for January 1, 2005 to July 31, 2015. The study was nested within the 
general-population-representative, open, dynamic cohort that persons with a Geisinger 
primary care provider represent [182]. We searched patient records for at least one 
International Classification of Disease (ICD-9) diagnosis code of 428.x for heart failure 
from inpatient, outpatient, or emergency department (ED) encounters and medication 
records, excluding those from laboratory orders and the EHR problem list. We identified 
16,098 subjects with a heart failure ICD-9 code. From these 16,098 subjects, we 
excluded 435 individuals with ICD-9 codes for congenital heart anomalies (n = 424) and 
endocardial fibroelastosis (n = 14) (746.x or 425.3, respectively). We also excluded 321 
individuals who did not reside in Pennsylvania or did not have geocoded residential 
information, and 2 individuals with missing demographic information. The analysis was 
limited to 2008 to 2015, resulting in exclusion of 2071 more persons with heart failure, to 
coincide with the onset of UNGD activity in Pennsylvania, resulting in 13,183 subjects. 
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We identified all events for these subjects and excluded all subjects who were not at 
least 18 years of age at the date of both the event and at time of heart failure diagnosis 
(i.e., their first ICD-9 code of “428.x”), leaving us with 13,183 subjects eligible. Lastly, we 
excluded 853 subjects who did not have an ICD-9 code for 428.x in 2008-2015. After all 
exclusions, there were 12,330 individuals who were eligible for selection in the case-
control study (Figure 3.1).  
 
3.3.2 CASE IDENTIFICATION 
From the pool of 12,330 eligible subjects with heart failure, we identified 5,839 
subjects who were hospitalized for heart failure during the study period (i.e., these 
subjects had the 428.x ICD code associated with an inpatient encounter or an encounter 
designated as emergency to inpatient). We included only incident heart failure 
hospitalizations, i.e., only the first hospitalization recorded within the study period, in this 
analysis.  
3.3.3 CONTROL SELECTION 
Subjects with heart failure were eligible for control selection if they had not been 
hospitalized for heart failure up to 30 days before their randomly selected encounter date 
in the year of the case’s heart failure hospitalization. To limit the potential for 
confounding by age, sex, and calendar year, we used incidence density sampling with 
replacement of selected controls and frequency-matched cases to control encounters by 
these variables [220]. Age was categorized for frequency-matching as: > 18–30 years, > 
30–40 years, > 40–50 years, > 50–60 years, > 60–70 years, > 70–80 years, > 80–90 
years, and > 90–100 years. Subjects who did not yet or did not ever have a 
hospitalization for heart failure were eligible for control selection encounters, which 
included any outpatient visit or medication order that did not include a heart failure 
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diagnosis; a subject was able to be selected only once per calendar year for a maximum 
of five control encounters. Other aspects of timing were not used in the control selection 
process, however we evaluated EHR contact time as well as duration of heart failure 
diagnosis in our model building process. Using this frequency-matching strategy, we 
randomly selected 5839 control encounters in the year of hospitalization for cases 
because time-varying covariates required a date for calculation. In sensitivity analyses, 
analysis was repeated using a 4:1 control to case matching ratio to optimize power; this 
was not the primary analysis because, in order to match at a 4:1 ratio according to age 
category, sex, and year, control subjects in the tails of the age distribution were used 
multiple times, and we wanted to limit any undue influence from utilizing some controls 
multiple times in our primary analysis. 
 
3.3.4 COVARIATE ASSIGNMENT 
Information for time-invariant subject characteristics, such as sex and 
race/ethnicity, were available from the EHR demographics file. We calculated a number 
of time-varying covariates for all subjects in the analysis, including age at hospitalization 
or control encounter date, smoking status (never, previous, current), Charlson index of 
morbidity [221], and receipt of Medical Assistance (a surrogate for family socioeconomic 
status) as previously reported [192, 222]. We also identified the presence of co-morbid 
conditions based on at least two encounter diagnosis codes (ICD-9) on any date 
between January 1, 2008 and the day of the hospitalization or control encounter date, 
including type 2 diabetes (250.x), hypertension (401.9), chronic obstructive pulmonary 
disease (496.x), coronary artery disease (414.01), valve disorders (V43.3, 424.x, 396.9, 
391.1, 392.0, 390, 395.9, or 421.9), previous myocardial infarction (410.x), or diagnosis 
of chronic kidney disease (585.x).  
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We calculated the duration (days) from subjects’ first contact with Geisinger to 
the date of the hospitalization or encounter date. Season of hospitalization or control 
encounter was defined as: winter (December 22 – March 20); spring (March 21 – June 
20); summer (June 21 – September 21); and fall (September 22 – December 21). We 
used medication records to identify current medication use by verifying that the date of 
hospitalization or control encounter date was between the start and end dates of the 
medication order. Current medication use was identified for the following classes of 
medications: antihypertensive, antihyperlidemic, and anticoagulant, all of which could 
impact a subject’s experience of symptoms, exacerbation status, and likelihood of 
hospitalization [223-225].  
We used available height and weight measurements to calculate body mass 
index (BMI, kg/m2) at the date closest to, but no more than 365 days prior to, either the 
heart failure hospitalization date or control encounter date. Only biologically plausible 
values were used (height from 36 to 90 inches, weight from 50 to 600 pounds). For 
individuals without sufficient height and weight data to calculate BMI within one year of 
the case event or control encounter date (n = 339, or approximately 3.7% of the 9054 
study subjects), we imputed BMI using multiple imputation based on age, sex, and 
receipt of Medical Assistance [226]. 
3.3.5 ASSIGNMENT OF COMMUNITY METRICS 
We used subjects’ residential addresses from the EHR to obtain latitude and 
longitude coordinates as previously reported [13, 190, 192]. These coordinates were 
used to identify the community type of the residential location as township, borough, or 
city, first using minor civil division shape files, and then further subdivided residential 
locations in cities to the census tract using census tract shape files, as previously 
reported [161, 189, 198]. Residential locations were also grouped into five sub-regions of 
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our 38-county study area consisting of 5 to 15 contiguous counties each, identified as 
northeast, southeast, central, southwest, and northwest, to account for potential spatial 
confounding at a scale larger than the level of community type. This variable was 
created after visualizing assigned UNGD activity metric values across the study area 
and observing different spatial distributions comparing the spud metric (i.e., drilling 
activity) to the production metric (i.e., cumulative natural gas production). For townships, 
boroughs, and census tracts in cities we calculated community socioeconomic 
deprivation using 2010-2014 data from the US Census American Community Survey as 
previously reported [161, 189, 190, 198]. Community socioeconomic deprivation was 
standardized for direction such that higher values represented more deprivation and was 
in standard deviation units (after z-transformation of its components before summing). 
CSD was categorized into quartiles for analysis based on the entire study population.  
We also obtained the locations of major (i.e., highways) and minor roads (i.e., 
arterial and local roads) from the Federal Highway Administration. Using ArcGIS (ESRI 
2011. ArcGIS Desktop: Release 10. Redlands, CA: Environmental Systems Research 
Institute), we calculated the Euclidian distance from each subject’s residential address to 
both major and minor roads separately, in meters. In the same manner, we also 
obtained the geographic locations of all Geisinger facilities, and we calculated, in meters, 
the distance from each subject’s residential address to the location of the nearest 
hospital or clinic. 
3.3.6 UNGD ACTIVITY ASSIGNMENT 
UNGD activity metric data and calculation have been previously reported [190]. 
In brief, we obtained data from the Pennsylvania Department of Environmental 
Protection on UNGD wells for the years 2005 to 2015, documenting the dates and 
locations of four phases of UNGD activity: well pad preparation (e.g., clearing of site, 
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delivery of equipment and personnel), drilling of well (i.e., starting at the spud date), 
stimulation (hydraulic fracturing) of well, and production of natural gas. We assigned 
UNGD activity metrics using R (R Core Team, 2014. R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria) that 
incorporated number, phase, size, and location of wells, and divided by the squared 
distance from residential locations to all wells in the state, as previously reported  [13, 
15, 17, 62, 190]. UNGD activity assignments used Equation 1 [15]  where j identified 
subject, n was the number of wells, and d2ij was the squared distance (m
2) between 
subject j ‘s residential address and well i.  





For the pad preparation and spud activity metric, mi = 1. For the stimulation and 
production metrics, mi was total well depth (m) or total daily volume of natural gas (m
3) 
produced for well i, respectively [15]. We calculated each of these activity metrics for a 
duration of 30 days before the hospitalization or control encounter date with a one day 
lag (i.e., activity was not counted in the day before, Figure 3.2). A one-day lag was 
chosen because we hypothesized that there would be a lag between UNGD activity and 
the worsening of heart failure symptoms that would lead a subject to seek care and 
become hospitalized, which is consistent with many studies of air pollution and 
respiratory and cardiovascular outcomes that also use a relatively short exposure period 
with a 1-day lag prior to hospitalization [26, 142, 227]. We also examined correlations 
between various durations to understand the extent to which these UNGD activity 
metrics were correlated (see Chapter 2, Section 2.5).  
3.3.7 STATISTICAL METHODS 
 We compared the distribution of individual-level covariates, community metrics 
(i.e., community socioeconomic deprivation, distance to roads and hospitals), and UNGD 
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activity metrics by case and control subjects. Because our study population resided 
throughout Pennsylvania, and because our study spanned 7.5 years, we examined the 
distributions of UNGD activity metrics by phase, by quartile of each phase, and by year 
to understand any temporal patterns in the distribution of quartiles of UNGD activity 
metrics. Similarly, we examined the frequencies of subjects in each quartile of the four 
phases of UNGD activity by heart failure hospitalization status (i.e., comparing subjects 
who were hospitalized for heart failure at any point to those who were never hospitalized 
for heart failure) to understand the crude associations before developing a model for 
heart failure hospitalization.  
We used the melogit function in Stata v13.1 (StataCorp LP 2016. Stata/MP 13.1. 
College Station, TX.) to develop multi-level logistic regression models that estimated the 
odds of hospitalization, comparing cases to controls, by quartile of UNGD activity. We 
included random intercepts for subject (to account for correlation within individuals over 
time who were included in analysis more than once as control then as case) and 
community type (to account for the correlation of measures for persons clustered in 
communities). We evaluated non-linearity for continuous variables (e.g., BMI, duration of 
heart failure, and distance to road measures) by evaluating linear, quadratic, and cubic 
terms after centering of the variable; higher order terms were only included if the 
association crossed an inferential threshold (p < 0.05). Age was included in models as 
the categorized frequency-matching variable, although we did evaluate age as a linear, 
quadratic and cubic term after centering, in the same manner as we evaluated other 
linear variables. 
Our initial model (Table 3.6, Model 1) included the following variables: sex 
(female vs. male), age category at hospitalization or control encounter date (as 
previously described), as well as race/ethnicity (nonwhite vs. white), BMI, and Medical 
Assistance based on prior evidence that these are strongly associated with 
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hospitalization for heart failure [228]. Additional models evaluated, in a stepwise fashion, 
the inclusion of year of hospitalization or control encounter (Table 3.6, Model 2); 
geographic region (Table 3.6, Model 3); both year and region (Table 3.6, Model 4); and 
lastly, the additional inclusion of season, EHR contact time (the date of a subject’s 
hospitalization or control encounter minus the date of the subject’s first observation in 
the EHR), and distance to nearest hospital or clinic (Table 3.6, Model 5). We also 
evaluated models that additionally adjusted for distance to both major and minor roads. 
We retained variables in the model if they changed the effect estimates for any of the 
four UNGD activity metrics by more than 5%. Model fit was assessed by comparing the 
Akaike’s information criterion (AIC) and examining the distribution of model residuals 
from the fixed effects portion of our models. We did not include models that adjusted for 
medication use or comorbidities in our main analysis (Table 6) because we 
hypothesized that some of these (e.g., diagnoses of myocardial infarction or 
hypertension, anti-hypertensive medications) could be both measures of disease 
severity and potential effect modifiers, and also potentially mediators of the association 
between UNGD activity and HF hospitalization. Therefore, we evaluated the impact of 
comorbid conditions and relevant medication use in sensitivity analyses.  
3.3.8 SENSITIVITY ANALYSES 
We conducted several sensitivity analyses. First, we evaluated multilevel logistic 
regression models that included only one random intercept for each subject’s place type 
identifier, whereas our original models included two random intercepts for both place 
type identifiers and for each subject included in the model (Table 3.7, Model 1). Second, 
to assess the extent to which very young or very old subjects could be influencing our 
results, we evaluated associations between UNGD activity and hospitalization for heart 
failure, including only subjects in the age range of 40-80 years (Table 3.7, Model 2). 
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Third, we included a variable for the number of days since a subject’s heart failure 
diagnosis instead of duration of contact with the health care system (Table 3.7, Model 3) 
to evaluate the extent to which our results were affected by differing ways of measuring 
a subject’s duration of care ascertained from the EHR. Fourth, to increase our statistical 
power to detect an association between UNGD activity and hospitalization for heart 
failure, we replicated our study sample using a 4:1 instead of a 1:1 matching strategy 
and evaluated our final models in this 4:1 matched sample using both days since heart 
failure diagnosis (Table 3.8, Model 1) and duration of contact with the health care 
system (Table 3.8, Model 2). Fifth, we evaluated a model that included inverse 
probability weights (Table 3.9) to account for potential selection bias from the 13,183 
subjects eligible for either this case-control study or the Chapter 4 study of laboratory 
measures (see Chapter 3.2, Figure 1). Sixth, to evaluate whether spatial confounding 
could account for our observed associations, we conducted a negative exposure control 
analysis (Figure 3.6). In this analysis, we assigned UNGD activity metrics in a 
temporally nonsensical way, such that the UNGD activity metrics could not have caused 
heart failure hospitalization [229, 230]. We limited our analyses to events from 2008 and 
2009, and we assigned UNGD activity to these events from six years after the 
hospitalization or control encounter date (i.e., 2014 and 2015 UNGD activity). Lastly, we 
evaluated the impact of medication use (Table 3.10) and comorbid diagnoses (Table 
3.11) on the associations between UNGD activity metrics and hospitalization for heart 
failure. All analyses were conducted using Stata v13.1 (StataCorp LP 2016. Stata/MP 
13.1. College Station, TX.), R (R Core Team, 2014. R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria), and 
ArcGIS (ESRI 2011. ArcGIS Desktop: Release 10. Redlands, CA: Environmental 
Systems Research Institute).  
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3.4 RESULTS  
3.4.1 DESCRIPTION OF STUDY SUBJECTS  
Of the 12,330 subjects eligible for selection into this study (Figure 3.1), 5839 had 
a first hospitalization for heart failure between 2008-2015, and were thus identified as 
the cases for this analysis. Because we used a 1:1 control to case frequency matching 
strategy based on year, sex, and age at event, there were some controls that were used 
multiple times to meet these criteria (Table 3.1). As years progressed in the study 
period, the mean number of times that subjects without hospitalizations were selected as 
a control steadily increased (Table 3.1).  Similarly, the number of subjects eligible for 
selection into the study increased with year, with the exception of the year 2015, 
because our 2015 data only included hospitalizations through July 31, 2015. This is also 
evident in the relatively smaller number of hospitalizations included in 2015 compared to 
earlier years (Table 3.1).   
Nearly half (47.5 %) of the eligible heart failure subjects had at least one 
hospitalization for heart failure during the study period. There were significant 
differences between subjects with and without hospitalizations for mean duration of 
contact with the health system and mean distance to major and minor roads, as well as 
the distribution of subjects by community type, smoking status, and proportion deceased 
at the end of the study period, according to analysis of variance (ANOVA) (Table 3.2). 
However, the differences in subjects with and without hospitalization for duration of 
contact; distance to major and minor roads; and smoking status, were not clinically 
meaningful (Table 3.2). Differences between subjects with and without hospitalization by 
community type, however, appeared to be meaningfully different, with 9.3 % of subjects 
who were never hospitalized living in census tracts vs. 12.9% who were ever 
hospitalized for heart failure (Table 3.2). This is a major reason for including a random 
intercept for each subject’s community type identifier in primary models of 
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hospitalization. We also compared the presence of medications and comorbidities by 
subjects with and without hospitalizations and observed statistically significant 
differences in antihypertensive medication use, with a higher proportion of usage 
(44.1%) in subjects who were never hospitalized compared to those who were (39.8%) 
hospitalized for heart failure (Table 3.3). The presence of a number of comorbidities also 
differed significantly comparing subjects who were hospitalized to those who were not, 
with a higher proportion of subjects having chronic obstructive pulmonary disease, 
coronary artery disease, hypertension, valve disorders, type 2 diabetes, and chronic 
kidney disease, comparing those who were ever hospitalized to those who never were 
(Table 3.3). Lastly, subjects who were hospitalized for heart failure had slightly higher 
values for the Charlson Index of morbidity, which is driven by the presence of these 
other comorbidities (Table 3.3).  
3.4.2 EVALUATION OF TEMPORAL AND SPATIAL CHARACTERISTICS OF UNGD 
ACTIVITY METRICS 
The proportion of persons in the 4th quartile of the UNGD activity metrics was 
greatest in the years 2010-2012 for the pad preparation, spud, and stimulation metrics 
(Table 3.4). The production metric was the only metric that did not have a termination 
date and thus accumulates over time, which is why no subjects were within the 1st 
quartile of UNGD production activity in the later years of the study (Table 3.4). The 
temporal trends in UNGD activity by phase support the use of our control to case 
frequency matching strategy, where control encounters were matched to cases based 
on year of event in addition to sex and age category. Additionally, since the temporal 
trends in each of the four UNGD metrics were different, estimating the odds of 
hospitalization in this study separately for each of the four UNGD activity metrics 
reduces concern about the temporal patterns in each of the metrics.  
When we examined the distributions of subjects who were ever hospitalized, 
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never hospitalized, and those who were selected as a control by UNGD activity metric 
quartiles (Table 3.5), we found that a higher proportion of cases were in the 4th quartile 
of UNGD activity for the pad preparation metric, the stimulation metric, and the 
production metric compared to subjects who were never hospitalized and those who 
were selected as a control. The proportion of subjects in the 4th quartile of the spud 
(drilling) metric, however, was relatively lower in those who were ever hospitalized 
compared to those who only served as a control or served as a control and then a case 
later (Table 3.5).  
Similar to the temporal patterns in the UNGD activity metrics, spatial patterns 
varied depending on the metric considered; subjects in the 4th quartile of the spud metric 
(Figure 3.3) were more likely to be located in the central, southwest and northwest 
regions (Figure 3.5), whereas subjects in the 4th quartile of the production metric (Figure 
3.4) were more concentrated in the northeast, southeast, and central regions. These 
spatial patterns by UNGD activity metrics motivated us to evaluate how inclusion of a 
regional variable, which could account for spatial variability at a level beyond each 
subject’s community type or individual county, in our final models of UNGD activity and 
heart failure hospitalization changed UNGD associations.  
 
3.4.3 ADJUSTED ASSOCIATIONS OF UNGD ACTIVITY METRICS WITH HEART FAILURE 
HOSPITALIZATION 
We observed exposure-effect relations, with increasing levels of covariate 
control, for three of the four UNGD activity metrics with the adjusted odds of heart failure 
hospitalization (Table 3.6). After adjustment for a priori covariates (Table 3.6, Model 1), 
all four UNGD metrics had at least some significant associations in individual quartiles, 
but the clearest exposure-effect relations were observed for the stimulation and 
production metrics. After addition of year of hospitalization or control encounter date 
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(Table 3.6, Model 2), exposure-effect relations for stimulation and production 
strengthened and one for pad preparation emerged. For the spud metric, a significant 
protective association emerged in the 4th quartile. After addition of a regional indicator 
variable (Figure 3.5), all associations were attenuated (Table 3.6, Model 3), and the 4th 
quartile protective association for the spud metric was no longer present. When both 
region and year (Table 3.6, Model 4) and then observation time, distance to nearest 
Geisinger hospital or clinic, and season (Table 3.6, Model 5), were added to models, 
associations with spud were no longer present, while those for pad preparation, 
stimulation, and production metrics evidenced exposure-effect relations. Additional 
adjustment for distance to major or minor road did not substantively change either 
associations or inferences (results not shown). 
3.4.5 SENSITIVITY ANALYSES 
Associations from models with only one random intercept for a subject’s 
community identifier (Table 3.7, Model 1) or with age restrictions (Table 3.7, Models 2 
and 3) were inferentially similar to the results from our primary models (Table 3.6). We 
did notice, however, that the adjustment for duration of heart failure (i.e., the date of 
encounter minus the date of first heart failure diagnosis) in Table 3.7, Model 3 resulted 
in smaller effect estimates compared to the use of duration of contact with the health 
care system (Table 3.7, Model 2). However, these differences did not exceed a 10% 
change in effect estimates and did not impact the inference from these models.  
Associations from models from 4:1 control to case matching (Table 3.8) were 
substantively similar to those of the primary analysis (Table 3.6), with the exception that, 
in the 4:1 matched analysis, we observed exposure-effect relations for the spud metric 
(Table 3.8). The negative exposure control analysis did not reveal associations between 
UNGD activity metrics from 2014 and 2015 assigned to events six years before (Figure 
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3.6), although associations for the 4th quartile of UNGD production activity showed 
increased odds of hospitalization (OR (95% CI): 1.35 (1.00, 1.82).  
Additional adjustment for medication use by class (Table 3.9) or selected 
comorbidities (Table 3.10) did not substantively change associations or inferences 
regarding associations between UNGD activity phases, by quartile, and odds of 
hospitalization. It is worth noting that adjustment for coronary artery disease and for 
chronic kidney disease (Table 3.10) yielded slightly higher odds ratios for hospitalization 
with each metric of UNGD activity, except for the spud metric, which was consistently 
null. Adjustment for hypertension diagnoses (Table 3.10) also had a minor effect on the 
odds ratios, which slightly reduced the odds ratios for hospitalization across all metrics.  
3.5 DISCUSSION 
The goal of this analysis was to evaluate the adjusted associations between 
metrics of UNGD activity and hospitalization among subjects with heart failure in a large 
region of UNGD activity over approximately 10 years. To our knowledge, this question 
had never before been evaluated. The study was motivated by strong biologic rationale 
and a priori hypotheses regarding how the environmental impacts of UNGD [2, 17, 60] 
could affect cardiovascular health. Our findings support candidate exposure pathways of 
air pollution and stress, and they suggest that individuals living with heart failure are 
more likely to be hospitalized when exposed to greater UNGD activity. To our 
knowledge, this is the first study of UNGD in relation to a health outcome that primarily 
affects older persons, who likely would be more susceptible to the exposures associated 
with UNGD. The findings are thus an interesting and important contribution to the 
expanding literature of UNGD and health. 
We observed exposure-effect relations with quartile of UNGD activity and odds of 
hospitalization for heart failure. These effects were robust to increasing spatiotemporal 
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covariate adjustment and several sensitivity analyses. The strongest and most robust 
associations (OR [95% CI]) were observed in the 4th (vs. 1st) quartile of the pad 
preparation, stimulation, and production metrics, as 1.70 (95% CI: 1.35, 2.13), 1.80 (95% 
CI: 1.35, 2.40), and 1.62 (95% CI: 1.07, 2.45), respectively (Table 3.6, Model 5). 
Because our UNGD activity metrics had strong temporal trends (Table 3.4) and spatial 
patterns (Figures 3.3 and 3.4), we believe that the adjustment for year and region is 
necessary and sufficient given that quartiles of UNGD activity were well represented 
across regions. The effect of adjusting for these variables is especially evident in the 
differing associations between Models 1-4 in Table 3.6 which we believe reflect the 
underlying spatiotemporal trends in the data. In Models 1-5, we still observed consistent 
exposure-effect relations with quartile of UNGD activity for the pad preparation, 
stimulation, and production metrics, across all models. We consistently found null 
associations with the spud metric, except for in our 4:1 control to case matched 
sensitivity analysis.  
To assess whether unmeasured spatial confounding could account for our 
associations, we completed a negative exposure control analysis, assigning UNGD 
activity metrics from 2014 and 2015 to hospitalizations and matched control dates in 
2008 and 2009 (Figure 3.6). If there was time-invariant spatial confounding, that is, 
features of people in places or places themselves that differed geographically, we would 
expect such an analysis to show associations of UNGD activity with case status even 
though the causal temporality requirement would be violated. In the negative exposure 
control analysis, UNGD activity assigned in this way was not associated with earlier 
hospitalizations. We did not perform negative outcome control analyses (i.e., evaluating 
UNGD activity in relation to a biologically implausible outcome) because these have 
been conducted in this region using the same UNGD activity metrics and Geisinger data 
as used in this study, and all have found null associations, for diarrheal illness [15], skin 
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and soft tissue infections [13], and cold/flu, ear pain, or bad breath symptoms [17].  
We had initially suspected that medication classes and comorbidities would 
modify associations between UNGD activity and hospitalization for heart failure. As 
effect modifiers, medications and co-occurring conditions (such as those listed in Table 
3.3) could theoretically impact the association between UNGD activity and 
hospitalization. However, models that adjusted for each of these medication classes 
(Table 3.9) and comorbid conditions (Table 3.10) individually did not substantially 
change inference of the exposure-effect relations between UNGD activity and 
hospitalization for heart failure, and we did not observe any effect modification by 
medication use in models that included UNGD cross products. Models that adjusted for 
coronary artery disease and for chronic kidney disease resulted in slightly higher odds 
ratios for hospitalization by quartile of UNGD activity (Table 3.11), but this is probably 
because both of these conditions have an independent association with hospitalization. 
Across all models, including those from the several sensitivity analyses (Tables 3.7-
3.10, Figure 3.6), we consistently saw exposure-effect relations for the pad preparation, 
stimulation, and production metrics and hospitalization. 
The body of epidemiologic evidence demonstrating that UNGD activity is 
associated with adverse health outcomes is growing. The findings from this study are 
consistent with the majority of epidemiology studies on UNGD in Pennsylvania 
demonstrating biologically-plausible associations with health outcomes. These include 
nasal and sinus, migraine headache, and fatigue symptoms (Tustin, Hirsch et al. 2016), 
asthma exacerbations [15], depressive symptoms [18], respiratory and skin symptoms 
[63], and adverse birth outcomes [9, 10, 13, 17]). Similarly, recent studies have found 
associations between UNGD and quality of life [231], preterm birth [11], and 
inflammatory biomarkers relevant to cardiovascular disease [66] in Ohio, Texas, and 
Colorado, respectively. The findings of this study add to this growing body of evidence 
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and provides further evidence that UNGD is associated with a range of health impacts, 
which now includes hospitalizations for heart failure among heart failure subjects. 
3.5.1 STRENGTHS AND LIMITATIONS 
This study had the advantage of utilizing EHR data from a large, representative 
subject population in Pennsylvania living with varying intensity of UNGD activity over an 
eight-year study period. First, our inverse-distance weighted UNGD activity metrics were 
developed directly from data from Pennsylvania’s Department of Environmental 
Protection and are more reflective of intensity of UNGD activity than crude measures 
(i.e., distance buffers), which is an advantage for use in epidemiologic studies [190]. 
Second, we had a large sample size of 9054 subjects and 5839 hospitalizations. Third, 
because we had access to EHR information, we were able to understand each subject’s 
contact with the medical system, visit history, comorbidities and medications.  Because 
the occurrence of multiple comorbidities is common in subjects with heart failure (Table 
3.3), we were able to assess the extent to which the associations between UNGD 
activity and hospitalization were affected by additional adjustment for these medications 
and comorbidities (Tables 3.9 & 3.10). Fourth, we employed several other sensitivity 
analyses (e.g., restricting by age, utilizing a 4:1 matching strategy, inverse probability of 
selection weighting, using only one vs. two random intercepts in our models, a negative 
exposure control analysis) to assess the robustness of our primary models (Table 3.6), 
and none of these sensitivity analyses suggested that the association between UNGD 
activity and hospitalization was a result of unmeasured confounding. 
The study also had some limitations. Importantly, we did not have information on 
dietary intake, physical activity, and current or past occupations. Although there is some 
information on alcohol use available from the EHR, we did not consider alcohol use in 
this analysis because there is evidence that US adults, particularly older adults, do not 
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frequently discuss alcohol use with their provider [232]. This is evident in the EHR social 
history file’s data. Unlike information on tobacco smoking, we had limited information 
that our subjects used alcohol, with only 3966 of the 9054 subjects confirming alcohol 
use at any given time point. Of those with available alcohol use information, it was often 
not reported at the time of the hospitalization or control encounter. We also did not have 
information on occupation or occupational status, however we do not have any 
information to suggest that current or past occupation should be highly correlated with 
our UNGD activity metrics, and do not believe that most of these subjects with heart 
failure were likely to have been employed currently or in the recent past. Lastly, we did 
not have data for individuals who do not seek care from the health system, so there is 
potential for unmeasured differences in persons who sought care from the health system 
vs. those who did not. This is not a serious concern given the severity of heart failure 
and the high likelihood that care would be required. 
3.6 CONCLUSIONS AND FUTURE DIRECTIONS 
To the best of our knowledge, this is the first large scale epidemiologic study to 
evaluate associations of UNGD activity with heart failure hospitalization among subjects 
with heart failure. We observed significantly increased odds of hospitalization among 
heart failure subjects in relation to increasing UNGD activity for several phases, 
including pad preparation, stimulation, and production. These associations are plausible 
given the documented environmental impacts of UNGD (e.g., air pollution [233], water 
contamination [45], noise [3], traffic [6], and community impacts [54, 234]. The findings of 
this study support candidate exposure pathways involving air pollution and stress, as 
these are the most biologically plausible pathways to explain associations with heart 
failure hospitalization. Understanding how people living with heart failure are susceptible 
to environmental exposures, especially those associated with UNGD, is especially 
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important given the growing prevalence of heart failure [89]. Future studies should better 
characterize mechanistic pathways underlying these observed associations (i.e., 
differentiate between air pollution, stress, or other potential exposure pathways). In the 
next chapter, I evaluate associations between UNGD activity and laboratory measures of 
B-type natriuretic peptide (BNP) in blood, a clinical biomarker frequently used in heart 
failure diagnosis and management, and one that I hypothesize could be a marker of an 
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Figure 3.2. Timeline of UNGD activity assignment in relation to events 
(hospitalizations or control encounters) 
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Table 3.1. Description of cases and controls eligible for selection, and selected, by year, for the primary 
analysis of 1:1 case to control matching 
 
Under observation 
(n)   
 
Selected as 





























2008 0 3,966 670 3296 188 482 1 (0) 
2009 3,452 1,049 606 3895 187 419 1.10 (0.31) 
2010 3,572 932 582 3922 204 378 1.28 (0.50) 
2011 3,719 890 579 4030 248 331 1.76 (0.76) 
2012 3,975 1,152 765 4362 373 779 1.81 (0.84) 
2013 4,353 1,415 964 4804 577 387 1.85 (0.90) 
2014 6,768 1,604 1,143 5164 921 222 1.90 (0.93) 
2015 4,519 714 530 4703 530 0 1.97 (1.05) 
* Subjects who became eligible for control selection in the corresponding year 
** Heart failure subjects who did not have a heart failure hospitalization 







Table 3.2. Selected subject characteristics by case and control status 
  
 Never a case Ever a case 
 
Total subjects n = 9054 n = 3215 n = 5839 p-value* 
Sex, n (%) 
    Male 










Age at hospitalization or at control selection 







Age category at first event, n (%) years 
   > 18-30 
   > 30-40 
   > 40-50 
   > 50-60 
   > 60-70 
   > 70-80 
   > 80-90 




























Race/ethnicity, n (%) 
    White 
    Black 
    Hispanic 
    Other 



















Smoking status at event, n (%) 
    Current 
    Former 















 Never a case Ever a case 
 
Total subjects n = 9054 n = 3215 n = 5839 p-value* 
Community type, n (%) 
    Borough 
    Township 













CSD,** SD units, quartiles 
     1 ( -7.5, -2.6) 
     2 (-2.6, -0.5) 
     3 (-0.5, 2.3) 
















Patient status at end of study, n (%) 
   Alive 










Distance to major road † (meters), mean 
(SD) 
2908 (4,160) 2703 (4,282) 0.03 
Distance to minor road † (meters), mean 
(SD) 
1784 (2599) 1431 (2136) < 0.001 
Receipt of Medical Assistance‡ n (%) 368 (11.5) 681 (11.7) 0.8 
Body mass index (BMI) at event, kg/m2, 
mean (SD)  
31.9 (7.7) 31.5 (8.8) 0.5 
Duration of contact with health system, 
days§, mean (SD) 
3995 (1395) 3683 (1530) < 0.001 
*p-value obtained from chi
2 
tests comparing selected variable in cases and controls for categorical or binary variables; ANOVA F-test for continuous 
variables 
**Community socioeconomic deprivation (CSD) was calculated based on US Census indicators; further information is detailed in the text 
†Major and minor roads were identified from the Pennsylvania Department of Transportation (DOT) databases; distance from subject’s residential 
address to these roads was calculated in meters using the Generate Near Table tool function in ArcGIS 10.4. 
‡ Medical Assistance, a surrogate for family socioeconomic status, was calculated based on health insurance status at the time of encounters as 
previously reported 
§ Days from first to most recent (i.e., case event or control selection date) time a subject was observed in the EHR 
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Table 3.3. Selected diagnoses and medication use at time of hospitalization or control selection day, by 
heart failure hospitalization status 
 
 
 Never a case Ever a case  
 
Total subjects n = 9054 
 
n = 3215 
 
n = 5839 
 
p-value* 
Medication use, by class, n 
(%)** 
    Antihypertensive 
    Antihyperlipidemic 













Chronic obstructive pulmonary 




1106 (18.9)  
 
< 0.001 
Coronary artery disease, n (%) 492 (15.3) 1220 (20.9) < 0.001 
Hypertension, n (%) 1801 (56.0) 3962 (67.9) < 0.001 
Myocardial infarction, n (%) 212 (6.59) 433 (7.42) 0.2 
Valve disorder, n (%) 496 (15.4) 1127 (19.3) < 0.001 
Diabetes, n (%) 989 (30.8) 2356 (40.3) < 0.001 
Chronic kidney disease, n (%) 610 (26.4) 1519 (29.6) 0.001 








*p-value obtained from chi
2 
tests comparing selected variable in cases and controls for categorical or binary variables; t-test for continuous variables 
** Relevant medication classes were identified based on the dates of physician orders 
† A composite measure of overall morbidity; definition described in text 
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Table 3.4. Frequencies of subjects by UNGD activity metric quartile and 
year 
Pad preparation metric 
Year 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total subjects 
(n) n (%) n (%) n (%) n (%) 
2008 589 (44.0) 560 (41.8) 147 (11.0) 44 (3.3) 1,340 
2009 221 (18.2) 314 (25.9) 371 (30.6) 306 (25.3) 1,212 
2010 11 (1.0) 84 (7.2) 294 (25.3) 775 (66.6) 1,164 
2011 5 (0.4) 23 (2.0) 355 (30.7) 775 (66.9) 1,158 
2012 33 (2.2) 347 (22.7) 573 (37.5) 577 (37.7) 1,530 
2013 411 (21.3) 664 (34.4) 585 (30.3) 268 (13.9) 1,928 
2014 789 (34.5) 790 (34.6) 550 (24.1) 157 (6.9) 2,286 
2015 861 (81.2) 137 (12.9) 45 (4.2) 17 (1.6) 1,060 
Spud metric 
Year 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total subjects 
(n) n (%) n (%) n (%) n (%) 
2008 1,340 (100) 0 0 0 1,340 
2009 904 (75.6) 247 (20.4) 44 (3.6) 17 (1.4) 1,212 
2010 74 (6.4) 288 (24.7) 419 (36.0) 383 (32.9) 1,164 
2011 0 131 (11.3) 244 (21.1) 783 (67.6) 1,158 
2012 135 (8.8) 441 (28.8) 486 (31.8) 468 (30.6) 1,530 
2013 104 (5.4) 835 (43.3) 619 (32.1) 370 (19.2) 1,928 
2014 37 (1.6) 481 (21.0) 929 (40.6) 839 (36.7) 2,286 
2015 326 (30.8) 496 (46.8) 179 (16.9) 59 (5.6) 1,060 
Stimulation metric 
Year 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total subjects 
(n) n (%) n (%) n (%) n (%) 
2008 1,298 (96.8) 31 (2.3) 5 (0.4) 6 (0.5) 1,340 
2009 1,073 (88.5) 105 (8.7) 16 (1.3) 18 (1.5) 1,212 
2010 250 (21.5) 472 (40.6) 321 (27.6) 121 (10.4) 1,164 
2011 9 (0.8) 298 (25.7) 468 (40.4) 383 (33.1) 1,158 
2012 9 (0.6) 230 (15.0) 537 (35.1) 754 (49.3) 1,530 
2013 21 (1.1) 568 (29.5) 636 (33.0) 703 (36.5) 1,928 
2014 39 (1.7) 728 (31.9) 733 (32.1) 786 (34.4) 2,286 
2015 221 (20.9) 487 (45.9) 204 (19.3) 148 (14.0) 1,060 
Production metric 
Year 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total subjects 
(n) n (%) n (%) n (%) n (%) 
2008 1,340 (0) 0 0 0 1,340 
2009 1,138 (93.9) 68 (5.6) 4 (0.3) 2 (0.2) 1,212 
2010 433 (37.2) 703 (60.4) 17 (1.5) 11 (1.0) 1,164 
2011 9 (0.8) 966 (83.4) 140 (12.1) 43 (3.7) 1,158 
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2012 0 608 (39.7) 698 (45.6) 224 (14.6) 1,530 
2013 0 339 (17.6) 787 (40.8) 802 (41.6) 1,928 
2014 0 167 (7.3) 851 (37.2) 1,268 (55.5) 2,286 
2015 0 68 (6.4) 423 (39.9) 569 (53.7) 1,060 
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Table 3.5. UNGD activity metrics by quartile and phase, by heart failure hospitalization status at date of 




Ever a case* Never a case
**




Total subjects, n = 9,054 
 
n = 5839 (%) 
 
n = 3215 (%) 
 




    Q1 (4.0 X 10
-9
, 3.3 X 10
-8
) 
    Q2 (3.3 X 10
-8
, 6.2 X 10
-8
) 
    Q3 (6.2 X 10
-8
, 1.2 X 10
-7
) 
    Q4 (1.2 X 10
-7





















    Q1 (1.9 X 10
-10
, 2.6 X 10
-9
) 
    Q2 (2.6 X 10
-9
, 3.8 X 10
-9
) 
    Q3 (3.8 X 10
-9
, 4.7 X 10
-8
) 
    Q4 (4.7 X 10
-9





















    Q1 (2.5 X 10
-6
, 2.7 X 10
-4
) 
    Q2 (2.7 X 10
-4
, 5.6 X 10-4) 
    Q3 (5.6 X 10
-4
, 9.7 X 10
-4
) 























    Q1 (2.2 X 10
-6
, 0.002) 
    Q2 (0.002, 0.02) 
    Q3 (0.02, 0.03) 
















* Distribution of UNGD activity metrics assigned at date of hospitalization 
**Distribution of UNGD activity metrics at first randomly selected control encounter date 
†




Table 3.6.  Associations of UNGD activity metrics, by phase, with 

























    Q1 (4.0 X 10
-9
, 3.3 X 10
-8
) 
    Q2 (3.3 X 10
-8
, 6.2 X 10
-8
) 
    Q3 (6.2 X 10
-8
, 1.2 X 10
-7
) 
    Q4 (1.2 X 10
-7





1.07 (0.92, 1.25) 
1.39 (1.19, 1.62) 
1.29 (1.10, 1.52) 
 
(ref) 
1.23 (1.04, 1.46) 
1.75 (1.44, 2.13) 
1.84 (1.45, 2.33) 
 
(ref) 
1.03 (0.88, 1.19) 
1.34 (1.15, 1.57) 
1.24 (1.06, 1.46) 
 
(ref) 
1.16 (0.98, 1.37) 
1.65 (1.36, 2.00) 
1.70 (1.34, 2.15) 
 
(ref) 
1.19 (1.01, 1.40) 
1.63 (1.35, 1.97) 




    Q1 (1.9 X 10
-10
, 2.6 X 10
-9
) 
    Q2 (2.6 X 10
-9
, 3.8 X 10
-9
) 
    Q3 (3.8 X 10
-9
, 4.7 X 10
-8
) 
    Q4 (4.7 X 10
-9





1.26 (1.08, 1.47) 
1.26 (1.09, 1.47) 
0.96 (0.82, 1.13) 
 
(ref) 
0.94 (0.76, 1.16) 
0.90 (0.71, 1.13) 
0.64 (0.49, 0.83) 
 
(ref) 
1.23 (1.06, 1.43) 
1.27 (1.09, 1.48) 
1.16 (0.99, 1.37) 
 
(ref) 
1.01 (0.82, 1.25) 
1.04 (0.82, 1.31) 
0.93 (0.71, 1.21) 
 
(ref) 
1.01 (0.82, 1.25) 
1.07 (0.85, 1.35) 




    Q1 (2.5 X 10
-6
, 2.7 X 10
-4
) 
    Q2 (2.7 X 10
-4
, 5.6 X 10-4) 
    Q3 (5.6 X 10
-4
, 9.7 X 10
-4
) 





0.96 (0.82, 1.12) 
1.45 (1.24, 1.70) 
1.65 (1.39, 1.96) 
 
(ref) 
1.03 (0.80, 1.31) 
1.67 (1.27, 2.20) 
1.98 (1.47, 2.67) 
 
(ref) 
0.99 (0.85, 1.16) 
1.41 (1.20, 1.65) 
1.62 (1.37, 1.92) 
 
(ref) 
1.00 (0.78, 1.28) 
1.50 (1.14, 1.98) 
1.78 (1.32, 2.40) 
 
(ref) 
1.03 (0.81, 1.31) 
1.56 (1.19, 2.04) 






    Q1 (2.2 X 10
-6
, 0.002) 
    Q2 (0.002,  0.02) 
    Q3 (0.02, 0.03) 
    Q4 (0.03, 16.5) 
 
(ref) 
1.01 (0.86, 1.18) 
1.19 (1.01, 1.40) 
1.72 (1.44, 2.06) 
 
(ref) 
0.89 (0.65, 1.21) 
1.34 (0.92, 1.96) 
2.17 (1.42, 3.30) 
 
(ref) 
1.07 (0.92, 1.26) 
1.15 (0.98, 1.34) 
1.66 (1.40, 1.98) 
 
(ref) 
0.83 (0.61, 1.14) 
1.00 (0.69, 1.47) 
1.54 (1.01, 2.34) 
 
(ref) 
0.87 (0.64, 1.19) 
1.10 (0.75, 1.60) 
1.62 (1.07, 2.45) 
* Model 1: [binary indicators] sex, race/ethnicity (white vs. non-white), receipt of Medical Assistance 
(ever/never), smoking status (ever/never), body mass index (BMI, kg/m
2
) (centered and centered-squared 
term), age category 
** Model 2: Model 1 + year 
§
 Model 3: Model 1+ region. Regions were defined by county of residence as northeast (reference), 
southeast, central, southwest, and northwest [see Figure 5]. 
† 
Model 4: Model 1+ year and region 
‡
 Model 5: Model 1+ year, region, season (winter [reference], spring, summer, fall), distance to 
hospital/clinic, and contact time (date of case or control encounter minus the date of the first encounter in 




Table 3.7. Summary of model results from sensitivity analyses 
 













    Q1 (4.0 X 10
-9
, 3.3 X 10
-8
) 
    Q2 (3.3 X 10
-8
, 6.2 X 10
-8
) 
    Q3 (6.2 X 10
-8
, 1.2 X 10
-7
) 
    Q4 (1.2 X 10
-7





1.11 (0.97, 1.26) 
1.40 (1.21, 1.63) 
1.47 (1.23, 1.76) 
 
(ref) 
1.15 (0.97, 1.36) 
1.60 (1.32, 1.93) 
1.63 (1.30, 2.05) 
 
(ref) 
1.12 (0.97, 1.29) 
1.49 (1.27, 1.75) 




    Q1 (1.9 X 10
-10
, 2.6 X 10
-9
) 
    Q2 (2.6 X 10
-9
, 3.8 X 10
-9
) 
    Q3 (3.8 X 10
-9
, 4.7 X 10
-8
) 
    Q4 (4.7 X 10
-9





0.97 (0.81, 1.15) 
1.03 (0.86, 1.25) 
0.95 (0.77, 1.18) 
 
(ref) 
0.98 (0.79, 1.21) 
1.04 (0.82, 1.32) 
0.90 (0.69, 1.18) 
 
(ref) 
0.97 (0.81, 1.17) 
1.02 (0.84, 1.25) 




    Q1 (2.5 X 10
-6
, 2.7 X 10
-4
) 
    Q2 (2.7 X 10
-4
, 5.6 X 10
-4
) 
    Q3 (5.6 X 10
-4
, 9.7 X 10
-4
) 





0.99 (0.82, 1.21) 
1.32 (1.06, 1.64) 
1.50 (1.19, 1.89) 
 
(ref) 
1.04 (0.82, 1.33) 
1.63 (1.25, 2.14) 
1.79 (1.34, 2.40) 
 
(ref) 
1.02 (0.83, 1.25) 
1.49 (1.19, 1.87) 






    Q1 (2.2 X 10
-6
, 0.002) 
    Q2 (0.002,  0.02) 
    Q3 (0.02, 0.03) 
    Q4 (0.03, 16.5) 
 
(ref) 
0.88 (0.68, 1.13) 
1.00 (0.74, 1.36) 
1.34 (0.96, 1.86) 
 
(ref) 
0.96 (0.70, 1.31) 
1.24 (0.85, 1.82) 
1.81 (1.19, 2.75) 
 
(ref) 
0.95 (0.73, 1.23) 
1.17 (0.85, 1.61) 
1.67 (1.18, 2.35) 
 
* Model 1: sex, race/ethnicity (white vs. non-white), receipt of Medical Assistance (ever/never), smoking 
status (ever/never), body mass index (BMI, kg/m
2
), age category, year, region, season (winter [reference], 
spring, summer, fall), distance to hospital/clinic, and days since heart failure diagnosis (centered and 
centered-squared term) 
**Model 2: same covariates as Model 1, but restricted by age categories (only ages 40-80), resulting in 8412 
subjects with 10812 case events and control encounters. Model 2 also adjusts for contact time (date of case 
or control encounter minus the date of the first encounter in medical record, in days) instead of days since 
heart failure diagnosis, and includes two random intercepts for both individual subjects and for place type 
identifiers  
§ 
Model 3: same as Model 2, with adjustment for days since heart failure diagnosis instead of contact time 
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Table 3.8. Summary of model results from sensitivity analyses for 4:1 control 
encounter to case event matching 









    Q1 (3.9 X 10
-9
, 3.2 X 10
-8
) 
    Q2 (3.2 X 10
-8
, 6.1 X 10
-8
) 
    Q3 (6.1 X 10
-8
, 1.2 X 10
-7
) 
    Q4 (1.2 X 10
-7





1.30 (1.14, 1.47) 
1.45 (1.26, 1.67) 
1.47 (1.23, 1.75) 
 
(ref) 
1.49 (1.27, 1.74) 
1.77 (1.48, 1.96) 




    Q1 (3.9 X 10
-9
, 3.2 X 10
-8
) 
    Q2 (3.2 X 10
-8
, 6.1 X 10
-8
) 
    Q3 (6.1 X 10
-8
, 1.2 X 10
-7
) 
    Q4 (1.2 X 10
-7





1.29 (1.14, 1.47) 
1.45 (1.26, 1.67) 
1.47 (1.23, 1.75) 
 
(ref) 
1.41 (1.20, 1.66) 
1.62 (1.25, 1.96) 




    Q1 (2.4 X 10
-6
, 2.6 X 10
-4
) 
    Q2 (2.6 X 10
-4
, 5.3 X 10
-4
) 
    Q3 (5.3 X 10
-4
, 9.2 X 10
-4
) 





1.00 (0.83, 1.20) 
1.34 (1.09, 1.64) 
1.70 (1.36, 2.13) 
 
(ref) 
1.08 (0.86, 1.37) 
1.54 (1.19, 2.00) 






    Q1 (1.9 X 10
-6
, 0.002) 
    Q2 (0.002,  0.01) 
    Q3 (0.01, 0.03) 
    Q4 (0.03, 21.2) 
 
(ref) 
0.84 (0.67, 1.05) 
1.04 (0.78, 1.38) 
1.47 (1.08, 2.02) 
 
(ref) 
0.82 (0.61, 1.09) 
1.06 (0.74, 1.52) 
1.63 (1.08, 2.45) 
*Model 1: 4:1 control to case sampling, 11774 subjects and 29051 case events or control encounters. Model 
1 adjusts for: sex, race/ethnicity (white vs. non-white), receipt of Medical Assistance (ever/never), smoking 
status (ever/never), body mass index (BMI, kg/m
2
) (centered and centered-squared term), age category, 
year, region, season (winter [reference], spring, summer, fall), and days since heart failure diagnosis 
(centered and centered-squared term) 
**Model 2: same covariates as Model 1, but adjusting for contact time (centered and centered-squared term) 





Table 3.9.  Associations of UNGD activity metrics, by phase, with hospitalization for HF, from models with 




(No medication adjustment) 
Model 1+ Antihypertensive 
medications 
Model 1 + Antihyperlipidemic 
medications 














    Q1 (4.0 X 10
-9
, 3.3 X 10
-8
) 
    Q2 (3.3 X 10
-8
, 6.2 X 10
-8
) 
    Q3 (6.2 X 10
-8
, 1.2 X 10
-7
) 
    Q4 (1.2 X 10
-7





1.13 (1.01, 1.41) 
1.64 (1.35, 1.98) 
1.70 (1.35, 2.13) 
 
(ref) 
1.19 (1.01, 1.40) 
1.62 (1.34, 1.95) 
1.68 (1.34, 2.11) 
 
(ref) 
1.19 (1.01, 1.41) 
1.63 (1.35, 1.97) 
1.69 (1.35, 2.13) 
 
(ref) 
1.19 (1.01, 1.41) 
1.64 (1.35, 1.98) 




    Q1 (1.9 X 10
-10
, 2.6 X 10
-9
) 
    Q2 (2.6 X 10
-9
, 3.8 X 10
-9
) 
    Q3 (3.8 X 10
-9
, 4.7 X 10
-8
) 
    Q4 (4.7 X 10
-9





1.01 (0.82, 1.25) 
1.08 (0.85, 1.36) 
0.97 (0.74, 1.26) 
 
(ref) 
1.02 (0.83, 1.25) 
1.08 (0.85, 1.35) 
0.97 (0.75, 1.26) 
 
(ref) 
1.01 (0.82, 1.25) 
1.08 (0.85, 1.36) 
0.97 (0.75, 1.26) 
 
(ref) 
1.01 (0.82, 1.25) 
1.08 (0.85, 1.36) 




    Q1 (2.5 X 10
-6
, 2.7 X 10
-4
) 
    Q2 (2.7 X 10
-4
, 5.6 X 10
-4
) 
    Q3 (5.6 X 10
-4
, 9.7 X 10
-4
) 





1.03 (0.81, 1.32) 
1.57 (1.20, 2.05) 
1.80 (1.35, 2.41) 
 
(ref) 
1.03 (0.81, 1.31) 
1.56 (1.19, 2.03) 
1.79 (1.34, 2.38) 
 
(ref) 
1.03 (0.81, 1.31) 
1.56 (1.20, 2.05) 
1.80 (1.35, 2.41) 
 
(ref) 
1.03 (0.81, 1.32) 
1.57 (1.20, 2.06) 






    Q1 (2.2 X 10
-6
, 0.002) 
    Q2 (0.002,  0.02) 
    Q3 (0.02, 0.03) 
    Q4 (0.03, 16.5) 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.62) 
1.63 (1.08, 2.48) 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.61) 
1.62 (1.07, 2.45) 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.62) 
1.63 (1.08, 2.47) 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.62) 
1.63 (1.08, 2.48) 
*
Model 1: [binary indicators] sex, race/ethnicity (white vs. non-white), receipt of Medical Assistance (ever/never), smoking status (ever/never), body mass 
index (BMI, kg/m
2
) as a centered and centered-squared term, age category, year, region, season (winter [reference], spring, summer, fall), distance to 
hospital/clinic, and observation time as a centered and centered-squared term (date of case or control encounter – date of first encounter in medical 




Table 3.10.  Associations of UNGD activity metrics, by phase, with hospitalization for HF, from models with 










Model 1 + Type II 
diabetes 
Model 1 + 
Coronary artery 
disease 
Model 1 + 
Myocardial 
infarction 
Model 1 + 
Hypertension 
Model 1 + chronic 
kidney disease 




















    Q1 
    Q2 
    Q3 
    Q4 
 
(ref) 
1.19 (1.01, 1.41) 
1.64 (1.35, 1.98) 
1.70 (1.35, 2.13) 
 
(ref) 
1.20 (1.01, 1.41) 
1.64 (1.36, 1.98) 
1.70 (1.35, 2.14) 
 
(ref) 
1.19 (1.01, 1.41) 
1.64 (1.35, 1.98) 
1.71 (1.36, 2.15) 
 
(ref) 
1.21 (1.02, 1.42) 
1.66 (1.37, 2.01) 
1.74 (1.38, 2.19) 
 
 (ref) 
1.20 (1.01, 1.42) 
1.66 (1.37, 2.01) 
1.72 (1.36, 2.16) 
(ref) 
1.19 (1.01, 1.41) 
1.63 (1.35, 1.97) 
1.68 (1.34, 2.12) 
 
(ref) 
1.19 (1.00, 1.40) 
1.64 (1.35, 1.98) 
1.70 (1.35, 2.14) 
(ref) 
1.19 (1.01, 1.41) 
1.64 (1.36, 1.98) 
1.70 (1.35, 2.14) 
Spud (drilling)  
    Q1 
    Q2 
    Q3 
    Q4 
 
(ref) 
1.01 (0.82, 1.25) 
1.08 (0.85, 1.36) 
0.97 (0.74, 1.26) 
 
(ref) 
1.01 (0.82, 1.24) 
1.07 (0.85, 1.35) 
0.97 (0.74, 1.26) 
 
(ref) 
1.01 (0.82, 1.25) 
1.07 (0.85, 1.36) 
0.97 (0.74, 1.26) 
 
(ref) 
1.02 (0.82, 1.26) 
1.08 (0.85, 1.37) 
0.98 (0.75, 1.28) 
 
(ref) 
1.01 (0.82, 1.25) 
1.07 (0.85, 1.35) 
0.97 (0.74, 1.26) 
(ref) 
1.01 (0.82, 1.25) 
1.07 (0.85, 1.35) 
0.96 (0.74, 1.26) 
(ref) 
1.01 (0.81, 1.24) 
1.06 (0.84, 1.35) 
0.96 (0.74, 1.26) 
(ref) 
1.01 (0.82, 1.25) 
1.08 (0.85, 1.36) 
0.97 (0.75, 1.26) 
Stimulation 
    Q1 
    Q2 
    Q3 
    Q4 
 
(ref) 
1.03 (0.81, 1.32) 
1.57 (1.20, 2.05) 
1.80 (1.35, 2.41) 
 
(ref) 
1.03 (0.81, 1.32) 
1.57 (1.20, 2.05) 
1.80 (1.35, 2.41) 
 
(ref) 
1.03 (0.81, 1.32) 
1.57 (1.20, 2.06) 
1.81 (1.36, 2.42) 
 
(ref) 
1.04 (0.82, 1.33) 
1.60 (1.22, 2.10) 
1.84 (1.37, 2.47) 
 
(ref) 
1.02 (0.80, 1.30) 
1.54 (1.18, 2.03) 
1.79 (1.34, 2.40) 
(ref) 
1.03 (0.81, 1.31) 
1.56 (1.19, 2.04) 
1.79 (1.34, 2.40) 
(ref) 
1.06 (0.83, 1.35) 
1.61 (1.23, 2.12) 
1.87 (1.39, 2.49) 
(ref) 
1.03 (0.81, 1.32) 
1.57 (1.20, 2.05) 
1.81 (1.35, 2.42) 
Production 
    Q1 
    Q2 
    Q3 
    Q4 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.62) 
1.63 (1.08, 2.48) 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.62) 
1.64 (1.08, 2.48) 
 
(ref) 
0.88 (0.65, 1.20) 
1.11 (0.76, 1.63) 
1.64 (1.08, 2.48) 
 
(ref) 
0.89 (0.65, 1.22) 
1.13 (0.77, 1.66) 
1.69 (1.11, 2.58) 
 
(ref) 
0.87 (0.63, 1.18) 
1.10 (0.75, 1.61) 
1.63 (1.07, 2.48) 
(ref) 
0.87 (0.64, 1.18) 
1.10 (0.75, 1.60) 
1.61 (1.06, 2.43) 
(ref) 
0.90 (0.66, 1.23) 
1.14 (0.78, 1.68) 
1.70 (1.12, 2.59) 
(ref) 
0.87 (0.64, 1.20) 
1.11 (0.76, 1.62) 
1.63 (1.08, 2.48) 
*
Model 1: [binary indicators] sex, race/ethnicity (white vs. non-white), receipt of Medical Assistance (ever/never), smoking status (ever/never), body mass 
index (BMI, kg/m
2
) as a centered and centered-squared term, age category, year, region, season (winter [reference], spring, summer, fall), distance to 
hospital/clinic, and observation time as a centered and centered-squared term (date of case or control encounter – date of first encounter in medical 





Figure 3.3. Map of subjects included in analysis from 2008 to 2015, by quartile of 









Figure 3.5. Map of the distribution of the regional indicator variable, by county of 
residence. For the analysis, northeast was the reference region. 
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Figure 3.6. Forest plots of adjusted odds ratio for heart failure 




*Negative exposure control models limited our analyses to years 2008 and 2009, however UNGD activity 
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Background: B-type natriuretic peptide (BNP) has been increasingly used in clinical 
settings to aid in the diagnosis and management of heart failure. Given associations 
between unconventional natural gas development (UNGD) activity and heart failure 
hospitalization observed in Chapter 3, we sought to understand whether UNGD activity 
was similarly associated with BNP. To date, epidemiologic studies have not yet 
evaluated UNGD activity and other environmental factors in relation to biomarkers of 
heart failure in a large patient population. BNP levels may offer advantages over heart 
failure hospitalization in several ways: 1) it may be an earlier marker of exacerbating 
heart failure; 2) it is more routinely measured and would not be biased, for example, by 
health care system programs to increase outpatient management of heart failure and 
reduce hospitalization; and 3) it is mechanistically and pathophysiologically important to 
heart failure.  
Objectives: To estimate the association between metrics of UNGD activity, related 
environmental factors, and BNP concentrations in a large patient population in 
Pennsylvania.  
Methods: We obtained Geisinger electronic health record (EHR) data for patients with 
heart failure diagnoses and laboratory orders for BNP. We generated quantitative 
estimates of UNGD activity in the 30 days prior to the BNP laboratory order date, by 
phase (i.e., pad preparation, spud drilling, stimulation, and production), with a one-day 
lag. We also generated metrics of community socioeconomic deprivation (CSD), 
residential greenness, and distances to major and minor roads as well as comorbidities 
and medication use from the EHR. We evaluated associations of these variables with 
BNP levels dichotomized at greater than or equal to 400 pg/mL (vs. lower), a common 
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clinically-used cutoff, using logistic regression and generalized estimating equations 
(GEE).  
Results: We identified 6501 laboratory values for BNP among 3938 subjects with heart 
failure in the years 2008-2015. The mean (SD) BNP concentration for the 6501 
laboratory measures was 478.8 pg/mL (637.5). Adjusted associations (odds ratio [OR] 
and 95% confidence interval [CI]) of UNGD activity with BNP levels  400 pg/mL were 
1.36 (1.08, 1.71), 1.42 (1.05, 1.93), and 1.52 (1.07, 2.17), for the 2nd, 3rd, and 4th 
quartiles of UNGD production compared to the first, respectively. We did not observe 
any consistent associations for other UNGD metrics with BNP  400 pg/mL. In sensitivity 
analyses using linear regression and ln-transformed BNP, the geometric mean (95% CI) 
BNP was 1.28 (1.15, 1.43), 1.30 (1.12, 1.51), and 1.39 (1.17, 1.65) times greater for the 
2nd, 3rd, and 4th quartiles of UNGD production compared to the 1st quartile, after adjusting 
for covariates. We did not see consistent associations with other UNGD metrics (pad 
preparation, stimulation) or with CSD, NDVI, and distance to major roads. The second 
quartile of distance to minor roads (vs. the first), however, showed a geometric mean 
ratio of 0.90 (95 % CI: 0.81, 0.99).  
Conclusions: Higher levels of UNGD production activity were associated with higher 
BNP in both continuous and dichotomous outcome models. The exposure-effect relation 
became apparent with increasing covariate control. These findings are consistent with 
the results of Chapter 3, which showed exposure-effect relations between UNGD 
activity metrics and heart failure hospitalization; however, unlike Chapter 3, exposure-
effect relations in this chapter were only present for the UNGD production metric. There 
are several possible explanations for the discordant results between this chapter and 
those in Chapter 3, having to do with the timing of BNP measurements, the fact that the 
production metric is the only one that is cumulative (the others have defined beginnings 
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and endings), and possibly unique aspects of production activity exposures. These are 
discussed herein.  
 
4.2 INTRODUCTION  
 
 Clinical measures from EHRs provide a valuable data resource for understanding 
the epidemiology of prevalent and burdensome diseases for which persons must seek 
and receive health care. Heart failure is a disease with a high public health burden, and 
heart failure patients provide many clinical measures when in contact with the health 
care system. In particular, blood levels of B-type natriuretic peptide (BNP) are frequently 
used in a clinical setting as diagnostic and prognostic markers among heart failure 
patients [28, 235, 236], even those who are asymptomatic [237]. At the population-level, 
recent epidemiologic studies underscore the importance and utility of blood BNP 
measures obtained from EHRs in defining clinical management and understanding 
patient survival and risk prediction [31, 238].   
 In vivo, BNP is a vasodilator that is released by cardiac myocytes in response to 
increases in volume and pressure in the left ventricle [28]. The release of BNP into the 
bloodstream leads to diuresis, natriuresis, vasodilation, and the inhibition of renin, 
aldosterone, and fibrosis [235]. It is cleared from the blood via both receptor-mediated 
mechanisms and by endopeptidase enzymes [107, 235]. The reported half-life of BNP in 
the blood varies from 3.9 to 22.6 minutes [107], which allows clinicians to utilize blood 
BNP levels for diagnosis of acute heart failure [235]. Specifically, blood BNP levels can 
be used to exclude acute heart failure (< 30 pg/mL), to identify acute heart failure (> 100 
pg/mL), to screen asymptomatic patients for heart failure in an outpatient setting (> 20 
pg/mL), and to rule in acute heart failure for persons experiencing acute dyspnea (> 400 
pg/mL) [235]. For these reasons, many heart failure patients, and patients suspected to 
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have heart failure, will have multiple BNP laboratory measurements over the duration of 
their care. A patient’s blood BNP concentration can vary over time and can be impacted 
by certain medications (e.g., diuretics, angiotensin-II inhibitors) and various comorbid 
conditions (e.g., chronic kidney disease, obesity) [235]. Growing evidence links the 
circulation of BNP and related cardiac biomarkers to metabolic dysfunction and 
dysregulation of glucose and blood lipids, providing a potential mechanism for the 
interplay between heart failure, hypertension, and metabolic disorders [239, 240]. 
Because of these complexities, epidemiologic studies of BNP need to consider a suite of 
medications and comorbid conditions, many of which are documented in EHRs. 
 
4.2.1 EPIDEMIOLOGY AND BIOLOGIC RATIONALE FOR ASSOCIATIONS BETWEEN 
ENVIRONMENTAL FACTORS AND BNP 
There is substantial epidemiologic evidence that environmental exposures 
adversely affect cardiac health. Air pollution, and particulate matter less than 2.5 microns 
in diameter (PM2.5) in particular, is consistently associated with increased cardiovascular 
mortality and morbidity in epidemiologic studies [128]. These associations also apply to 
heart failure patients, where multiple epidemiologic studies have found short-term 
associations between criteria air pollutants, such as PM2.5, NOx, and ozone, and 
hospitalization among heart failure patients [26]. The biologic mechanisms underlying 
these associations are complex, but candidate pathways responsible for these 
associations include systemic inflammation [134] and endothelial injury [241, 242], 
leading to vasoconstriction [243]. Associations between air pollution and elevations in 
blood pressure are also well-documented in epidemiologic studies [244]. In addition to 
air pollution, there is evidence that both psychosocial stress and noise exposure are 
directly associated with endothelial dysfunction [245, 246]. Increasing evidence 
implicates environmental noise exposure as an independent risk factor for 
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cardiovascular disease [132, 247]. To the best of our knowledge, however, there are 
only a few epidemiologic studies of exposure to environmental factors (e.g., air pollution, 
noise) and psychosocial stress in relation to BNP [124-126, 248, 249]. Notably, as 
discussed throughout this dissertation, each of these exposures can be caused by 
UNGD. Lastly, although there is evidence that community socioeconomic deprivation is 
independently associated with cardiovascular disease [158, 250], and that residential 
greenness is associated with improved cardiovascular outcomes [52, 151, 251], reduced 
odds of heart failure [52], we have not been able to identify any epidemiologic studies 
that evaluate associations of residential greenness, proximity to major and minor roads, 
or community socioeconomic deprivation (CSD) in relation to BNP.  
 
4.3 OBJECTIVE  
Heart failure is a heterogeneous disease and associations between 
environmental factors and hospitalization for heart failure likely reflect multiple biologic 
pathways that lead a subject to seek care and become hospitalized. Because BNP 
levels in heart failure patients are associated with prognosis and severity [30], and 
because of our observed associations between UNGD activity and hospitalization 
among heart failure subjects (Chapter 3), we hypothesized that UNGD activity might 
also be associated with BNP measurements as a biomarker of early biologic effect in the 
association between UNGD activity and exacerbation of heart failure. Although we do 
not believe that BNP is a unique marker of exposure to UNGD activity, examining 
associations between UNGD activity and BNP allowed us to see if this biologically 
plausible association was present in a large population of heart failure subjects, which 
can inform understanding of the biologic pathways through which environmental factors 
contribute to heart failure outcomes. By contrasting associations of UNGD activity 
separately with heart failure hospitalization and BNP levels, we hypothesized that we 
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could learn about key aspects of how UNGD may affect heart failure, the utility of EHR 
data for environmental epidemiology, and possibly gain mechanistic insight.  BNP may 
be an earlier marker of exacerbating heart failure, it is more routinely measured, and it 
would not be biased, for example, by health care system programs to increase 
outpatient management of heart failure and reduce hospitalization. The objective of this 
study was to estimate the association between metrics of UNGD activity, related 




4.4.1 STUDY POPULATION AND LABORATORY MEASURES 
We identified 16,098 individuals who were evaluated at Geisinger and had at 
least one ICD-9 code for heart failure (428.x) between 2003 - 2015 included in their 
medical record. We applied the subject eligibility criteria that is described in Chapter 2, 
Figure 2.1 (i.e., requiring a residential address in Pennsylvania, excluding subjects with 
missing demographic information or with diagnoses of endocardial fibroelastosis or 
congenital heart anomalies) to the laboratory orders we identified, so that 13,183 
subjects were eligible for potential selection. We identified 7224 subjects who had at 
least one laboratory procedure code order for “83880.01” or “83880.03” for B-type 
natriuretic peptide (see Chapter 2, Table 2.1). Because we wanted the laboratory 
measurements from this study population to coincide with the timing of UNGD activity in 
Pennsylvania, we restricted our study to the years 2008 - 2015, leaving us with 4893 
potentially eligible subjects with BNP measures for this analysis. We then excluded 
laboratory measures from 922 subjects whose BNP laboratory measures were recorded 
before their first diagnosis for heart failure and 33 subjects who did not have a BNP 
value despite the laboratory order; resulting in 3938 subjects in this analysis, all of whom 
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were over the age of 18 years at the time of each laboratory measurement. We further 
limited the number of laboratory measurements to be included in the model to be no 
more than five (Table 4.1), so that individuals with many observations, many of which 
were clustered in time and possibly indicating acute exacerbation, would not have undue 
influence in our model. We also restricted these BNP orders to be at least 90 days 
before or after the adjacent BNP order. We created variables to indicate the number of 
days before or after a subject’s BNP order and the date of hospitalization for heart 
failure, if present.  
4.4.2 COVARIATE ASSIGNMENT FOR EHR VARIABLES 
 
The Geisinger EHR allowed for identification of demographic characteristics such 
as race/ethnicity and sex. For each subject in this analysis, we also created time-varying 
variables based on each laboratory order date, including age at time of event, receipt of 
Medical Assistance (ever vs. never), smoking status (ever vs. never), and body mass 
index (BMI, mg/kg2). We used each subject’s most recently available height and weight 
data prior to the date of the laboratory order to calculate BMI. For a small (i.e., < 5%) 
subset of subjects, height and weight data were missing from the medical record. We 
imputed BMI for these subjects using multiple imputation based on: age at laboratory 
order date (centered), sex, race/ethnicity, smoking status, and receipt of Medical 
Assistance. We assigned smoking status in the same manner as it was assigned in 
Chapter 3. 
We created variables for a subject having comorbid conditions associated with 
BNP levels or clearance of BNP from the blood by identifying at least two ICD-9 
diagnosis codes for each condition from inpatient, outpatient, ER visits and medication 
orders. These conditions were dichotomized as ever vs. never, considering all available 
EHR data for the subject prior to the date of the laboratory order. The comorbid 
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conditions that we deemed important for this analysis included: hypertension (401.9), 
type 2 diabetes (250.x), myocardial infarction (410.x), chronic obstructive pulmonary 
disease (496.x), heart valve disorders and disease (V43.3, 424.x, 396.9, 391.1, 392.0, 
390, 395.9, or 421.9), coronary artery disease (414.01), and chronic kidney disease 
(585.x).  
We used stringent criteria to define our medication variables. We used the Medi-
Span Generic Product Identifier Therapeutic Classification System [191] to identify 
medication orders by the following medication classes: antihypertensive, 
antihyperlipidemic, and anticoagulant medications. We created a binary variable for 
whether or not a subject had a valid medication order that encompassed the date of the 
laboratory order. Lastly, we calculated the Charlson index, a 17-item morbidity scale, at 
the date of the laboratory order. More than a quarter of subjects (n = 1082, 27.5 %) did 
not have all of the necessary information in their medical record to generate this 17-item 
scale, so we imputed Charlson index for these subjects using multiple imputation based 
on: age at laboratory order (centered), sex, race/ethnicity, smoking status, and receipt of 
Medical Assistance.  
4.4.3 ENVIRONMENTAL AND COMMUNITY VARIABLES 
 
We assigned environmental and community variables in the same manner as 
described in Chapter 3. For each subject, we generated several place-based variables 
that we hypothesized might be relevant to heart failure and BNP. First, we assigned 
each subject a community type based on latitude and longitude coordinates geocoded 
from the residential address listed in the EHR (census tracts [cities], boroughs, and 
townships), as previously reported [13, 190, 192]. We obtained information from the 
2010-2014 US Census American Community Survey [198] to generate a standardized 
index of community socioeconomic deprivation (CSD) at each community type [252]. 
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Similar to our methods in Chapter 3, CSD was categorized into quartiles for the 
analysis. 
4.4.3.1 UNGD ACTIVITY 
 
Similar to the methods used in Chapter 3, we obtained the dates and locations of 
unconventional natural gas wells drilled and assigned UNGD activity for a 30-day 
duration and one-day lag prior to date of laboratory order (see Chapter 2, Section 5.1 
for detail on determining UNGD activity durations and lags). We did this for four phases 
of UNGD activity: pad preparation, spud (drilling), stimulation, and production of the well. 
These methods are consistent with previous epidemiological work on UNGD in this 
region and patient population [15, 190]. Because we wanted to identify phase-specific 
associations between 30-day UNGD activity and BNP measures, we created separate 
models for each of these four UNGD metrics. 
4.4.3.2 NORMALIZED DIFFERENCE VEGETATION INDEX (NDVI) ASSIGNMENT 
 
To evaluate the association between residential greenness and BNP, we first 
obtained data from the NASA MODIS satellite for the 16-day periods of annual maximum 
greenness for each calendar year from 2008-2015. We assigned the normalized 
difference vegetation index (NDVI), a measure of greenness, to subjects based on the 
NDVI values in the 1250 m x 1250 m grid surrounding their residential address, as has 
been done previously [57] (see Chapter 2, Section 2.5 for further detail on this data 
source). Maximum greenness values were assigned by the calendar year of each BNP 
laboratory order.  
4.4.3.3 DISTANCE TO MAJOR & MINOR ROAD AND NEAREST HOSPITAL OR CLINIC 
 
We obtained road network data from the Federal Highway Administration for both 
major and minor road classifications. Using ArcGIS 10.4, we calculated the Euclidian 
distance (in meters) from each subject’s residential address to both the nearest major 
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and minor roads using the Generate Near Table function. Similarly, we obtained the 
geographic locations of Geisinger’s clinics and hospitals in Pennsylvania, and we 
calculated the Euclidian distance (in meters) of each subject’s residential address to the 
nearest Geisinger hospital or clinic. 
 
4.4.4 STATISTICAL ANALYSIS 
 
We first examined the distribution of laboratory orders by person (see Chapter 6, 
Figures 6.3-6.12) to understand how subjects’ BNP values changed over time. We 
suspected that laboratory order setting (i.e., inpatient vs. outpatient) could be a 
confounder in our main analysis, so we examined subject characteristics by laboratory 
order setting (Table 4.2). To do so, we used only one measure per person (i.e., each 
subject’s first BNP laboratory measure) and conducted analysis of variance (ANOVA) F-
tests for continuous variables, and chi2 tests for categorical variables, to assess if any of 
these variables differed by subjects whose first BNP values were obtained in either an 
inpatient or outpatient setting. We then examined differences in mean BNP values 
across all selected BNP measures per subject by categorical factors using GEE models 
(Table 4.3). 
We dichotomized BNP measurements by clinical guidelines (i.e., whether a BNP 
value was < 400 pg/mL or ≥ 400 pg/mL, a common definition of acute heart failure 
[235]), and we examined descriptive statistics of the study population divided in this way 
(Table 4.4). We decided to dichotomize BNP for this analysis because this is a standard 
clinical approach to evaluate if acute dyspnea in individuals with heart failure is due to 
heart failure exacerbation [235], and because BNP evidences considerable intra-
individual and inter-individual variation that may not be biologically relevant to this 
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analysis [253], suggesting that modeling BNP on a continuous scale may be less 
meaningful.  
Since we standardized the minimum time period between adjacent laboratory 
measurements from each subject and limited the number of values per subject to no 
more than five, we were able to utilize logistic regression with generalized estimating 
equations to estimate the adjusted associations of UNGD metrics, CSD, NDVI, and 
distance to major/minor roads with the odds of high (≥ 400 pg/mL) vs. low (< 400 pg/mL) 
BNP values. We examined the associations between environmental factors in separate 
models because the metrics for UNGD, CSD, NDVI, and distance to major/minor roads 
evidenced non-positivity [254, 255] when included together, and our conceptual 
framework did not suggest that these were potential confounding variables (we were 
mainly interested in their main effect associations). In each of these models, we 
implemented an exchangeable correlation matrix [256].  
We first built our models for BNP based on our a priori knowledge of important 
factors such as: age, sex, race/ethnicity, smoking status, and receipt of Medical 
Assistance. We then evaluated how these associations changed after adjusting for 
medication use (antihyperlipidemic and anticoagulant medications), comorbidities as 
measured by the Charlson index, BMI, and inpatient vs. outpatient setting. For 
continuous variables such as the Charlson index and BMI, we first centered each of 
these variables and evaluated them as both centered and centered-squared terms to 
account for nonlinearity. Additionally, we evaluated several variables related to the 
timing of subjects’ BNP measurements: we suspected that the duration of the subjects’ 
heart failure might be important for their BNP measures, so we evaluated duration, in 
days, from each subjects’ first heart failure ICD-9 code to the date of the BNP laboratory 
value. Since these variables concerning time were measured as continuous variables 
(i.e. days), we centered these variables and evaluated them separately in models as 
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both centered and centered-squared terms. In model building, we retained variables if 
they resulted in more than a 5% change in the main effect of each environmental 
variable on BNP levels. We display this process of model building in Table 4.5. We 
evaluated model fit by examining the plots of model residuals and by goodness of fit 
tests [257]. 
We first adjusted for sex (female vs. male), race/ethnicity (nonwhite [including 
some Hispanic subjects] vs. white), smoking status (ever vs. ever), age at time of BNP 
value (centered), laboratory setting (inpatient vs. outpatient), receipt of Medical 
Assistance (ever vs. never up to time of BNP value), Charlson index (centered and 
centered squared), BMI (centered and centered squared), and chronic kidney disease 
(Model 1). We deemed it important to include chronic kidney disease in our base model 
because the condition directly impacts BNP levels, however we did not observe any 
effect modification of the associations between UNGD and BNP by chronic kidney 
disease [258]. Model 2 additionally adjusted for anticoagulant and antihyperlipidemic 
medications, and Model 3 included adjustment for duration of heart failure. Finally, we 
evaluated additional adjustment for year (Model 4), region (Model 5), and both region 
and year together (Model 6). These adjustments were important because the UNGD 
production metric considers total volume of natural gas produced, and so it only 
increases in value over time (i.e., it is the only UNGD activity metric that is cumulative 
over time – during our study period, once production started in a given well it did not 
stop, in contrast to the other three activity metrics, which each have defined starts and 
ends). We deemed adjustment for region important as well, as there were spatial 
patterns in the environmental metrics considered, and we wanted to adjust for to 
estimate more precisely the association between UNGD activity and odds of a BNP 




4.4.4.1 SENSITIVITY ANALYSES 
 
We conducted several sensitivity analyses. First, to evaluate whether our initial 
models could be biased from individuals who had more than one BNP laboratory value 
in the analysis, we randomly selected one BNP value per person and repeated models 
(Table 4.6). Second, we repeated models with inverse probability weights generated 
from the odds of being selected from the 13,183 eligible subjects (details on inverse 
probability weighted analysis in Chapter 2, Section 8.2).  We evaluated Inverse 
probability weighted models in two ways: first, we utilized all generated weights (Table 
4.7, Model 1), and second, we truncated weights at the 99th percentile and evaluated a 
model that accounted for truncated inverse probability weights (Table 4.7, Model 2). A 
final sensitivity analysis used linear regression to model ln-BNP as a continuous 
outcome (Table 4.8). Because the distribution of raw BNP values was right-skewed 
(Figure 4.1a), we natural log transformed BNP values (Figure 4.1b) so that we did not 
violate normality assumptions in this model. 
4.5 RESULTS 
4.5.1 DESCRIPTION OF STUDY SUBJECTS, BNP VALUES, AND UNGD METRICS 
We identified 3938 subjects with 6501 laboratory measurements for BNP. These 
subjects had a mean (SD) age of 71.7 (12.0) years and were comprised of 2097 (53.2%) 
males and 1841 (46.7%) females. Study subjects were predominantly white (n = 3834, 
97.4%) and 408 (10.4%) had ever received Medical Assistance. The mean (SD) BNP 
value among these 6501 laboratory measurements was 478.8 (637.5) pg/mL with a 
median value of 258 pg/mL. The majority (62.0%) of the 3938 subjects had only one 
BNP value (Table 4.1), however we included up to a maximum of five BNP measures for 
the individuals who had this information (n = 128). We also observed spatial patterns in 
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the environmental metrics we evaluated (Figures 4.2a-e), with clearer spatial patterns in 
the UNGD metrics (Figures 4.2b-e) than in the distribution of NDVI quartiles across 
study subjects (Figure 4.2a). 
 
4.5.2 UNADJUSTED ASSOCIATIONS 
 
We examined the setting of each subjects’ first BNP laboratory order and 
determined that 2235 (56.8%) were obtained in an inpatient setting and 1703 (43.3%) in 
an outpatient setting. We used these first laboratory measures to present descriptive 
statistics of the study population (Table 4.2) by inpatient vs. outpatient setting. Subjects 
whose laboratory orders were obtained from an outpatient (vs. inpatient) setting had a 
higher usage of antihypertensive (p < 0.001), antihyperlipidemic (p < 0.001), and 
anticoagulant (p = 0.003) medications. Subjects whose laboratory orders were obtained 
from an inpatient (vs. outpatient) setting were more likely to have a diagnosis of chronic 
kidney disease (p < 0.001), hypertension (p < 0.001), myocardial infarction (p = 0.02), 
chronic obstructive pulmonary disease (p < 0.001), and type 2 diabetes (p < 0.001). 
Those who had their laboratory measures obtained from an inpatient (vs. outpatient) 
setting were slightly younger (mean age = 70.7 years vs. 72.2 years, p < 0.001) and 
lived slightly closer to the nearest hospital or clinic (p = 0.009) (Table 4.2).  
We next evaluated associations of several comorbidities, medications, and 
demographic factors with continuous BNP levels using GEE models of ln-BNP (Table 
4.3) across all 6501 laboratory measures from the 3938 subjects. We observed higher 
BNP levels in inpatient (vs. outpatient, p < 0.001) settings. Individuals receiving Medical 
Assistance had, on average, lower BNP levels than those who never received Medical 
Assistance (p < 0.001). Laboratory orders with the presence of comorbidities such as 
hypertension, myocardial infarction, valve disease, chronic obstructive pulmonary 
 127 
disease, type 2 diabetes, and coronary artery disease had higher mean BNP values than 
those who did not (p < 0.001, p < 0.001, p < 0.001, p = 0.04, p = 0.01 and p = 0.002, 
respectively).  
There were no differences in mean BNP values by quartile of CSD or the pad 
preparation, stimulation, or production UNGD metrics. In contrast, mean BNP did differ 
by quartiles of the spud metric (p = 0.01), but not in a clear exposure-effect pattern. 
Mean BNP values declined across quartiles of NDVI (p for trend = 0.06).  
We evaluated associations of selected variables with BNP values divided at 400 
pg/mL as previously described. There was a lower proportion of subjects in the 4th 
quartile of NDVI with high (vs. low) BNP values (p = 0.08, Table 4.4). Subjects with BNP 
values  400 pg/mL (vs. lower) were slightly older (mean age of 73.7 years vs. 71.0 
years, p < 0.001), had higher Charlson index scores (9.7 vs. 8.6, p < 0.001), and a 
higher prevalence of such comorbidities as chronic kidney disease (p < 0.001), previous 
myocardial infarction (p < 0.001), valve disease (p < 0.001), and hypertension (p = 
0.007) (Table 4.4). Subjects with high (vs. low) BNP values lived closer to minor roads 
(1384 meters vs. 1615 meters, p = 0.003).  
4.5.3 ADJUSTED ASSOCIATIONS OF UNGD AND OTHER ENVIRONMENTAL FACTORS 
WITH BNP 
We next used logistic regression with generalized estimating equations (GEE) 
with an exchangeable correlation matrix to evaluate associations between UNGD 
activity, NDVI, CSD, and distance to major/minor roads with high (vs. low) BNP values 
(Table 4.5). There were no associations (OR [95% CI]) of UNGD metrics with high (vs. 
low) BNP values in Model 1, with the exception of the 2nd quartile of the production 
metric (1.20 [1.04, 1.37]). After adjusting for anticoagulant and antihyperlipidemic 
medications, the 2nd (vs. 1st) quartiles of both the spud metric and distance to minor 
roads were associated with BNP (Table 4.5, Model 2). Additional adjustment for 
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duration of heart failure did not substantially change any associations (Table 4.5, Model 
3). Finally, we evaluated additional adjustment for year (Table 4.5, Model 4), region 
(Table 4.5, Model 5), and both region and year together (Table 4.5, Model 6). In the 
final, fully-adjusted model (Table 4.5, Model 6), there was an exposure-effect relation 
(OR [95% CI]) of UNGD production activity with BNP across UNGD quartiles of 1.36 
(1.08, 1.71), 1.42 (1.05, 1.93), and 1.52 (1.07, 2.17) for the 2nd, 3rd, and 4th quartiles (vs. 
1st), respectively. 
4.5.4 SENSITIVITY ANALYSES 
First, when we included only one randomly selected observation per subject from 
the final model there were no associations of UNGD activity metrics with BNP levels 
(Table 4.6). Using the same values, in this model there was an association (OR [95% 
CI]) of the 4th quartile (vs. 1st) of NDVI with high (vs. low) BNP, of 0.80 (0.66, 0.98). 
Second, we evaluated models weighted for the inverse probability of inclusion in the 
analysis in two ways, first using native inverse probability weights and second using 
truncated weights. These two analyses did not reveal substantive changes in 
associations (Table 4.7, Model 1 and Figure 4.3a [native] and Model 2 and Figure 
4.3b [truncated]). Finally, we used linear regression to model ln-BNP on a continuous 
scale (Table 4.8) In this analysis, associations of the UNGD production metric with BNP 
were substantively the same as for the dichotomized analysis. 
4.6 DISCUSSION 
To our knowledge, no prior studies have evaluated associations of such 
community and environmental factors as UNGD, greenness (using NDVI), and 
community social conditions leading to stress (using CSD) with BNP values in a large-
scale, population-based epidemiologic study. BNP was considered to be an excellent 
candidate biomarker for this purpose because it is released by cardiac tissue under 
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stress due to ischemia, fibrosis, congestion, or cardiac remodeling [235] and can be 
measured in the blood. BNP is also associated with heart failure severity and survival 
[30, 123, 237]. Given our prior findings (Chapter 3) of associations of UNGD activity 
metrics with hospitalization among subjects with heart failure, we sought to evaluate 
whether these metrics were also associated with BNP. We hypothesized that UNGD 
metrics and CSD would be associated with greater blood BNP concentrations among 
heart failure patients, and that NDVI and distances to major and minor roads would be 
associated with lower blood BNP concentrations among heart failure patients.  
We found consistent exposure-effect associations between quartiles of UNGD 
production activity and higher levels of BNP in both continuous and logistic models of 
6501 BNP values among 3938 subjects with heart failure diagnoses from 2008 - 2015. 
We did not see any consistent associations between other UNGD metrics, NDVI, CSD, 
or distance to major and minor roads, and odds of BNP  400 pg/mL. We are confident 
that our models accounted for the various measured risk factors and comorbid 
conditions that are related to both heart failure and blood concentrations of BNP. These 
included sex, age, smoking status, relevant medication use (antihyperlipidemic and 
anticoagulant medications) at the time of the laboratory order, chronic kidney disease, 
BMI, and the Charlson index of morbidity. Additionally, we attempted to account for the 
duration of subjects’ heart failure, by measuring the time (in days) from the first 
diagnosis code for heart failure in the EHR to the date of laboratory order.  
Exposure-effect relations between UNGD production activity and higher BNP 
levels were present in sensitivity analyses that accounted for the inverse probability of 
being selected into this study and also in a linear model of ln-BNP. However, the 
association between UNGD production activity and BNP was not present in a sensitivity 
analysis that included only one randomly selected observation per person, utilizing 3938 
laboratory orders as opposed to 6501 laboratory orders. Although this sensitivity 
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analysis was adequately powered, it is possible that we did not see an association with 
the production metric because we limited our analysis to only 61% of the available 
laboratory measurements, and the associations present in our main analysis were driven 
by the values for the remaining 39% of laboratory measurements. We speculate that 
these contrasting associations may also be because first BNP values were routinely 
obtained but subsequent measures were obtained due to concern of exacerbating heart 
failure. Because of this sensitivity analysis, the association present in the main analysis 
and in the inverse probability weighted analysis should be interpreted with caution. The 
contrasting ways that BNP is used and how heart failure hospitalization occurs also 
could explain, at least in part, the discordant results between this chapter and those in 
Chapter 3. 
 It is well-documented that UNGD is associated with a suite of environmental 
factors that can negatively impact community health, including air pollution (e.g., NOx, 
PM2.5, volatile organic compounds [VOCs], ozone), noise, traffic, and psychosocial 
stress [27, 132]. Of the four UNGD metrics that we calculated, the production metric is 
the only phase that did not end at a given well during our study period. Whereas the pad 
preparation, spud, and stimulation activity metrics reflect intermittent and limited-duration 
activities, the production metric cumulates over time as more and more wells are drilled, 
completed, enter production, and stay in production. The numerator for the production 
metric is the daily total volume of natural gas produced by the well, and once a well 
begins to produce natural gas, it continues to produce a nonzero volume on a daily 
basis. We speculate that a cumulating activity metric is more likely to evidence 
associations with a biomarker of heart failure than are the short-term activities at UNGD 
sites. 
Another possible explanation for the contrasting associations of the UNGD 
activity metrics is that the UNGD production metric can also be an indicator for 
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compressor engine activity, which has been associated with increased noise levels [4]. 
Additionally, it is well documented that several air pollutants (PM2.5, VOCs, NOx, CO) are 
associated with the production phase of development [27, 233]. This might explain why 
we saw associations between the production metric and BNP but not the other UNGD 
metrics, as we observed for heart failure hospitalization in Chapter 3. However, since 
we have not been able to measure air pollutants, noise levels, or experiences of 
psychosocial stress directly, we cannot distinguish among these potential exposure and 
mechanistic pathways. 
We suspect that we saw associations between multiple metrics (pad preparation, 
stimulation, and production) of UNGD activity and hospitalization for heart failure in 
Chapter 3, but only associations between UNGD production and odds of BNP  400 
pg/mL in this analysis for several reasons. First, we believe that measurements of blood 
concentrations of BNP are more objective measures than hospitalization, which is 
dependent upon clinical decision making (i.e., a physician must make a determination to 
hospitalize a patient, a decision that could include such patient factors as frailty, social 
support, and access to the hospital) and heart failure management protocols that are 
designed to reduce health care costs by keeping patients out of the hospital. BNP can 
also be elevated among individuals with heart failure who are asymptomatic [237], and it 
has been associated with survival in individuals with and without heart failure [121]. 
Second, the different UNGD activity metrics reflect different exposure scenarios; pad 
preparation and stimulation activity metrics represent a substantial amount of truck 
traffic, whereas the production metric reflects compressor engine activity and the off-
gassing of volatile organic compounds from produced natural gas. Third, although each 
UNGD activity metric was measured for a 30-day duration with a 1-day lag prior to the 
date of the BNP laboratory order, the production metric captures and cumulates ongoing 
UNGD activity, since production of natural gas at any individual well did not end during 
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our study period and total natural gas production in the state increased very dramatically 
during our study period. It is possible, then, that the association of UNGD production 
with BNP was the only one observed among the activity metrics because as it cumulated 
it was the only one to exceed a threshold of proximity to and intensity of sustained 
natural gas production. Fourth, it should be noted that the associations between the 
UNGD production metric were not present in a sensitivity analysis using only one 
observation per subject; thus the associations between UNGD production activity and 
BNP are driven primarily by individuals who have received multiple BNP measurements, 
and were presumably more severe in their heart failure, compared to individuals who 
only had one BNP measurement. Lastly, the laboratory measures in this analysis were 
obtained from both inpatient and outpatient settings, so this analysis reflects BNP levels 
from heart failure subjects who may not be experiencing an acute exacerbation, and who 
may be actively managing their heart failure through routine medical supervision and 
continued treatment. 
Recent studies have called for more research into heart failure risk factors and 
outcomes because the public health burden of heart failure is increasing, and 
socioeconomic disparities in incidence have widened in recent years, suggesting that 
environmental factors could play a role in heart failure burden [210, 259]. Despite this, 
we have not been able to identify any large, population based studies of associations 
between environmental factors and BNP. Of the few studies that have assessed how 
environmental factors may be associated with BNP, generalizability of the results is 
limited by small sample sizes (i.e., n = 28 - 45) [124-126]. However, there is some 
evidence from these studies that air pollution exposure may impact BNP levels; in a 
study of both heart failure diagnosed subjects and healthy controls exposed to filtered 
and unfiltered diesel exhaust, the heart failure subjects had higher BNP levels and 
measures of endothelial dysfunction after exposure to unfiltered diesel exhaust, and that 
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filtered diesel exhaust reduced both measures of endothelial dysfunction and BNP [125]. 
Although this sample size was relatively small (n = 45), the findings support the biologic 
rationale for evaluating associations between environmental factors and BNP in a larger 
population. Similarly, a recent study in Colorado assessed cross-sectional associations 
of oil and gas activity with several other cardiac biomarkers in 249 healthy individuals 
and found that the highest levels of oil and gas activity and intensity were associated 
with higher blood pressure and slightly higher levels of IL-1 and -TNF, two 
inflammatory markers [66]. This study considered oil production in addition to natural gas 
production and was also limited by a small sample size, but the findings support the 
plausible biologic pathway that implicates systemic inflammation in the progression of 
cardiac disease.  
Our study limitations include the lack of information regarding individual 
socioeconomic status (e.g., household income), occupation, and reported well-being, all 
of which could impact an individual’s heart failure prognosis [80, 143, 206]. A major 
limitation to this study is that we were not able to directly measure the air pollutants, 
noise levels, or psychosocial stress that we suspect are coming from the specific phases 
of UNGD. Therefore, it is not possible to disentangle psychosocial stress due to UNGD 
activity from the pollutants that UNGD activity is known to emit and which are known to 
have adverse cardiovascular impacts on exposed populations [24, 124, 129, 130, 260]. 
All three of these factors (air pollution, noise, psychosocial stress) are associated with 
systemic inflammation and endothelial dysfunction and thus could act on the same 
pathway leading to increased BNP. The lack of associations with NDVI could be due to 
our choice of peak greenness, as a feature of community context, rather than short-
latency, time-varying measures of NDVI, for example, during the two weeks before the 
BNP measure. The lack of associations of CSD with BNP levels may be due to the fact 
that it is a measure of community context rather than a direct measure of individual-level 
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exposure to stress-causing events. Finally, future studies should evaluate network, 
rather than Euclidian, distances to health care facilties. 
 The study had several strengths, including the objective and independent 
assessment of environmental and community conditions and outcome; the large sample 
size; the general population representative sample; increasing covariate control; and 
systematic recording of data in the EHR for several years of observation. Furthermore, 
all of the BNP laboratory measurements were made at a central Geisinger laboratory 
facility, reducing the possibility of inter-laboratory variation in BNP measurements.  
4.7 CONCLUSIONS  
 This is the first study to examine the clinical cardiac biomarker BNP in a large 
scale epidemiologic study of relevant environmental factors: UNGD activity, greenness, 
CSD, and distance to major and minor roads. In adjusted models, we observed 
exposure-effect relations of the UNGD production metric with high (vs. low) BNP values 
using a clinically-relevant cutoff [235]. The associations between greater UNGD activity 
and increased blood levels of BNP are biologically plausible given the functionality of 
BNP in response to exposure to air pollution, ventricular blood pressure, and subsequent 
acute cardiac myocyte stress [107, 125, 235, 239]. This has public health relevance 
because higher BNP levels have been associated with poor prognosis and mortality 
among individuals with and without heart failure [121]. Lastly, these findings are 
consistent with previous epidemiologic studies of UNGD activity phases and objectively 
measured health outcomes, adding to a growing body of literature supporting the 
negative impacts of UNGD on population health [13, 15, 17, 18, 65].  
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Figure 4.1a. Histogram of unadjusted B-type natriuretic peptide (BNP) values (n 
= 6501) 
 
Figure 4.1b. Histogram of unadjusted B-type natriuretic peptide (BNP) values 
after ln-transformation (ln-BNP) (n = 6501) 
 
Figure 4.2a. Greenness using normalized difference vegetation index (NDVI) 
quartiles assigned to residential address of subjects’ with B-type natriuretic 
peptide (BNP) measures in study area in Pennsylvania 
 
Figure 4.2b. Unconventional natural gas development (UNGD) pad activity 
metric quartiles assigned to residential address of subjects’ with B-type 
natriuretic peptide (BNP) measures in study area in Pennsylvania. 
 
Figure 4.2c. Unconventional natural gas development (UNGD) spud activity 
metric quartiles assigned to residential address of subjects’ with B-type 
natriuretic peptide (BNP) measures in study area in Pennsylvania. 
Figure 4.2d. Unconventional natural gas development (UNGD) stimulation 
activity metric quartiles assigned to residential address of subjects’ with B-type 
natriuretic peptide (BNP) measures in study area in Pennsylvania. 
Figure 4.2e. Unconventional natural gas development (UNGD) production 
activity metric quartiles assigned to residential address of subjects’ with B-type 
natriuretic peptide (BNP) measures in study area in Pennsylvania. 
 
Figure 4.3a. Histogram of inverse probability weights to account for selection into 
the study. The model to generate these weights adjusted for: smoking status, 
time of contact with the electronic health records (EHRs), Charlson index, age, 
diagnosis of myocardial infarction, coronary artery disease, valve disease, 
chronic kidney disease, and anticoagulant medication. Subjects with very high 
weights in the right tail of this distribution had a very low probability of being 
selected into the BNP study according to this model (i.e., these subjects did not 
have many comorbidities, were generally younger, and had less time of 
observation in the EHR than those who had a higher probability of being selected 
into the study). Thus, the inverse probability weights for these subjects are very 
high. 
 
Figure 4.3b. Histogram of inverse probability weights to account for selection, 
truncated at the 99th percentile of weights for all 3938 subjects (maximum inverse 





Table 4.1. Number of B-type natriuretic peptide (BNP) values per subject 
 
BNP values in analysis per 
person Subjects*, n (%) 
1 2441 (62.0) 
2 858 (21.8) 
3 340 (8.6) 
4 171 (4.3) 
5 128 (3.3) 
Total 3938 
*Number of unique subjects by number of BNP measure
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Table 4.2. Descriptive statistics of study population by first B-type natriuretic peptide (BNP) laboratory 
order, by setting, n = 3938 
Variable 
Laboratory Order Setting  
Outpatient Inpatient  
n = 1703 n = 2235 p-value* 
Age, mean (SD) 72.2 (11.6) 70.7 (12.3) < 0.001 
Charlson index, mean (SD) 8.7 (2.7) 8.9 (3.1) 0.01 
Sex, n (%) 
    Female 










Race/ethnicity, n (%) 
    White 










Community type, n (%) 
    Borough 
    Township 













Receipt of Medical Assistance, n 
(%) 
    Prior to laboratory date 149 (8.8) 259 (11.6) 
 
0.004 
Body mass index (BMI) at event, 







Smoking status, n (%) 
    Ever 










Antihyperlipidemic medication, n 
(%) 







Anticoagulant medication, n (%) 







Antihypertensive medication, n 
(%) 838 (49.2) 847 (37.9) < 0.001 
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    At laboratory date 
Diagnosis of chronic kidney 
disease, n (%) 







Diagnosis of myocardial 
infarction,  
n (%) 







Diagnosis of valve disease, n (%) 
    Prior to laboratory date 319 (18.7) 432 (19.3) 0.6 
Diagnosis of chronic obstructive 
pulmonary disease, n (%) 







Diagnosis of hypertension, n (%) 
    Prior to laboratory date 1005 (59.0) 1566 (70.1) < 0.001 
Diagnosis of diabetes, n (%) 
    Prior to laboratory date 592 (34.8) 985 (44.1) < 0.001 
Distance to nearest hospital or 
clinic, mean (SD), meters 6890.6 (7866.3) 6213.4 (8104.8) 0.009 
Distance to nearest major road, 







Distance to nearest minor road, 







Pad preparation metric, n 
(%),1/m2 ** 
    Q1 (1.22 X 10-10, 1.76 X 10-9) 
    Q2 (1.76 X 10-9, 3.61 X 10-9) 
    Q3 (3.61 X 10-9, 6.04 X 10-9) 
















Spud metric, n (%),1/m2 ** 
    Q1 (4.9 X 10-12, 4.13 X 10-11) 











    Q3 (1.17 X 10-10, 1.59 X 10-10) 







Stimulation metric, n (%), m/m2 ** 
    Q1 (0, 2.49 X 10-6) 
    Q2 (2.50 X 10-6, 1.24 X 10-5) 
    Q3 (1.24 X 10-5, 2.68 X 10-5) 
















Production metric, n (%), m3/m2 ** 
    Q1 (1.03 X 10-7, 9.64 X 10-6) 
    Q2 (9.69 X 10-6, 8.95 X 10-5) 
    Q3 (8.97 X 10-5, 3.07 X 10-4) 
















NDVI***, n (%), unitless  
    Q1 (0.17, 0.58) 
    Q2 (0.58, 0.68) 
    Q3 (0.68, 0.77) 
















CSD†, n (%), SD units  
    Q1 (-14.6, -8.3) 
    Q2 (-8.3, - 5.9) 
    Q3 (-5.9, -3.1) 
















*p-value obtained from one-way analysis of variance (ANOVA) F-test for continuous variables, chi
2
 test statistic for categorical variables 
** Ranges for quartiles of UNGD activity metrics are listed next to each quartile 
***
Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 250 m grid surrounding a subject’s residential 
address for the period of maximum annual greenness in the year of each laboratory measurement 
†




Table 4.3. Unadjusted bivariate associations of selected categorical variables with B-type natriuretic 
peptide (BNP) values on a continuous scale 
 
Variable 
Number (%) out 
of 6501 values 





    Female 











    White 











    Borough 
    Township 














    Outpatient 










Receipt of Medical Assistance 
    Ever prior to laboratory date 











    Yes 










Type 2 diabetes diagnosis** 
    Yes 










Myocardial infarction diagnosis** 
    Yes 









 < 0.001 
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Chronic obstructive pulmonary 
disease diagnosis** 
    Yes 










Valve disorder diagnosis** 
    Yes 






455.5 (623.1)  < 0.001 
Coronary artery disease 
diagnosis** 
    Yes 











    Ever 











at time of laboratory date 
    Yes 










Anticoagulant medication, at 
time of laboratory date 
    Yes 













Antihypertensive medication, at 
time of laboratory date 
    Yes 









Diagnosis of chronic kidney 
disease** 
    Yes 








Pad preparation metric, n 
(%),1/m2*** 
    Q1 (1.22 X 10-10, 1.76 X 10-9) 
    Q2 (1.76 X 10-9, 3.61 X 10-9) 
    Q3 (3.61 X 10-9, 6.04 X 10-9) 
















Spud metric, n (%),1/m2 *** 
    Q1 (4.9 X 10-12, 4.13 X 10-11) 
    Q2 (4.2 X 10-11, 1.17 X 10-10) 
    Q3 (1.17 X 10-10, 1.59 X 10-10) 
















Stimulation metric, n (%), m/m2 
*** 
    Q1 (0, 2.49 X 10-6) 
    Q2 (2.50 X 10-6, 1.24 X 10-5) 
    Q3 (1.24 X 10-5, 2.68 X 10-5) 
















Production metric, n (%), m3/m2 
*** 
    Q1 (1.03 X 10-7, 9.64 X 10-6) 
    Q2 (9.69 X 10-6, 8.95 X 10-5) 
    Q3 (8.97 X 10-5, 3.07 X 10-4) 
















NDVI†, n (%), unitless  
    Q1 (0.17, 0.58) 
    Q2 (0.58, 0.68) 
    Q3 (0.68, 0.77) 

















CSD††, n (%), SD units  
    Q1 (-14.6, -8.3) 
    Q2 (-8.3, - 5.9) 
    Q3 (-5.9, -3.1) 
















*p-value obtained from unadjusted generalized estimating equations with ln-BNP as the outcome 
** Diagnoses were classified as yes if subject had at least two diagnosis codes for the condition prior to the laboratory date 
*** Ranges for quartiles of UNGD activity metrics are listed next to each quartile 
†
Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 250 m grid surrounding a subject’s residential 
address for the period of maximum annual greenness in the year of each laboratory measurement 
††
Community socioeconomic deprivation (CSD), measured from the 2010 US Census American Community Survey at each subject’s designated place. 
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Table 4.4. Descriptive statistics of study population at the time of the first 
BNP laboratory order, by diagnostic cutoff of 400 pg/mL, n = 3838 
Variable 
Laboratory value  
< 400 pg/mL ≥ 400 pg/mL  
n = 2459 n = 1479 p-
value* 
Age, mean (SD) 
71.0 (12.2) 73.7 (11.6) 
< 
0.001 
Charlson index, mean (SD) 
8.6 (3.2) 9.7 (3.3) 
< 
0.001 
Sex, n (%) 
    Female 




820 (55.4) 0.03 
Race/ethnicity, n (%) 
    White 




35 (2.4) 0.4 
Community type, n (%) 
    Borough 
    Township 






196 (13.3) 0.002 
Receipt of Medical Assistance, 
n (%) 
     Prior to laboratory date 282 (11.5) 126 (8.5) 0.003 
Body mass index (BMI) at 
event, kg/m2, mean (SD) 33.4 (8.4) 29.5 (7.7) 
< 
0.001 
Smoking status, n (%) 
    Ever 




604 (40.8) 0.01 
Antihyperlipidemic medication, 
n (%) 
    At laboratory date 1369 (55.7) 744 (50.3) 0.001 
Anticoagulant medication, n (%) 
    At laboratory date 673 (27.4) 440 (29.8) 0.1 
Antihypertensive medication, n 
(%) 
    At laboratory date 1288 (52.4) 676 (45.7) 
< 
0.001 
Diagnosis of chronic kidney 
disease, n (%) 
    Prior to laboratory date 1132 (46.0) 817 (55.2) 
< 
0.001 
Diagnosis of myocardial 
infarction, n (%) 
    Prior to laboratory date 223 (9.1) 214 (14.5) 
< 
0.001 
Diagnosis of valve disease, n 
(%) 




Diagnosis of chronic obstructive 
pulmonary disease, n (%) 
    Prior to laboratory date 627 (25.5) 350 (23.7) 0.2 
Diagnosis of hypertension, n 
(%) 
    Prior to laboratory date 1583 (64.4) 1014 (68.6) 0.007 
Diagnosis of diabetes, n (%) 
    Prior to laboratory date 988 (40.2) 623 (42.1) 0.2 
Distance to nearest hospital or 
clinic, mean (SD), meters 6574 (7834) 6395 (8292) 0.5 
Distance to nearest major road, 
mean (SD), meters 2650 (4008) 2622 (4270) 0.8 
Distance to nearest minor road, 
mean (SD), meters 1615 (2448) 1384 (2085) 0.003 
Pad preparation metric, n 
(%),1/m2 ** 
    Q1 (1.22 X 10-10, 1.76 X 10-9) 
    Q2 (1.76 X 10-9, 3.61 X 10-9) 
    Q3 (3.61 X 10-9, 6.04 X 10-9) 








397 (26.8) 0.1 
Spud metric, n (%),1/m2 ** 
    Q1 (4.9 X 10-12, 4.13 X 10-11) 
    Q2 (4.2 X 10-11, 1.17 X 10-10) 
    Q3 (1.17 X 10-10, 1.59 X 10-
10) 









428 (28.9) 0.2 
Stimulation metric, n (%), m/m2 
** 
    Q1 (0, 2.49 X 10-6) 
    Q2 (2.50 X 10-6, 1.24 X 10-5) 
    Q3 (1.24 X 10-5, 2.68 X 10-5) 












Production metric, n (%), m3/m2 
** 
    Q1 (1.03 X 10-7, 9.64 X 10-6) 
    Q2 (9.69 X 10-6, 8.95 X 10-5) 
    Q3 (8.97 X 10-5, 3.07 X 10-4) 












NDVI***, n (%), unitless  
    Q1 (0.17, 0.58) 
    Q2 (0.58, 0.68) 
    Q3 (0.68, 0.77) 








250 (23.7) 0.08 
CSD†, n (%), SD units  




361 (24.4) 0.4 
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    Q2 (-8.3, - 5.9) 
    Q3 (-5.9, -3.1) 





*p-value obtained from one-way analysis of variance (ANOVA) F-test for continuous variables, chi
2
 test 
statistic for categorical variables 
** Ranges for quartiles of UNGD activity metrics are listed next to each quartile 
***Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 
250 m grid surrounding a subject’s residential address for the period of maximum annual greenness in the 
year of each laboratory measurement 
†
Community socioeconomic deprivation (CSD), measured from the 2010 US Census American Community 







































































Figure 4.2b.  
 
 155 
Figure 4.2c.  
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Table 4.5. Adjusted associations (odds ratio [OR], 95% confidence interval [CI]) of unconventional natural gas 
development (UNGD), normalized difference vegetation index (NDVI), community socioeconomic deprivation 
(CSD), and distance to roads (in quartiles) with B-type natriuretic peptide (BNP) value ≥ 400 pg/mL (vs. lower) 
  Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
Metric Quartile OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) 
Pad preparation 1 Ref Ref Ref Ref Ref Ref 
 2 0.97 (0.84, 1.12) 0.98 (0.85, 1.13) 0.98 (0.85, 1.14) 0.97 (0.82, 1.14) 0.98 (0.85, 1.14) 0.97 (0.83, 1.14) 
 3 1.09 (0.95, 1.26) 1.11 (0.96, 1.28) 1.12 (0.97, 1.30) 1.09 (0.91, 1.30) 1.15 (0.99, 1.33) 1.12 (0.93, 1.35) 
 4 1.04 (0.90, 1.21) 1.06 (0.91, 1.23) 1.08 (0.92, 1.25) 1.02 (0.84, 1.24) 1.10 (0.94, 1.29) 1.06 (0.87, 1.30) 
Spud 1 Ref Ref Ref Ref Ref Ref 
 2 1.15 (1.00, 1.32) 1.16 (1.01, 1.34) 1.17 (1.01, 1.35) 1.12 (0.91, 1.38) 1.17 (1.01, 1.35) 1.11 (0.90, 1.37) 
 3 1.04 (0.90, 1.20) 1.05 (0.91, 1.22) 1.06 (0.92, 1.23) 1.04 (0.81, 1.34) 1.07 (0.92, 1.24) 1.02 (0.80, 1.32) 
 4 1.10 (0.95, 1.28) 1.12 (0.96, 1.30) 1.15 (0.98, 1.34) 1.15 (0.88, 1.50) 1.13 (0.96, 1.32) 1.10 (0.83, 1.44) 
Stimulation 1 Ref Ref Ref Ref Ref Ref 
 2 1.08 (0.94, 1.24) 1.09 (0.94, 1.25) 1.10 (0.95, 1.27) 1.01 (0.85, 1.20) 1.10 (0.95, 1.26) 1.01 (0.85, 1.21) 
 3 1.06 (0.92, 1.23) 1.08 (0.93, 1.25) 1.10 (0.94, 1.27) 0.99 (0.79, 1.24) 1.10 (0.95, 1.28) 1.02 (0.81, 1.27) 
 4 1.02 (0.88, 1.18) 1.03 (0.89, 1.19) 1.03 (0.89, 1.20) 0.97 (0.76, 1.23) 1.04 (0.90, 1.22) 1.00 (0.79, 1.28) 
Production 1 Ref Ref Ref Ref Ref Ref 
 2 1.20 (1.04, 1.37) 1.21 (1.06, 1.39) 1.24 (1.07, 1.42) 1.33 (1.06, 1.68) 1.23 (1.07, 1.42) 1.36 (1.08, 1.71) 
 3 1.12 (0.97, 1.29) 1.14 (0.98, 1.32) 1.16 (1.00, 1.35) 1.36 (0.99, 1.81) 1.17 (1.01, 1.36) 1.42 (1.05, 1.93) 
 4 1.10 (0.95, 1.28) 1.13 (0.97, 1.31) 1.12 (0.96, 1.31) 1.39 (0.99, 1.96) 1.14 (0.97, 1.34) 1.52 (1.07, 2.17) 
NDVI* 1 Ref Ref Ref Ref Ref Ref 
 2 0.97 (0.82, 1.14) 0.97 (0.83, 1.14) 0.97 (0.82, 1.14) 0.98 (0.84, 1.16) 0.96 (0.82, 1.13) 0.97 (0.83, 1.15) 
 3 1.01 (0.85, 1.19) 1.01 (0.85, 1.19) 1.01 (0.85, 1.19) 1.04 (0.88, 1.23) 1.00 (0.84, 1.18) 1.03 (0.87, 1.22) 
 4 0.90 (0.76, 1.07) 0.90 (0.76, 1.07) 0.89 (0.75, 1.06) 0.93 (0.78, 1.10) 0.88 (0.74, 1.04) 0.91 (0.77, 1.09) 
CSD** 1 Ref Ref Ref Ref Ref Ref 
 2 0.82 (0.78, 1.10) 0.92 (0.77, 1.09) 0.92 (0.77, 1.09) 0.92 (0.77, 1.09) 0.90 (0.75, 1.07) 0.90 (0.75, 1.07) 
 3 0.92 (0.78, 1.10) 0.92 (0.77, 1.10) 0.92 (0.77, 1.10) 0.92 (0.77, 1.10) 0.93 (0.78, 1.11) 0.93 (0.78, 1.11) 
 4 1.11 (0.93, 1.32) 1.10 (0.92, 1.31) 1.10 (0.92, 1.31) 1.10 (0.92, 1.31) 1.10 (0.92, 1.31) 1.10 (0.93, 1.32) 









1.06 (0.89, 1.27) 
1.09 (0.91, 1.30) 
1.00 (0.83, 1.19) 
Ref 
1.06 (0.89, 1.26) 
1.09 (0.92, 1.30) 
0.99 (0.83, 1.18) 
Ref 
1.07 (0.90, 1.28) 
1.10 (0.92, 1.31) 
1.00 (0.84, 1.19) 
Ref 
1.07 (0.89, 1.27) 
1.10 (0.92, 1.31) 
1.00 (0.84, 1.20) 
Ref 
1.08 (0.90, 1.28) 
1.09 (0.91, 1.31) 
1.00 (0.84, 1.20) 
Ref 
1.07 (0.89, 1.29) 
1.09 (0.91, 1.31) 
1.00 (0.84, 1.20) 
 159 









0.85 (0.71, 1.01) 
0.93 (0.78, 1.10) 
0.91 (0.77, 1.09) 
Ref 
0.84 (0.70, 1.00) 
0.92 (0.78, 1.10) 
0.91 (0.76, 1.08) 
Ref 
0.83 (0.70, 0.99) 
0.92 (0.77, 1.09) 
0.91 (0.76, 1.08) 
Ref 
0.83 (0.70, 0.99) 
0.92 (0.77, 1.10) 
0.91 (0.76, 1.08)  
Ref 
0.83 (0.69, 0.99) 
0.91 (0.76, 1.08) 
0.88 (0.74, 1.05) 
Ref 
0.83 (0.70, 0.99) 
0.91 (0.77, 1.09) 
0.88 (0.74, 1.05) 
*Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 250 m grid surrounding a subject’s residential 
address for the period of maximum annual greenness in the year of each laboratory measurement 
**Community socioeconomic deprivation (CSD), measured from the 2006-2010 US Census American Community Survey at each subject’s designated 
community type. 
†
Distance from each subject’s residential address to major and minor roads was calculated in meters using road data from the Federal Highway 
Administration and ArcGIS 10.4’s Generate Near Table function 
Model 1: GEE model with an exchangeable correlation matrix, adjusted for sex (female vs. male), nonwhite vs.white, smoking status (ever vs.never), age 
at time of laboratory date (centered), laboratory setting (inpatient/outpatient), receipt of Medical Assistance (ever vs. never prior to laboratory date), 
Charlson index (centered and centered squared), body mass index BMI (centered and centered squared), and diagnosis of chronic kidney disease 
Model 2: Model 1 + antihyperlipidemic medication and anticoagulant medication 
Model 3: Model 2 + duration of HF (date of lab order – the date of first HF diagnosis, included as a centered and centered squared term) 
Model 4: Model 3 + year 
Model 5: Model 3 + region 
Model 6: Model 5 + year
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Table 4.6. Summary of the adjusted odds ratios for a B-type natriuretic peptide 
(BNP) value ≥ 400 pg/mL, by quartile of various environmental metrics, sensitivity 
analyses with only one observation per person 
  Model 1 
Metric Quartile OR (95% CI) 
Pad preparation 1 Ref 
 2 0.88 (0.71, 1.08) 
 3 1.01 (0.82, 1.23) 
 4 0.92 (0.75, 1.14) 
Spud 1 Ref 
 2 1.07 (0.88, 1.31) 
 3 0.90 (0.73, 1.10) 
 4 0.99 (0.81, 1.22) 
Stimulation 1 Ref 
 2 1.10 (0.90, 1.34) 
 3 0.95 (0.77, 1.16) 
 4 0.93 (0.75, 1.14) 
Production 1 Ref 
 2 1.10 (0.35, 1.33) 
 3 1.01 (0.82, 1.23) 
 4 1.00 (0.81, 1.24) 
NDVI* 1 Ref 
 2 0.89 (0.73, 1.09) 
 3 0.98 (0.80, 1.20) 
 4 0.80 (0.66, 0.98) 
CSD** 1 Ref 
 2 0.88 (0.72, 1.07) 
 3 0.93 (0.76, 1.14) 
 4 1.10 (0.91, 1.35) 









1.02 (0.84, 1.25) 
0.97 (0.79, 1.18) 
0.93 (0.76, 1.13) 









0.82 (0.67, 0.99) 
0.88 (0.73, 1.07) 
0.81 (0.66, 0.99) 
*Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 250 
m grid surrounding a subject’s residential address for the period of maximum annual greenness in the year 
of each laboratory measurement 
**Community socioeconomic deprivation (CSD), measured from the 2010 US Census American Community 
Survey at each subject’s designated place. 
†
Distance from each subject’s residential address to major and minor roads was calculated in meters using 




Table 4.7. Adjusted odds ratios for a B-type natriuretic peptide (BNP) value ≥ 
400 pg/mL, by quartile of environmental metrics, accounting for native (Model 1) 
or truncated (Model 2) inverse probability weights for all those potentially eligible 
for inclusion (n = 6501 laboratory measures among 3938 subjects, weighted to 
sample of n = 13,183) 
 
*Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 250 
m grid surrounding a subject’s residential address for the period of maximum annual greenness in the year 
of each laboratory measurement 
**Community socioeconomic deprivation (CSD), measured from the 2010 US Census American Community 
Survey at each subject’s designated place. 
†
Distance from each subject’s residential address to major and minor roads was calculated in meters using 
road data from the Federal Highway Administration and ArcGIS 10.4’s Generate Near Table function 
Model 1: GEE model with an exchangeable correlation matrix, adjusts for sex (female vs. male), nonwhite 
vs. white, smoking status (ever  vs. never), age at time of lab (centered), laboratory setting (inpatient vs. 
outpatient), receipt of Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered 
and centered squared), body mass index (BMI) (centered and centered squared), diagnosis of chronic 
kidney disease, duration of heart failure (date of laboratory order – the date of first heart failure diagnosis, 
included as a centered and centered squared term), year, region, and covariates used in generating inverse 
probability weights: myocardial infarction, coronary artery disease, and valve disease 
Model 2: Model 1, with inverse probability weights truncated at the 99
th
 percentile 
  Model 1 Model 2 
Metric Quartile OR (95% CI) OR (95% CI) 
Pad preparation 1 Ref Ref 
 2 0.97 (0.81, 1.17) 0.97 (0.80, 1.17) 
 3 1.06 (0.85, 1.31) 1.05 (0.85, 1.30) 
 4 1.01 (0.80, 1.26) 0.99 (0.79, 1.25) 
Spud 1 Ref Ref 
 2 1.08 (0.86, 1.37) 1.08 (0.86, 1.37) 
 3 0.98 (0.74, 1.30) 0.07 (0.73, 1.28) 
 4 1.09 (0.80, 1.48) 1.08 (0.80, 1.48) 
Stimulation 1 Ref Ref 
 2 1.07 (0.88, 1.31) 1.07 (0.88, 1.30) 
 3 1.03 (0.80, 1.33) 1.04 (0.81, 1.34) 
 4 0.99 (0.75, 1.31) 1.00 (0.76, 1.32) 
Production 1 Ref Ref 
 2 1.36 (1.05, 1.76) 1.35 (1.04, 1.75) 
 3 1.48 (1.05, 2.08) 1.44 (1.02, 2.02) 
 4 1.56 (1.05, 2.32) 1.53 (1.04, 2.28) 
NDVI* 1 Ref Ref 
 2 0.94 (0.77, 1.14) 0.94 (0.78, 1.13) 
 3 0.98 (0.81, 1.19) 0.99 (0.81, 1.20) 
 4 0.85 (0.69, 1.04) 0.85 (0.70, 1.04) 
CSD** 1 Ref Ref 
 2 0.92 (0.76, 1.13) 0.90 (0.74, 1.09) 
 3 0.92 (0.75, 1.12) 0.91 (0.75, 1.11) 
 4 1.14 (0.93, 1.39) 1.14 (0.94, 1.38) 









1.03 (0.84, 1.26) 
1.06 (0.87, 1.30) 
0.95 (0.77, 1.16) 
Ref 
1.02 (0.83, 1.24) 
1.04 (0.85, 1.27) 
0.93 (0.77, 1.14) 









0.83 (0.68, 1.02) 
0.89 (0.73, 1.09) 
0.88 (0.71, 1.08) 
Ref 
0.85 (0.70, 1.03) 
0.90 (0.74, 1.10) 
0.89 (0.72, 1.08) 
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Table 4.8. Associations (e*, 95% confidence interval [CI]) of environmental and 
community metrics, by quartile, from linear regression models using generalized 
estimating equations of ln-B-type natriuretic peptide (BNP) value (pg/mL)  
   
Metric Quartile e
* (95% CI) 
Pad preparation 1 Ref 
 2 1.02 (0.94, 1.11) 
 3 1.11 (1.01, 1.21) 
 4 1.05 (0.95, 1.15) 
Spud 1 Ref 
 2 1.15 (1.04, 1.28) 
 3 1.11 (0.98, 1.26) 
 4 1.13 (0.99, 1.29) 
Stimulation 1 Ref 
 2 1.04 (0.95, 1.13) 
 3 1.02 (0.92, 1.14) 
 4 1.07 (0.94, 1.20) 
Production 1 Ref 
 2 1.28 (1.15, 1.43) 
 3 1.30 (1.12, 1.51) 
 4 1.39 (1.17, 1.65) 
NDVI** 1 Ref 
 2 1.00 (0.92, 1.09) 
 3 1.01 (0.92, 1.10) 
 4 0.94 (0.85, 1.03) 
CSD*** 1 Ref 
 2 1.00 (0.90, 1.11) 
 3 1.00 (0.90, 1.10) 
 4 1.08 (0.98, 1.20) 









1.07 (0.96, 1.18) 
1.06 (0.96, 1.18) 
1.00 (0.90, 1.11) 









0.90 (0.81, 0.99) 
0.92 (0.83, 1.02) 
0.91 (0.82, 1.00) 
* e represents the ratio of the geometric means of B-type natriuretic peptide (BNP), comparing upper 
quartiles to the reference quartile 
**Normalized difference vegetation index (NDVI), a measure of greenness, was measured by a 250 m x 250 
m grid surrounding a subject’s residential address for the period of maximum annual greenness in the year 
of each laboratory measurement 
***Community socioeconomic deprivation (CSD), measured from the 2010 US Census American Community 
Survey at each subject’s designated place. 
†
Distance from each subject’s residential address to major and minor roads was calculated in meters using 







Chapter 5a: Examination of the association between UNGD 




Background: In Chapter 3, we observed that higher quartiles of three UNGD activity 
metrics (pad preparation, stimulation, and production) were associated with greater odds 
of hospitalization and there was evidence of exposure-effect relations with increasing 
quartile of UNGD activity. In this chapter, given that heart failure pathophysiology is 
known to differ by phenotypic status (i.e., heart failure with reduced or preserved ejection 
fraction [HFrEF or HFpEF]), we evaluated effect modification by heart failure phenotype 
on the associations of UNGD with heart failure hospitalization.  
Methods: We used eMERGE heart failure phenotypes that had been previously 
assigned to the subjects in Chapter 3 and evaluated differences in demographics, 
comorbidities, and medication use by phenotype categories: not phenotyped (including 
“eMERGE not applied,” and eMERGE applied but not able to phenotype [“eMERGE no 
phenotype”] groups), HFrEF, and HFpEF subjects. We evaluated effect modification by 
these phenotype categories on associations of each UNGD activity metric with heart 
failure hospitalization, by adding cross-product terms to the final adjusted models used 
in Chapter 3. We first hypothesized that that associations of UNGD with heart failure 
hospitalization would be stronger in subjects with HFpEF (vs. HFrEF). We then 
completed a second post hoc analysis based on observations from prior chapters and 
analysis herein that phenotyped subjects (vs. not phenotyped) had a higher prevalence 
of comorbidities and medication use; shorter duration of disease; and greater risk of 
hospitalization and death. We thus hypothesized that having any phenotype (i.e., HFrEF 
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and HFpEF vs. subjects in the two groups without phenotypes) could be used as a 
surrogate measure of heart failure severity, and we evaluated effect modification by 
heart failure severity on the associations of UNGD with hospitalization.  
Results: We observed increased odds of hospitalization among the HFrEF subjects (OR 
[95% CI] = 1.16 [1.00, 1.35]) and decreased odds of hospitalization among the eMERGE 
not applied (0.39 [0.34, 0.44] and no phenotype groups (0.62 [0.53, 0.74]), all compared 
to HFpEF. We observed, in models of the pad metric only, the global test of significance 
of the cross-products between HFrEF and UNGD metric quartiles was p = 0.03. For the 
pad, spud, and production metrics, the global test of significance for the cross-products 
between each metric and the eMERGE not applied group was p = 0.0002, p = 0.03, and 
p = 0.04, respectively. In post hoc analyses, an indicator of heart failure severity 
modified associations between UNGD activity and odds of hospitalization for the pad 
preparation and spud metrics. Although we did not observe this association in the stim or 
production metrics, stratum-specific odds ratios reflected trends of increasing odds of 
hospitalization with increasing quartile of UNGD activity in both heart failure severity 
groups. 
Conclusions: HFrEF subjects, compared to HFpEF subjects and subjects without a 
phenotype, had higher odds of hospitalization independent of UNGD activity. 
Associations of UNGD activity with heart failure hospitalization did not differ by the two 
primary heart failure phenotypes. However, results from post hoc analyses indicated that 
disease severity modified associations between UNGD activity and hospitalization, 
consistent with the hypothesis that the study may have identified an important group of 




UNGD activity has been associated with a number of health outcomes, which 
now includes greater odds of hospitalization among heart failure patients (Chapter 3). 
Within the context of heart failure epidemiology, studies that evaluated differences 
between HFrEF and HFpEF phenotypes are scarce, but sorely needed [209, 259]. 
Specifically, HFpEF subjects are more likely to die from related comorbidities than from 
cardiovascular disease itself [261]. Yet, few studies have examined environmental 
factors or psychosocial stressors in relation to heart failure hospitalization by phenotype 
[87, 89] despite evidence for phenotypic differences in related risk factors [81, 82, 85, 
262]. Understanding associations between UNGD activity and heart failure 
hospitalizations by phenotype would therefore address a need in the environmental 
epidemiology of heart failure and add to the epidemiologic literature on UNGD and 
health outcomes, which to date has primarily studied health outcomes in early to mid-life 
and notably has not studied UNGD in relation to health conditions that are more 
prevalent in older persons [9, 11, 13, 16, 64]. 
Examining the relations between UNGD and heart failure hospitalization by 
phenotype could also provide insight into potential exposure pathways involved in 
UNGD-health associations. We hypothesized that associations between UNGD activity 
metrics and heart failure hospitalizations would be stronger among those with HFpEF 
(vs. HFrEF) because the community and environmental impacts of UNGD are related to 
risk factors and exposures (e.g., obesity, diabetes, high blood pressure and 
hypertension, air pollution with oxides of nitrogen [NO2]) that are more strongly 
associated with HFpEF than HFrEF [81, 262, 263].  
5A.3 METHODS 
We used eMERGE heart failure phenotypes that had been previously assigned 
[179, 185] to the subjects in our hospitalization study (Chapter 3), which was able to 
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categorize case and control subjects into four phenotypic groups: HFpEF, HFrEF, those 
without enough information to be phenotyped (“eMERGE not applied”), and those who 
had information to have the eMERGE algorithm applied but did not have a clear HFpEF 
or HFrEF phenotype (“eMERGE no phenotype”). Greater detail on the eMERGE heart 
failure phenotyping algorithm can be found in Chapter 2, section 2.2 and in Appendix 
A. Heart failure algorithm). In analyses in Chapter 2 and herein, we observed that 
subjects in the hospitalization study who had the eMERGE algorithm applied to their 
EHR data had a greater proportion of subjects who were deceased by the end of the 
study period compared to those who did not have the eMERGE algorithm applied (Table 
2.10). We also observed that subjects in the hospitalization study who had the eMERGE 
algorithm applied had a higher proportion of antihypertensive, antihyperlipidemic, and 
anticoagulant medications and a higher proportion of comorbidities (i.e., chronic 
obstructive pulmonary disease, coronary artery disease, hypertension, myocardial 
infarction, valve disorder, type 2 diabetes, chronic kidney disease) and a greater mean 
Charlson index of morbidity value  compared to subjects who did not have the eMERGE 
algorithm applied (Table 2.14).  Finally, in model building for the analysis presented in 
this chapter, we observed that persons with HFrEF were more likely to be hospitalized 
for heart failure.  Taken together, we hypothesized that phenotyped subjects had more 
severe heart failure and used phenotype status as a surrogate measure of the severity 
of the disease. 
We first evaluated differences in patient characteristics (i.e., demographics, 
comorbidities, medications) between subjects who were not able to be phenotyped, 
those who were phenotyped as HFrEF, and those who were phenotyped as HFpEF. We 
determined that the ability to be phenotyped was dependent on observation time, 
disease severity, and the presence of comorbidities, so we did not attempt to impute 
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phenotype information for subjects who were not able to be phenotyped by the eMERGE 
algorithm.  
In our primary analysis, we used the phenotypic categories (eMERGE not 
applied, eMERGE no phenotype, HFpEF, and HFrEF) to create three binary indicators, 
designating HFpEF as the reference group. We first assessed the association between 
each phenotype indicator and hospitalization, independent of UNGD activity in adjusted 
multilevel logistic regression models (from Chapter 3). We next examined adjusted 
multilevel logistic regression models of hospitalization (from Chapter 3) that included the 
main effects of each phenotype indicator and quartiles of UNGD activity. Lastly, we 
evaluated models that included cross-product terms between these three indicators and 
each UNGD metric quartile indicator. To assess whether the inclusion of these cross-
products improved the model, we calculated the global p-value of these cross-product 
terms with chi2 tests, which tested the hypothesis that the coefficients for each cross-
product were equal to zero. We generated linear combinations of both main effects (i.e., 
main effect of UNGD, main effect of phenotype groups) and the cross-products between 
these to estimate stratum-specific odds ratios for hospitalization. Using the “ggplot2” 
package in R v.3.4.2 [264], we generated forest plots to visually display these odds 
ratios by phenotype group and by UNGD quartile. 
In post hoc analyses, we assessed effect modification by heart failure severity 
(i.e., an indicator for having a phenotype [either HFpEF or HFrEF] vs. no phenotype) on 
the associations between UNGD metrics and hospitalization. We used the same 
multilevel logistic regression models in our primary analysis (and from Chapter 3) and 
also included cross-products between each UNGD activity metric and the heart failure 
severity indicator. We calculated the global p-values of these cross-product terms with 
chi2 tests, which tested the null hypothesis that the coefficients for any one of the cross-
products were equal to zero. To understand the association between UNGD activity 
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metrics and odds of hospitalization, after accounting for the independent effects of the 
heart failure severity indicator, we generated linear combinations of both main effects 
(i.e., main effect of UNGD, main effect of severity indicator) and the cross-products 
between these to estimate stratum-specific odds ratios for hospitalization, which we also 
displayed in forest plots generated in R v.3.4.2 [264]. We conducted chi2 tests on the 
inclusion of the cross-product terms between the binary indicator for having a phenotype 
and each UNGD metric. 
5A.4 RESULTS 
5A.4.1 DESCRIPTIVE CHARACTERISTICS OF PHENOTYPE GROUPS 
Comparing subjects by phenotype groups, a greater proportion of subjects with a 
HFpEF phenotype were female (59.8%), whereas a greater proportion of HFrEF 
subjects were male (63.7%); in the group of subjects without a phenotype, the 
distribution of sex was 52.2% male and 47.8% female (Table 5a.1). Subjects with the 
HFpEF phenotype were, on average, older (mean age = 74 years compared to 70 years 
for HFrEF and 71 years for the subjects without a phenotype, Table 5a.1). The HFpEF 
group also had the highest proportion of subjects with hypertension, diabetes, chronic 
obstructive pulmonary disease, and chronic kidney disease (Table 5a.2). Meanwhile, 
subjects with HFrEF had a higher prevalence of coronary artery disease and of having 
had a myocardial infarction compared to HFpEF subjects and those without a phenotype 
(Table 5a.2). Comparing these two phenotype groups to the subjects without a 
phenotype, we observed that subjects with a phenotype had a greater proportion of 
medication use (antihypertensive, antihyperlipidemic, and anticoagulant), comorbidities 
(chronic obstructive pulmonary disease, coronary artery disease, hypertension, valve 
disorder, diabetes, and chronic kidney disease), and subjects who were deceased by the 
end of the study period (39% of subjects were deceased in the phenotyped groups, 
compared to 30% among the no phenotype group) (Tables 5a.1-2). We also noticed that 
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subjects who were not phenotyped had a longer mean duration of heart failure 
compared to those who had a phenotype (855 days vs. 754 and 670 days, p < 0.0001), 
suggesting less severe disease among those without phenotypes, because severe heart 
failure is associated with worse outcomes and thus shorter duration of disease (Table 
5a.1). 
5A.4.2 ASSOCIATIONS OF PHENOTYPE WITH HOSPITALIZATION AND WITH UNGD 
ACTIVITY  
We first evaluated phenotype in relation to heart failure hospitalization without 
UNGD activity in the models and found that HFrEF was associated with greater odds of 
hospitalization (OR [95 % CI] = 1.16 [1.00, 1.35]) compared to HFpEF; the other 
phenotype groups had a reduced odds of hospitalization (OR [95 % CI] = 0.62 [0.53, 
0.74]) for the no phenotype group and 0.39 [0.34, 0.44] for the eMERGE not applied 
group) compared to HFpEF (Table 5a.3). UNGD activity was next added to these 
models and we found some evidence of confounding by phenotype,  as associations of 
UNGD activity with hospitalization were slightly attenuated, although previously 
described associations of pad preparation, stimulation, and production metrics  with 
hospitalization were still present (Table 5a.4), with significantly higher odds of 
hospitalization for quartiles 2 - 4 of the pad metric compared to the first quartile (OR 
[95% CI] = 1.16 [1.01, 1.33], 1.52 [1.31, 1.78], and 1.57 [1.30, 1.89]). For the stimulation 
metric, we saw higher odds for the 3rd and 4th quartiles (1.42 [1.14, 1.77] and 1.60 [1.26, 
2.02], respectively); and for the production metric, we only saw a 4th quartile association 
(1.55 [1.11, 2.17]). These phenotype-adjusted associations of UNGD activity with 
hospitalization exhibited similar exposure-effect and 4th quartile associations as did the 
associations reported in Chapter 3, where associations in quartiles 2 – 4 of the pad 
metric compared to the first quartile were OR (95% CI) = 1.19 (1.01, 1.40), 1.63 (1.35, 
1.97), and 1.70 (1.35, 2.13). Similarly the associations in the 3rd and 4th quartiles of the 
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stim metric (from Chapter 3) were 1.56 (1.19, 2.04), and 1.80 (1.35, 2.40), and the 4th 
quartile effect was present for the production metric 1.62 (1.07, 2.45). 
5A.4.3 EFFECT MODIFICATION BY PHENOTYPE ON ASSOCIATIONS OF UNGD 
ACTIVITY WITH HOSPITALIZATION 
In models that evaluated cross-products between these phenotypic indicators 
and UNGD metrics, we observed that HFrEF phenotype modified associations of the 
pad metric with hospitalization (p = 0.03 for global test of three cross-products, Table 
5a.5), although this effect modification was primarily driven by cross-products of the 2nd 
quartiles of the pad preparation metric rather than the cross-products of the 3rd and 4th 
quartiles of the pad preparation metric. This could suggest that effect modification is only 
present in lower levels of UNGD activity, or that these associations are spurious. We did 
not observe effect modification by HFrEF (vs. HFpEF) for the other UNGD metrics 
(Tables 5a.6 – 5a.8). However, we observed effect modification by eMERGE not applied 
(part of the not phenotyped, vs. HFpEF) for the pad metric (p = 0.0002 for global test of 
three cross-products, Table 5a.5), spud metric (p = 0.03 for global test of three cross-
products, Table 5a.6), and production metric (p = 0.04 for global test of three cross-
products, Table 5a.8).  
From the models that incorporated cross-products between phenotypic indicators 
and UNGD metrics (i.e., model results displayed in Tables 5a.5-8), we were able to 
estimate stratum-specific odds ratios of hospitalization by UNGD activity metrics and 
heart failure phenotype groups (Figures 5a.1-4). The figures display the linear 
combinations of the stratum-specific odds ratio of hospitalization for each UNGD activity 
metric, as the combined odds of the phenotype group, UNGD activity metric quartiles, 
and their cross-products. The forest plots show that the associations of UNGD with heart 
failure hospitalization were elevated but relatively similar for the HFpEF and HFrEF 
groups, but reduced and relatively similar for the not phenotyped groups. These results 
 173 
did not provide evidence that the associations of UNGD with heart failure hospitalization 
differed directly comparing HFpEF and HFrEF, our primary a priori hypothesis of 
interest.   
5A.4.4 POST HOC ANALYSIS: EFFECT MODIFICATION BY HEART FAILURE SEVERITY ON 
RELATIONS OF UNGD ACTIVITY WITH HOSPITALIZATION 
In post hoc analyses, there was evidence that heart failure severity (phenotyped 
vs. no phenotype) modified relations of UNGD activity metrics with hospitalization. The 
cross-products between this severity indicator and spud metric quartiles were associated 
with increased odds of hospitalization (OR [95 % CI]) in third quartile = 1.30 [1.01, 1.68]; 
fourth quartile = 1.34 [1.03, 1.73]), and the global test of significance for these cross-
products was p = 0.009 (Table 5a.9). The cross-products between quartiles of the pad 
metric and the severity indicator were associated with reduced odds of hospitalization in 
the second (vs. first) quartile (OR [95 % CI] = 0.71 [0.55, 0.23]), but not in the third or 
fourth quartiles, although the global test of significance for this cross product was p = 
0.03 (Table 5a.9). Although the second (vs. first) quartile of the cross-product of our 
severity indicator and the production metric was associated with increased odds of 
hospitalization (OR [95 % CI] = 1.40 [1.08, 1.80]), we observed null associations in the 
third and fourth quartiles of these cross-products, and the global test of significance for 
these cross-products was p = 0.08 (Table 5a.9).  We also observed null associations for 
the cross-products between quartiles of the stimulation metric and the severity indicator, 
and the global test of significance for these terms was p = 0.4 (Table 5a.9). 
To observe the combined effect of each UNGD activity metric, severity indicator, 
and cross-products between the severity indicator and each UNGD activity metric, we 
generated forest plots from the combined associations with odds of hospitalization. We 
display these for each UNGD activity metric in Figures 5a.5-8. There was evidence that 
the severe heart failure indicators modified relations of both the pad (Figure 5a.5) and 
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spud (Figure 5a.6) UNGD activity metrics with hospitalization. Although the associations 
of the stimulation metric (Figure 5a.7) and the production metric (Figure 5a.8) were 
stronger among the more severe subjects and increased with increasing quartile of 
UNGD activity, the global tests of significance of the cross-products suggested that the 
trends observed were due to the combined main effects of each metric and the severity 
indicator, not a statistical interaction between the two. 
5A.5 DISCUSSION  
The purpose of this analysis was to evaluate the association between heart 
failure phenotype with heart failure hospitalization, and to evaluate if heart failure 
phenotype modified the previously observed (Chapter 3) associations between UNGD 
activity and heart failure hospitalization. We also observed that the HFrEF indicator was 
associated with increased odds of hospitalization, and that not phenotyped groups were 
associated with reduced odds of hospitalization. These main effects, in addition to 
descriptive analyses comparing phenotyped subjects to those who were not phenotyped, 
led us to use phenotyped status as a surrogate for heart failure severity. This was further 
supported by the greater prevalence of comorbidities, medication use, and a higher 
proportion of subjects who became deceased by the end of the study period among 
those with either a HFrEF or HFpEF phenotype compared to those without a phenotype. 
When we incorporated the main effects of phenotype indicators (i.e., HFrEF, eMERGE 
no phenotype, and eMERGE not applied vs. HFpEF), the main effects of UNGD activity 
metrics, and the cross-products for each of these indicators with each respective UNGD 
activity metric, we did not find evidence that our a priori hypothesis was correct (i.e., 
stronger associations among HFpEF vs. HFrEF subjects). However, we did find, in post 
hoc analyses, that phenotyped subjects with either HFpEF or HFrEF, that is, more 
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severe heart failure, evidenced stronger associations of UNGD with heart failure 
hospitalization than did those with less severe heart failure. 
The results of this analysis support the findings of Chapter 3, since we also 
observed associations of the UNGD pad preparation metric, the stimulation metric, and 
the production metric with hospitalization for heart failure. However, in our phenotype-
adjusted models, we saw a small attenuation of the associations of each UNGD activity 
metric compared to our findings in Chapter 3. This suggested that phenotype could be a 
confounder of the association between UNGD activity and heart failure hospitalization. 
When we included cross-products between UNGD activity metrics and our heart failure 
severity indicator (i.e., HFpEF or HFrEF) in post hoc analyses, we observed that heart 
failure severity modified relations of the UNGD spud metric with heart failure 
hospitalization, which was of particular interest because we did not observe associations 
between the spud metric and hospitalization in Chapter 3, except for in a sensitivity 
analysis when we used 4:1 control to case frequency matching. This association 
suggests that, although not observed in our original analysis, the spud metric may be 
associated with heart failure hospitalization among the most severe cases. 
Even though we were not able to assign all subjects a phenotype category with 
the eMERGE algorithm, we consider the successful application of the phenotyping 
algorithm an informative finding. We observed that subjects with more frequent contact 
with the health care system; who had more comorbidities and medication use; a shorter 
duration of disease; and were more likely to be deceased by the end of the study period, 
were more likely to have an assigned phenotype by the eMERGE algorithm, and they 
had a greater likelihood of hospitalization compared to those who were not assigned a 
phenotype with the algorithm. Although the eMERGE algorithm was developed in 2015 
[179], we have not been able to identify any environmental epidemiology studies that 
utilize this method in a large population. 
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We have not been able to identify any epidemiologic studies that have evaluated 
associations between any environmental variables and heart failure hospitalization that 
evaluated effect modification by HFpEF and HFrEF phenotypes or by disease severity. 
One study in Spain identified 353 individuals admitted to a tertiary care hospital with a 
diagnosis of heart failure and found that, comparing individuals with HFpEF to those with 
HFrEF, those with HFpEF had higher levels of ambient NO2 in the previous week before 
their hospital admission [87]. Another study of heart failure hospitalizations in Medicare 
beneficiaries in Pittsburgh, Pennsylvania found that air pollutants (carbon monoxide 
[CO], particulate matter less than 2.5 microns in diameter [PM2.5], oxides of nitrogen 
[NO2] and oxides of sulfur [SO2]) were associated with increased rates of hospitalization 
and that having a recent myocardial infarction diagnosis modified the association 
between PM2.5 and hospitalization rate [130]. However, these two studies did not 
specifically evaluate whether heart failure phenotype modified this association, nor did 
they evaluate indicators of heart failure severity as effect measure modifiers of the air 
pollution and hospitalization associations. 
Strengths of this study include the large sample size from EHR data, from 
subjects who are representative of the general population in Pennsylvania [182]. This 
data source, coupled with the novel advantages of the eMERGE heart failure phenotype 
algorithm [179, 185], allowed us to distinguish subjects into phenotype groups with a 
high positive predictive value (> 95%) [179]. The validity of the phenotype groups is 
supported by our observations of characteristics and comorbidities associated with 
HFpEF and HFrEF phenotypes that are consistent with the epidemiologic literature on 
HFpEF and HFrEF; we found that a greater proportion of HFpEF subjects were female 
and had comorbidities such as type 2 diabetes, chronic obstructive pulmonary disease, 
hypertension, and chronic kidney disease, whereas HFrEF subjects had a higher 
proportion of coronary artery disease and a previous myocardial infarction diagnosis 
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[263, 265]. Further, this study is the first to have applied the eMERGE heart failure 
algorithm in an environmental epidemiology study of heart failure subjects with different 
phenotypes. 
Limitations of this study include the inability to measure dietary, behavioral, and 
occupational factors through the EHR, which is a limitation that is common to EHR-
based epidemiology studies. Another limitation is that not all subjects were able to be 
phenotyped with the eMERGE algorithm because the algorithm required 
echocardiogram measures and consistent contact with the health care system 
(Appendix A. Heart failure algorithm). However, we learned that the presence of a 
phenotype was informative as an indicator of disease severity, which might have 
applications to other epidemiology studies that utilize EHR-based phenotyping 
algorithms.  
5A.6 CONCLUSIONS 
 We observed that phenotyped subjects, with HFpEF or HFrEF, had a greater 
odds of hospitalization compared to the no phenotype and eMERGE not applied groups. 
We initially hypothesized that the HFpEF phenotype (vs. HFrEF) would modify the 
association between UNGD activity and hospitalization but did not find evidence of this. 
However, we did observe that disease severity, based on the results of the application of 
the eMERGE algorithm to EHR data (phenotyped vs. not phenotyped), modified the 
association between UNGD activity and hospitalization that we observed in Chapter 3, 





1. von Lueder, T.G. and S. Agewall, The burden of heart failure in the general 
population: a clearer and more concerning picture. Journal of thoracic disease, 
2018. 10(Suppl 17): p. S1934-S1937. 
2. Conrad, N., et al., Temporal trends and patterns in heart failure incidence: a 
population-based study of 4 million individuals. The Lancet, 2018. 391(10120): p. 
572-580. 
3. Gerber, Y., et al., A contemporary appraisal of the heart failure epidemic in 
Olmsted County, Minnesota, 2000 to 2010. (2168-6114 (Electronic)). 
4. Dominguez-Rodriguez, A., et al., Air pollution and heart failure: Relationship with 
the ejection fraction. World Journal of Cardiology, 2013. 5(3): p. 49-53. 
5. Bui, A.L., T.B. Horwich, and G.C. Fonarow, Epidemiology and risk profile of heart 
failure. Nature reviews. Cardiology, 2011. 8(1): p. 30-41. 
6. Borlaug, B.A., Heart failure with preserved and reduced ejection fraction: different 
risk profiles for different diseases. European Heart Journal, 2013. 
7. Lee, D.S., et al., Relation of Disease Pathogenesis and Risk Factors to Heart 
Failure With Preserved or Reduced Ejection Fraction. Circulation, 2009. 119(24): 
p. 3070-3077. 
8. Brouwers, F.P., et al., Incidence and epidemiology of new onset heart failure with 
preserved vs. reduced ejection fraction in a community-based cohort: 11-year 
follow-up of PREVEND. European Heart Journal, 2013. 34(19): p. 1424-1431. 
9. Eaton, C.B., et al., Risk Factors for Incident Hospitalized Heart Failure With 
Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of 
Postmenopausal Women. LID - e002883 [pii]. (1941-3297 (Electronic)). 
10. McKenzie, L.M., et al., Birth outcomes and maternal residential proximity to 
natural gas development in rural Colorado. Environmental health perspectives, 
2014. 122(4): p. 412-417. 
11. Stacy, S., et al., Perinatal outcomes and unconventional natural gas operations 
in Southwest Pennsylvania. PLoS One, 2015. 10(6): p. e0126425. 
12. Willis, M.D., et al., Unconventional natural gas development and pediatric asthma 
hospitalizations in Pennsylvania. (1096-0953 (Electronic)). 
13. Whitworth, K.W., A.K. Marshall, and E. Symanski, Maternal residential proximity 
to unconventional gas development and perinatal outcomes among a diverse 
urban population in Texas. PloS one, 2017. 12(7): p. e0180966-e0180966. 
14. Casey, J.A., et al., Unconventional Natural Gas Development and Birth 
Outcomes in Pennsylvania, USA. Epidemiology, 2015. 
15. Tsao, C.W., et al., Temporal Trends in the Incidence of and Mortality Associated 
With Heart Failure With Preserved and Reduced Ejection Fraction. (2213-1787 
(Electronic)). 
16. Bielinski, S.J., et al., A Robust e-Epidemiology Tool in Phenotyping Heart Failure 
with Differentiation for Preserved and Reduced Ejection Fraction: the Electronic 
Medical Records and Genomics (eMERGE) Network. 2015(1937-5395 
(Electronic)). 
17. Bielinski;, S.J., Heart Failure (HF) with Differentiation between Preserved and 
Reduced Ejection Fraction, in PheKB, M. Clinic., Editor. 2013. 
18. Team;, R.C., R: A language and envrionment for statistical computing. R 
Foundation for Statistical Computing. 2012: Vienna, Austria. 
19. Wellenius, G.A., et al., Particulate Air Pollution and the Rate of Hospitalization for 
Congestive Heart Failure among Medicare Beneficiaries in Pittsburgh, 
Pennsylvania. American Journal of Epidemiology, 2005. 161(11): p. 1030-1036. 
 179 
20. Casey, J.A., et al., Using Electronic Health Records for Population Health 
Research: A Review of Methods and Applications. Annual Review of Public 
Health, 2016. 37(1): p. 61-81. 
21. Wolsk, E., et al., Contribution of cardiac and extra-cardiac disease burden to risk 







Figure 5a.1. Associations (OR and 95% CI) of quartiles of UNGD pad activity 
metric with hospitalization in heart failure phenotype strata. The reference group 
is the HFpEF subjects in the first quartile of the pad metric.  
Figure 5a.2. Associations (OR and 95% CI) of quartiles of UNGD spud activity 
metric with hospitalization in heart failure phenotype strata. The reference group 
is the HFpEF subjects in the first quartile of the spud metric.  
Figure 5a.3. Associations (OR and 95% CI) of quartiles of UNGD stim activity 
metric with hospitalization in heart failure phenotype strata. The reference group 
is the HFpEF subjects in the first quartile of the stimulation metric. 
Figure 5a.4. Associations (OR and 95% CI) of quartiles of UNGD production 
activity metric with hospitalization in heart failure phenotype strata. The reference 
group is the HFpEF subjects in the first quartile of the production metric.  
Figure 5a.5. Associations (OR and 95% CI) of quartiles of UNGD pad activity 
metric with hospitalization in heart failure severity strata. The “More Severe Heart 
Failure” group includes HFpEF and HFrEF and the “Less Severe Heart Failure” 
group includes eMERGE not applied and eMERGE no phenotype. The reference 
group is the less severe heart failure subjects in the first quartile of the pad 
metric. P-values were obtained from chi2 tests of the three cross-product terms 
between the severity indicator and each pad metric quartile. 
Figure 5a.6. Associations (OR and 95% CI) of quartiles of UNGD spud activity 
metric with hospitalization in heart failure phenotype strata. The “More Severe 
Heart Failure” group includes HFpEF and HFrEF and the “Less Severe Heart 
Failure” group includes eMERGE not applied and eMERGE no phenotype. The 
reference group is the less severe heart failure subjects in the first quartile of the 
spud metric. P-values were obtained from chi2 tests of the three cross-product 
terms between the severity indicator and each spud metric quartile. 
Figure 5a.7. Associations (OR and 95% CI) of quartiles of UNGD stimulation 
activity metric with hospitalization in heart failure phenotype strata. The “More 
Severe Heart Failure” group includes HFpEF and HFrEF and the “Less Severe 
Heart Failure” group includes eMERGE not applied and eMERGE no phenotype. 
The reference group is the less severe heart failure subjects in the first quartile of 
the stim metric. P-values were obtained from chi2 tests of the three cross-product 
terms between the severity indicator and each stimulation metric quartile. 
Figure 5a.8. Associations (OR and 95% CI) of quartiles of UNGD production 
activity metric with hospitalization in heart failure phenotype strata. The “More 
Severe Heart Failure” group includes HFpEF and HFrEF and the “Less Severe 
Heart Failure” group includes eMERGE not applied and eMERGE no phenotype. 
The reference group is the less severe heart failure subjects in the first quartile of 
the production metric. P-values were obtained from chi2 tests of the three cross-
product terms between the severity indicator and each production metric quartile. 
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Table 5a.1. Selected subject characteristics by phenotype status, at time of randomly selected case event 
or control encounter 
 
Total subjects n = 9054 
Not phenotyped 
n = 5702 
HFrEF  
n = 1739 
HFpEF 
n = 1613 
 
p-value* 
Sex, n (%) 
    Male 













Race/ethnicity, n (%) 
    White 
    Black 
    Hispanic 
    Other 























Age at hospitalization or at 
control selection date, 






 < 0.0001 
Age category at first event, 
n (%) years 
   > 18-30 
   > 30-40 
   > 40-50 
   > 50-60 
   > 60-70 
   > 70-80 
   > 80-90 









































Community type, n (%) 
    Borough 
    Township 


































Total subjects n = 9054 
Not phenotyped 
n = 5702 
HFrEF  
n = 1739 
HFpEF 
n = 1613 
 
p-value* 
     1 
     2 
     3 





452 (26.0) 416 (25.8) 
Patient status at end of 
study, n (%) 
   Alive 

















Distance to major road † 









Distance to minor road † 









Distance to hospital/clinic 









Smoking status at event, n 
(%) 
    Current 
    Former 











714 (44.3) < 0.001 
Receipt of Medical 







Body mass index (BMI) at 








Time since first heart 
failure diagnosis, days§,  










* p-value obtained from either chi
2
 tests (for categorical variables) or analysis of variance (ANOVA) F-test (for continuous variables), comparing events for 
subjects who had an assigned phenotype (heart failure with reduced ejection fraction [HFrEF] or preserved ejection fraction [HFpEF]) vs. those who did 
not have phenotype information 
** Community socioeconomic deprivation (CSD) was calculated based on US Census indicators; further information is detailed in the text 
† Major & minor roads were identified from the Federal Highway Administration databases; distance from subject’s residential address to these roads was 
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calculated in meters 
‡
 Medical Assistance, a surrogate for family socioeconomic status, was calculated based on health insurance status at the time of encounters 
§ Days from first heart failure diagnosis to the date of case or control event
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Table 5a.2. Selected diagnoses and medication use at time of randomly selected case event or control 
encounter date, by heart failure phenotype status 
 
Total subjects n = 9054 
Not phenotyped 
n = 5702 
HFrEF  
n = 1739 
HFpEF 
n = 1613 p-value* 
Medication use, by class, n (%)** 
    Antihypertensive 
    Antihyperlipidemic 

















Chronic obstructive pulmonary 




354 (20.4)  
 
430 (26.7) < 0.001 
Coronary artery disease, n (%) 1182 (20.7) 520 (29.9) 421 (26.1) < 0.001 
Hypertension, n (%) 4284 (75.1) 1331 (76.5) 1372 (85.1) < 0.001 
Myocardial infarction, n (%) 688 (12.1) 340 (19.6) 143 (8.9) < 0.001 
Valve disorder, n (%) 1081 (19.0) 425 (24.4) 481 (29.8) < 0.001 
Diabetes, n (%) 2365 (41.5) 797 (45.8) 783 (48.5) < 0.001 
Chronic kidney disease, n (%) 1479 (25.9) 528 (30.4) 571 (35.4) < 0.001 







9.4 (3.2) < 0.0001 
* p-value obtained from either chi
2
 tests (for categorical variables) or analysis of variance (ANOVA) F-test (for continuous variables), comparing events for 
subjects who had an assigned phenotype (heart failure with reduced ejection fraction [HFrEF] or preserved ejection fraction [HFpEF]) vs. those who did 
not have phenotype information  
** Relevant medication classes were identified based on the dates of physician orders 
†
 A composite measure of overall morbidity; definition described in text 
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Table 5a.3. Adjusted associations (odds ratio [OR], 95% confidence interval 












events** (n) OR (95 % CI) 
HFrEF*** 1 2185 1.16 (1.00, 1.35) 
     0 9493 Ref 




0.62 (0.53, 0.74) 
Ref 




0.39 (0.34, 0.44) 
Ref 
* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance (ever vs. never received prior to case event or control encounter), 
smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared term), age 
category at case event or control encounter, days since first heart failure diagnosis code (centered), 
distance to nearest hospital or clinic (centered), season, region, and year. 
*Number of case events or control encounters represented by each phenotype indicator value 
***Heart failure with reduced ejection fraction (HFrEF)  
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Table 5a.4. Associations (odds ratio [OR], 95% confidence interval [CI]) of 
UNGD activity metrics with hospitalization adjusted for heart failure 
phenotype and other variables in final model*  
Metric Quartile OR (95 % CI) 
Pad preparation 1 Ref 
 2 1.16 (1.01, 1.33) 
 3 1.52 (1.31, 1.78) 
 4 1.57 (1.30, 1.89) 
Spud 1 Ref 
 2 0.99 (0.83, 1.18) 
 3 1.04 (0.86, 1.27) 
 4 0.96 (0.77, 1.19) 
Stimulation 1 Ref 
 2 1.01 (0.82, 1.23) 
 3 1.42 (1.14, 1.77) 
 4 1.60 (1.26, 2.02) 
Production 1 Ref 
 2 0.91 (0.70, 1.17) 
 3 1.06 (0.78, 1.45) 
 4 1.55 (1.11, 2.17) 
* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance (ever vs. never received prior to case event or control encounter), 
smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared term), age 
category at case event or control encounter, days since first heart failure diagnosis code (centered), 
distance to nearest hospital or clinic (centered), season, region, year, and three phenotype indicators: heart 
failure with reduced ejection fraction (yes vs. no), eMERGE algorithm applied, but unable to be phenotyped 




Table 5a.5. Adjusted* associations (odds ratio [OR], 95% confidence 
interval [CI]) of pad preparation metric, phenotype indicators, and cross-
products between the pad preparation metric and phenotype indicators 
with hospitalization, compared to HFpEF as reference group 
Metric or indicator 
Quartile or 
indicator 
value OR (95 % CI) 
p-value for 
interaction** 
Pad preparation 1 Ref  
 2 0.70 (0.52, 0.95)  
 3 1.36 (0.98, 1.88)  
 4 1.56 (1.11, 2.19)  
HFrEF*** 0 Ref  
 1 0.95 (0.70, 1.29)  
No phenotype 0 
1 
Ref 







0.31 (0.24, 0.40) 
 







1.74 (1.15, 2.65) 
1.17 (0.77, 1.79) 












1.67 (1.05, 2.65) 
0.98 (0.61, 1.56) 













1.92 (1.36, 2.70) 
1.19 (0.83, 1.69) 





* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance (ever vs. never received prior to case event or control encounter), 
smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared term), age 
category at case event or control encounter, days since first heart failure diagnosis code (centered), 
distance to nearest hospital or clinic (centered), season, region, year, and cross-products between the pad 
preparation metric and three phenotype indicators: heart failure with reduced ejection fraction (yes vs. no), 
eMERGE algorithm applied, but unable to be phenotyped (yes vs. no), and eMERGE algorithm not applied 
(yes vs. no). The reference group for these three indicators was the heart failure with preserved ejection 
fraction (HFpEF) subjects. 
**p-value obtained from chi
2
 tests for the cross-products between quartiles of UNGD activity and each 
phenotype indicator variable  
***Heart failure with reduced ejection fraction (HFrEF) 
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Table 5a.6. Adjusted* associations (odds ratio [OR], 95% confidence 
interval [CI]) of the spud metric, phenotype indicators, and cross-products 
between the spud metric and phenotype indicators with hospitalization, 




value OR (95 % CI) 
p-value for 
interaction** 
Spud 1 Ref  
 2 0.99 (0.72, 1.37)  
 3 1.47 (1.05, 2.05)  
 4 1.09 (0.77, 1.55)  
HFrEF*** 0 Ref  
 1 1.28 (0.96, 1.71)  
No phenotype 0 
1 
Ref 







0.45 (0.35, 0.58) 
 







0.89 (0.59, 1.34) 
0.70 (0.46, 1.05) 












1.11 (0.71, 1.74) 
0.69 (0.44, 1.09) 













1.01 (0.72, 1.42) 
0.64 (0.46, 0.91) 





* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance (ever vs. never received prior to case event or control encounter), 
smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared term), age 
category at case event or control encounter, days since first heart failure diagnosis code (centered), 
distance to nearest hospital or clinic (centered), season, region, year, and cross-products between the spud 
metric and three phenotype indicators: heart failure with reduced ejection fraction (yes vs. no), eMERGE 
algorithm applied, but unable to be phenotyped (yes vs. no), and eMERGE algorithm not applied (yes vs. 
no). The reference group for these three indicators was the heart failure with preserved ejection fraction 
(HFpEF) subjects. 
** p-value obtained from chi
2
 tests for the cross-products between quartiles of UNGD activity and each 
phenotype indicator variable  
***Heart failure with reduced ejection fraction (HFrEF) 
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Table 5a.7. Adjusted* associations (odds ratio [OR], 95% confidence 
interval [CI]) of the stimulation metric, phenotype indicators, and cross-
products between the stimulation metric and phenotype indicators with 




value OR (95 % CI) 
p-value for 
interaction** 
Stim 1 Ref  
 2 1.01 (0.82, 1.23)  
 3 1.42 (1.14, 1.77)  
 4 1.60 (1.26, 2.02)  
HFrEF*** 0 Ref  
 1 1.40 (1.05, 1.86)  
eMERGE applied, 











0.49 (0.38, 0.62) 
 







0.87 (0.57, 1.31) 
0.85 (0.57, 1.27) 





Stim metric x 
eMERGE applied 







0.79 (0.50, 1.24) 
0.89 (0.57, 1.39) 













0.79 (0.56, 1.12) 
0.77 (0.54, 1.08) 





* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance (ever vs. never received prior to case event or control encounter), 
smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared term), age 
category at case event or control encounter, days since first heart failure diagnosis code (centered), 
distance to nearest hospital or clinic (centered), season, region, year, and cross-products between the stim 
metric and three phenotype indicators: heart failure with reduced ejection fraction (yes vs. no), eMERGE 
algorithm applied, but unable to be phenotyped (yes vs. no), and eMERGE algorithm not applied (yes vs. 
no). The reference group for these three indicators was the heart failure with preserved ejection fraction 
(HFpEF) subjects. 
** p-value obtained from chi
2
 tests for the cross-products between quartiles of UNGD activity and each 
phenotype indicator variable 
***Heart failure with reduced ejection fraction (HFrEF) 
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Table 5a.8. Adjusted* associations (odds ratio [OR], 95% confidence 
interval [CI]) of the production metric, phenotype indicators, and cross-
products between the production metric and phenotype indicators with 




value OR (95 % CI) 
p-value for 
interaction** 
Prod 1 Ref  
 2 1.32 (0.91, 1.92)  
 3 1.20 (0.79, 1.81)  
 4 1.96 (1.26, 3.04)  
HFrEF*** 0 Ref  
 1 1.38 (1.04, 1.83)  
eMERGE applied, 











0.50 (0.39, 0.64) 
 







0.74 (0.49, 1.12) 
0.94 (0.63, 1.41) 





Prod metric x 
eMERGE applied 







0.65 (0.42, 1.01) 
1.12 (0.72, 1.76) 













0.60 (0.43, 0.86) 
0.79 (0.56, 1.11) 





* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance (ever vs. never received prior to case event or control encounter), 
smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared term), age 
category at case event or control encounter, days since first heart failure diagnosis code (centered), 
distance to nearest hospital or clinic (centered), season, region, year, and cross-products between the 
production metric and three phenotype indicators: heart failure with reduced ejection fraction (yes vs. no), 
eMERGE algorithm applied, but unable to be phenotyped (yes vs. no), and eMERGE algorithm not applied 
(yes vs. no). The reference group for these three indicators was the heart failure with preserved ejection 
fraction (HFpEF) subjects. 
**p-value obtained from chi
2
 tests for the cross-products between quartiles of UNGD activity and each 
phenotype indicator variable  
***Heart failure with reduced ejection fraction (HFrEF) 
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Table 5a.9. Adjusted* associations (odds ratio [OR], 95% confidence interval [CI]) of UNGD metrics, and 
cross-products between UNGD metrics and the severity indicator 
 
UNGD activity metric 
UNGD activity metric 
OR (95 % CI)** 
UNGD activity metric X 
Heart failure severity 
indicator*** 
p-value for global test of all 
UNGD metric by severity status 
terms† 
Pad metric 
    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
1.30 (1.11, 1.54) 
1.56 (1.30, 1.86) 
1.57 (1.28, 1.94) 
 
Reference 
0.71 (0.55, 0.23) 
0.95 (0.73, 1.23) 




    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
1.02 (0.84, 1.24)  
0.95 (0.77, 1.18) 
0.86 (0.68, 1.09) 
 
Reference 
0.93 (0.72, 1.20) 
1.30 (1.01, 1.68) 




    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
0.95 (0.76, 1.18) 
1.36 (1.07, 1.73) 
1.52 (1.18, 1.95) 
 
Reference 
1.21 (0.93, 1.56) 
1.17 (0.91, 1.51) 
1.22 (0.95, 1.58) 0.4 
Prod metric 
    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
0.82 (0.63, 1.07) 
1.02 (0.74, 1.41) 
1.51 (1.07, 2.14) 
 
Reference 
1.40 (1.08, 1.80) 
1.18 (0.92, 1.52) 
1.12 (0.88, 1.45) 0.08 
* Multilevel logistic regression models adjusted for: sex (male vs. female), race/ethnicity (white vs. nonwhite), receipt of Medical Assistance (ever vs. 
never received prior to case event or control encounter), smoking status (ever vs. never), body mass index (BMI, as a centered and centered squared 
term), age category at case event or control encounter, days since first heart failure diagnosis code (centered), distance to nearest hospital or clinic 
(centered), season, region, year, and interactions between the each respective UNGD metric and a binary indicator for having a phenotype 
**Odds ratio reflects the main effect of each UNGD activity metric among the phenotype reference group 
***e
 
(95 % CI) for the cross-product between each UNGD metric and severity status indicator (yes vs. no).  
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Chapter 5B: Examination of the association between UNGD 




Background: In Chapter 4, we observed an exposure-effect association between 
higher quartiles of UNGD production and greater odds of B-type natriuretic peptide 
(BNP) levels  400 pg/mL. In this chapter, given the known pathophysiological 
differences between heart failure phenotype status (i.e., heart failure with reduced or 
preserved ejection fraction [HFrEF or HFpEF]), and because very few large-scale 
epidemiologic studies of associations between environmental factors and BNP exist, we 
sought to evaluate if heart failure phenotype modified the association between UNGD 
activity and BNP levels. 
Methods: We used eMERGE heart failure phenotypes that had previously been 
assigned to 3938 subjects in Chapter 4, and we evaluated differences in demographics, 
comorbidities, and medication use by phenotype categories: not phenotyped (including 
“eMERGE not applied,” and eMERGE applied but not able to phenotype [“eMERGE no 
phenotype”]), HFrEF, and HFpEF subjects. We then included cross-products between 
these phenotype indicators and UNGD metrics in the analysis of effect modification of 
the UNGD association with greater BNP levels, adjusting for confounding variables. We 
evaluated the global significance of these cross-product terms using chi2 tests. We 
generated linear combinations of stratum-specific odds ratios for each phenotype group 
and quartile of the four phases of UNGD activity metrics to understand if phenotype 
category modified the associations observed in Chapter 4.  
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Results: To review, in this analysis and in Chapter 4 there were 3938 subjects and in 
Chapter 5a there were 9054 subjects, but despite the different samples with the relevant 
data, we observed some similar associations across chapters in the analysis before 
evaluation of effect modification. For example, similar to the what we observed in 
Chapter 5a, subjects in this analysis with a HFpEF or HFrEF phenotype had a greater 
proportion of comorbidities and medication use compared to subjects without a 
phenotype, suggesting more severe disease. We also observed that HFrEF subjects had 
higher odds of a BNP level  400 pg/mL compared to HFpEF subjects and to subjects in 
the no phenotype group; in Chapter 5a, HFrEF subjects had higher odds of 
hospitalization compared to HFpEF subjects and to subjects in the no phenotype group. 
Importantly, data suggest that the two samples of persons with BNP data, presented in 
Chapters 4 and 5b, and the subjects in the hospitalization analysis by phenotype 
(Chapter 5a) differed in important ways, with a greater proportion of subjects in this 
chapter being deceased by the end of the study period compared to the proportion who 
were deceased in Chapter 5a. Unlike differences between phenotyped and not 
phenotyped subjects in the hospitalization analysis (Chapter 5a), phenotyped and not 
phenotyped subjects in this chapter did not differ by duration of heart failure. In this 
analysis, after adjusting for phenotype indicators, we observed exposure-effect 
associations between quartiles of the UNGD production metric and odds of a BNP level 
 400 pg/mL, consistent with the findings of Chapter 4. We observed, in models of the 
spud, stimulation, and production metrics, the global test of significance of the cross-
products between the indicator for HFrEF and quartiles of the spud, stimulation, and 
production metrics was p = 0.01, 0.001, and 0.0009, respectively; the global test of 
significance of the cross-product for HFrEF and the pad metric yielded a p-value of 0.05. 
After adjusting for both the main effects of phenotype categories and the cross-products 
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between phenotype categories and UNGD metrics, we observed an increased odds of 
BNP levels  400 pg/mL among HFpEF subjects in the fourth quartile of the pad 
preparation metric (OR [95 % CI] = 1.61 [1.11, 2.35]), and in the third and fourth quartiles 
of the production metric (OR [95 % CI] = 2.08 [1.33, 3.26], 2.49 [1.54, 2.02], 
respectively). Although the global test of significance for the cross products between the 
spud metric and HFrEF indicators was p = 0. 01, and p = 0.001 for the stimulation 
metric, we did not observe exposure-effect associations among the HFrEF subjects, and 
we observed null associations with quartiles of spud and stimulation activity among the 
HFpEF and not phenotyped subjects for these metrics.  
Conclusions: This analysis was largely exploratory, and we were unable to determine if 
HFrEF phenotype modified the associations between UNGD activity and BNP levels  
400 pg/mL. Although HFrEF was associated with higher BNP levels independent of 
UNGD activity, our results suggest that HFpEF subjects had the strongest association 
with increasing quartiles of UNGD production and in the 4th quartile of the pad metric, 
and may therefore be driving the associations we observed between UNGD production 
metrics and increased odds of BNP  400 pg/mL in Chapter 4. Despite the three 
significant global tests of cross-products between HFrEF and UNGD activity metrics, 
associations among the HFrEF subjects with these UGND metrics did not have a clear 
exposure-effect trend with increasing quartile, and it is difficult to state whether effect 
modification was truly present. How associations across Chapters 4, 5a, and 5b could 
be influenced by the different samples of persons in each analysis will be discussed. 
5B2. INTRODUCTION 
 B-type natriuretic peptide (BNP), a neuroendocrine hormone, has been 
increasingly utilized in clinical settings for diagnosis and prognosis of heart failure in 
persons with the disease [1-3]. BNP levels become elevated when there is an increase 
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in intracardiac pressure, particularly within the left ventricle [4, 5]. We observed 
exposure-effect associations between UNGD production activity and odds of a BNP level 
 400 pg/mL in Chapter 4. A small number of studies have evaluated environmental 
factors in relation to BNP levels, but these studies are limited by small sample sizes and 
a lack of distinction between HFpEF and HFrEF subjects [6, 7].  
Despite pathophysiological differences between HFpEF and HFrEF [8-12], no 
large scale epidemiologic studies, to date, have evaluated environmental factors in 
relation to BNP levels among heart failure patients with differing phenotypes (i.e., HFpEF 
vs. HFrEF). Given the associations observed in Chapter 4 between UNGD production 
activity and odds of BNP levels   400 pg/mL, we sought to understand if the association 
between UNGD activity and BNP was modified by phenotype status. Because HFrEF 
subjects generally have higher BNP levels than subjects with HFpEF, and because we 
suspected HFpEF subjects might be more susceptible to environmental exposures 
associated with UNGD activity (e.g., exposure to air pollution, noise, community stress), 
we did not have a clear a priori hypothesis as to which phenotype would have a stronger 
association between UNGD production and BNP levels, and this analysis was largely 
exploratory. 
5B3. METHODS 
 We used eMERGE heart failure phenotypes that had been previously assigned 
[13, 14] to the subjects in our BNP analysis (Chapter 4). As first presented in Chapter 2, 
we observed that 2158 of the 3938 subjects in the BNP analysis had the eMERGE 
algorithm applied, and 1780 of these subjects did not have the eMERGE algorithm 
applied. Among those who had the eMERGE algorithm applied, 826 were phenotyped 
as HFrEF, 772 were phenotyped as HFpEF, and 558 subjects did not have a 
discernable phenotype. Similar to the application of this phenotyping method to the 
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hospitalization study subjects (Chapter 5a), we determined that missing phenotype 
information was missing not at random (MNAR), and so we created three binary 
indicators to categorize subjects into four phenotypic groups: HFpEF, HFrEF, those 
without enough information to be phenotyped (“eMERGE not applied”), and those who 
had enough information to have the eMERGE algorithm applied but did not have a clear 
HFpEF or HFrEF phenotype (“eMERGE no phenotype”). For descriptive analysis, we 
combined the “eMERGE not applied” and “eMERGE no phenotype” groups into a “not 
phenotyped” group. 
 We first evaluated frequencies of the number of laboratory orders and the 
number of subjects categorized into three phenotypic groups: not phenotyped, HFrEF, 
and HFpEF to evaluate potential for bias and confounding in our sample. We next 
evaluated differences in patient characteristics (i.e., demographics, comorbidities, 
medications) between subjects who were not able to be phenotyped, those who were 
phenotyped as HFrEF, and those who were phenotyped as HFrEF. We evaluated 
differences in these characteristics by analysis of variance (ANOVA) F-tests (for linear 
variables) and by chi2 tests (for categorical variables).  
 In our primary analysis, we used the three binary indicators to reflect our four 
phenotypic groups (eMERGE not applied, eMERGE no phenotype, HFrEF, and HFpEF), 
with HFpEF as the reference group as in our analysis for Chapter 5a. We added these 
indicators to the final adjusted GEE models of BNP levels  400 pg/mL (from Chapter 4) 
and assessed the association between each phenotype indicator and odds of a BNP 
level  400 pg/mL, independent of UNGD activity. Next, we evaluated the main effects of 
each UNGD activity metric, after adjusting for phenotype groups. Lastly, we evaluated 
the same GEE models of BNP levels   400 pg/mL but also included cross-product 
terms between each UNGD metric quartile indicator and the three phenotype group 
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indicators. We estimated the effects of each indicator, UNGD metric, and interaction 
term, and we evaluated the global significance of these interaction terms using chi2 tests. 
Similar to all evaluations of UNGD activity in this dissertation research, we evaluated 
each metric of UNGD activity separately. To estimate the odds of BNP levels  400 
pg/mL among each phenotype group and for each quartile of UNGD activity, we used 
the “ggplot2” package in R v.3.4.2 [15] to generate forest plots that visually displayed 
these odds ratios, with the first quartile of UNGD activity in the HFpEF group as the 
referent. Although Chapter 5a included a post hoc analysis of effect modification by an 
indicator of severity on the associations between UNGD activity and hospitalization, we 
did not combine HFrEF and HFpEF groups into an indicator of severity in this analysis 
because the associations between each phenotype group and BNP, independent of 
UNGD activity, differed greatly.  
5B3. RESULTS 
5B.3.1 DESCRIPTIVE CHARACTERISTICS OF PHENOTYPE GROUPS 
 We observed that the proportion of subjects and the proportion of laboratory 
orders was relatively similar across phenotype groups (i.e., no phenotype, HFrEF, and 
HFpEF), although HFrEF and HFpEF subjects represented a slightly larger proportion of 
laboratory orders (22.3% of laboratory orders were from HFrEF subjects, and 21.2% of 
laboratory orders were from HFpEF subjects) included in the analysis, compared to the 
number of subjects each group represented (21.0% of subjects were HFrEF and 19.7% 
of subjects were HFpEF, Table 5b.1). This suggests that there is little concern for bias 
or confounding in our analysis due to the distributions of laboratory orders across 
phenotype groups. Similar to the descriptive results of Chapter 5a, we observed some 
differences in subject characteristics among HFpEF, HFrEF, and not phenotyped 
subjects (Table 5b.2), with HFpEF subjects having a greater mean age and a higher 
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proportion of females compared to the other two groups (p < 0.001 for age and sex). We 
also observed that a greater proportion of HFrEF (52.5%) and HFpEF (50.8%) subjects 
were deceased by the end of the study compared to the not phenotyped subjects 
(46.7%, p = 0.008, Table 5b.2). Importantly, we observed some differences compared to 
the distribution of subjects who were deceased by the end of the study period in 
Chapter 5a, where 30.4% of not phenotyped subjects, 39.2% of HFrEF subjects, and 
39.6% of HFpEF subjects were deceased by the end of the study period (p < 0.001, 
Table 5a.1). The subjects in the BNP analysis, and particularly those who had an 
assigned phenotype, therefore appeared to have more severe disease than the subjects 
included in the hospitalization analysis. This observation is further supported by 
differences in mean heart failure duration by phenotype group, which differed in Chapter 
5a (not phenotyped = 855 days; HFrEF = 754 days; HFpEF = 670 days, p < 0.0001, 
Table 5a.1), but we did not observe differences related to the mean duration of heart 
failure across all three of these groups (not phenotyped = 806 days; HFrEF = 888 days; 
HFpEF = 801 days, p = 0.1) in this analysis (Table 5b.2).  
Although the subjects in this analysis were generally more severe than those 
included in the hospitalization analysis (i.e., considering duration of heart failure and 
proportion of subjects who were deceased by the end of the study period), the 
distribution of comorbidities by phenotype groups was similar to the distributions of 
comorbidities by phenotype groups observed in Chapter 5a. For example, we observed 
that HFpEF subjects also had a greater prevalence of chronic obstructive pulmonary 
disease, hypertension, diabetes, and chronic kidney disease than HFrEF and not 
phenotyped subjects (Table 5b.3). HFrEF subjects had a higher proportion of coronary 
artery disease and of previous myocardial infarctions (Table 5b.3). We observed that 
HFrEF and HFpEF subjects had a higher prevalence of antihypertensive, 
antihyperlipidemic, and anticoagulant medications, however none of these differences 
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were great enough to suggest statistically significant differences by chi2 test (p = 0.06, 
0.2, and 0.2, for each medication class, Table 5b.3). The calculated values of the 
Charlson index of morbidity differed across phenotype groups, with a mean (SD) value 
of 8.64 (3.0) in the not phenotyped group, 8.79 (3.0) in the HFrEF group, and 9.18 (2.6) 
in the HFpEF group (p < 0.001, Table 5b.3). 
5B.3.2 ASSOCIATIONS OF PHENOTYPE WITH BNP AND CONFOUNDING OF THE 
ASSOCIATIONS BETWEEN UNGD ACTIVITY AND BNP BY PHENOTYPE 
 In GEE models of BNP, without including any UNGD activity metrics, HFrEF 
subjects had a higher odds of BNP levels   400 pg/mL (OR [95% CI] = 2.24 [1.84, 2.72]) 
compared to HFpEF subjects, after adjusting for comorbidities, laboratory setting, 
medication use, and subject characteristics (Table 5b.4). We observed null associations 
of eMERGE no phenotype and eMERGE not applied with BNP (OR [95% CI] = 1.03 
[0.83, 1.28], 0.97 [0.80, 1.18], respectively, Table 5b.4). After adjusting for these 
phenotype indicators, we did not observe any significant associations between the pad 
preparation, spud, or stimulation metrics and BNP  400 pg/mL, however we did observe 
exposure-effect relations among HFpEF subjects (i.e., the reference group) with the 2nd, 
3rd and 4th quartiles of the production metric and BNP (OR [95% CI] = 1.36 [1.08, 1.73], 
1.45 [1.06, 1.97], 1.54 [1.08, 2.21], respectively, compared to the first quartile of 
production among HFpEF subjects. Table 5b.5). These effect estimates are very similar 
to those reported in Chapter 4, without adjustment for phenotype indicators, for the 
production metric (OR [95 % CI] = 1.36 [1.08, 1.71], 1.42 [1.05, 1.93], 1.52 [1.07, 2.17]), 
suggesting that phenotype did not confound the associations between UNGD production 
activity and BNP observed in Chapter 4. 
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5B.3.3 EFFECT MODIFICATION BY PHENOTYPE ON ASSOCIATIONS OF UNGD 
ACTIVITY WITH BNP 
 After calculating phenotype-adjusted odds ratios of UNGD activity with BNP, we 
next evaluated models that also included cross-products between each phenotype 
indicator and quartile of UNGD activity metrics. In these models, the global test of 
significance of the cross-products between an indicator for HFrEF subjects and quartiles 
of the pad preparation, spud, stimulation, and production metrics yielded p = 0.05, 0.01, 
0.001, and 0.009, respectively (Tables 5b.6-9). After inclusion of the cross-products 
between phenotype indicators and UNGD metrics, we observed an association between 
UNGD activity and BNP levels within the HFpEF group (compared to the first quartile of 
each metric within the HFpEF group) for the 4th quartile of the pad preparation metric 
(OR [95 % CI] = 1.61 [1.11, 2.35], Table 5b.6) and the 3rd and 4th quartiles of the 
production metric (OR [95 % CI] = 2.08 [1.33, 3.26], 2.49 [1.54, 4.02], respectively, 
Table 5b.9). Within the reference group (HFpEF), we did not see any associations of the 
spud or stimulation metrics with BNP levels (Tables 5b.7 and 5b.8). 
 After accounting for cross-products between UNGD activity metrics and 
phenotype indicators (i.e., models presented in Tables 5b.6-9), we plotted the linear 
combinations of the main effect of phenotype indicators, the main effect of UNGD 
activity, and the cross-products between these two indicators to observe stratum-specific 
estimates of odds of BNP  400 pg/mL for each phenotype group and quartile of UNGD 
activity (Figures 5b.1-4). In plots for each UNGD activity metric, it was evident that the 
HFrEF subjects had higher odds of BNP  400 pg/mL compared to the reference group, 
HFpEF subjects in the first quartile of each UNGD activity metric. Although there was no 
discernable exposure-effect association for the HFrEF subjects in models of the pad or 
spud metrics (Figures 5b.1 and 5b.2), there appeared to be a U-shaped association 
between increasing quartiles of UNGD activity and odds of BNP  400 pg/mL in the 
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models of the stimulation and production metrics (Figures 5b.3 and 5b.4), however the 
confidence intervals for each of these quartiles overlapped, so the shape of this 
association should be interpreted with caution. We did not observe any exposure-effect 
associations in models of the pad metric (Figure 5b.1), spud metric (Figure 5b.2), or 
stimulation metric (Figure 5b.3) for subjects without an assigned phenotype (i.e., 
eMERGE no phenotype and eMERGE not applied compared to the reference group, 
HFpEF subjects in the first quartile of each UNGD activity metric). However, we did see 
that, even among these less well-characterized phenotype groups, the 4th quartile of the 
UNGD production metric was associated with greater odds of BNP  400 pg/mL 
compared to the reference group, HFpEF subjects in the first quartile of UNGD 
production (Figure 5b.4). We also observed a 4th quartile association among HFpEF 
subjects for the pad preparation metric compared to the first quartile of the pad 
preparation metric (Figure 5b.1), although the clearest exposure-effect association and 
trend was observed for the production metric among the HFpEF subjects, with odds of 
BNP  400 pg/mL that increased with the 3rd and 4th quartiles of UNGD production 
activity compared to HFpEF subjects in the first quartile of the production metric (Figure 
5b.4).  
5B4. DISCUSSION 
The purpose of this analysis was to assess whether heart failure phenotypes 
(HFpEF and HFrEF) modified the associations evaluated in Chapter 4 between four 
UNGD activity metrics and odds of BNP  400 pg/mL. Combined effects of phenotype 
indicators and cross-products between these phenotype indicators and UNGD activity 
metrics illustrated that, for the pad preparation metric, HFpEF subjects had increased 
odds of BNP  400 pg/mL in the 4th quartile compared to HFpEF subjects in the first 
quartile. Among the HFpEF subjects, we observed an exposure-effect association with 
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increasing quartiles of the production metric and odds of BNP  400 pg/mL, compared to 
the HFpEF subjects in the first quartile of the production metric. Because we used three 
different phenotype groups in our analysis to assess effect modification, with HFpEF 
subjects as the reference group, the global tests of significance of the cross-products 
between phenotype indicators and UNGD activity metrics did not necessarily indicate 
effect modification after accounting for the main effects of each phenotype with BNP 
levels. For example, in models of the spud, stimulation, and production metrics, the 
global test of significance of the cross-products between the indicator for HFrEF and 
quartiles of the spud, stimulation, and production metrics was p = 0.01, 0.001, and 
0.0009, respectively; the global test of significance of the cross-product for HFrEF and 
the pad metric yielded a p-value of 0.05. However, we found that, after adjusting for 
phenotype indicators and cross-products between these indicators and UNGD activity 
metric quartiles, associations between the spud and stimulation metrics were null for 
HFpEF and not phenotyped subjects, and the HFrEF subjects did not evidence a clear 
exposure-effect association with these metrics. Although the cross-product terms were 
significant, determining if phenotype modified the associations between UNGD activity 
and BNP was difficult because, among the HFrEF subjects, there was no clear 
exposure-effect association. 
After adjusting for phenotype indicators and cross-product terms between UNGD 
activity metrics and phenotype indicators, we observed slightly stronger associations 
with UNGD production and BNP than we did in Chapter 4. There was also an 
emergence of a 4th quartile association between the pad metric and greater odds of BNP 
 400 pg/mL among the HFpEF subjects, which was not present in our Chapter 4 
analysis. Unlike Chapter 5a, where we observed effect modification by a severity 
indicator (i.e., combined HFrEF and HFpEF groups) of the associations between the pad 
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preparation and spud metrics and hospitalization, we did not evaluate effect modification 
by an indicator of severity. Our reasoning for this was because, comparing the subjects 
in this analysis to those included in Chapter 5a, we did not observe the same 
differences in duration of disease by phenotype groups as we did in the hospitalization 
analysis. Additionally, comparing subjects in this analysis to those in Chapter 5a, a 
greater proportion of subjects were deceased in the BNP analysis across all phenotype 
groups (48.8%) compared to the overall proportion of subjects who were deceased in 
the hospitalization analysis (33.4%). Therefore, we did not associate the presence of 
HFpEF or HFrEF phenotype with severity in the same way as in Chapter 5a, because 
subjects in this analysis, with or without a phenotype, also had severe outcomes and no 
discernable difference in duration of heart failure. Although the subjects had a greater 
proportion of subjects who were deceased by the end of the study period compared to 
Chapter 5a, we do not think that introduced bias into results in this chapter because the 
proportion of comorbidities and medications across phenotype groups (i.e., comparing 
HFpEF, HFrEF, and not phenotyped subjects) was similar to the distribution observed 
across these groups in Chapter 5a. 
A challenge to the interpretation of the results of this study is that the 
environmental epidemiology of BNP, and especially the environmental epidemiology of 
BNP among HFpEF and HFrEF subjects, is severely limited. We first sought to evaluate 
the association between UNGD activity and BNP levels in Chapter 4 because we 
hypothesized that BNP would be a useful biological marker of the physiological response 
mechanisms that we suspected UNGD activity would cause (i.e., through air pollution 
exposure, noise exposure, and experiences of psychosocial stress). Our initial thinking 
was that all of these exposure pathways would result in systemic inflammation, 
endothelial dysfunction, and increased systemic blood pressure, which would be 
correlated with intracardiac pressures and thus BNP levels. Because we observed an 
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exposure-effect association of UNGD production activity and higher BNP among HFpEF 
subjects and 4th quartile associations with UNGD production activity and higher BNP 
among the not phenotyped subjects, these findings make biological sense. Considering 
point estimates only, we observed a U-shaped association between quartiles of UNGD 
stimulation and production activity and greater BNP levels among the HFrEF subjects; 
however, each quartile had overlapping confidence intervals, so we cannot distinguish 
the shape of this association from a linear exposure-effect association across quartiles 
among the HFrEF subjects. Because no other studies of this kind exist to which we can 
compare these results, future studies would need to explore the associations between 
environmental exposures and BNP levels among HFrEF subjects. 
 A major strength of this study is that we were able to utilize EHR data from 
subjects who were representative of the general population in Pennsylvania [16] and 
were able to obtain phenotype information from the application of the validated eMERGE 
heart failure phenotyping algorithm [13, 14]. We have not been able to identify any other 
epidemiological studies that utilized the eMERGE heart phenotyping algorithm [13, 14] to 
examine whether HFpEF, HFrEF, and no phenotypes modified relations of 
environmental factors with any heart failure outcomes. Further, this is the first 
environmental epidemiology study of heart failure phenotypes and BNP. Unlike 
hospitalization for heart failure (Chapters 3 and 5a), BNP as an outcome can be present 
in asymptomatic patients [3] and can predict mortality in subjects with and without heart 
failure [17]; and, in this study and in Chapter 4, was obtained from both inpatient and 
outpatient settings. In this sense, the design of this BNP analysis could detect 
associations between UNGD activity and BNP that occur without the presence of a 
symptomatic exacerbation of heart failure. 
 Limitations of this study include the inability to measure dietary, behavioral, and 
occupational factors from the EHR, limitations that are common to EHR-based 
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epidemiology studies. Another limitation of this study, similar to a limitation in Chapter 
5a, is that not all of the subjects in this analysis were able to be assigned a phenotype 
status from the eMERGE algorithm because the eMERGE algorithm required 
echocardiogram measures and consistent contact with the health care system 
(Appendix A. Heart failure algorithm). Lastly, a limitation of this study is that we were 
unable to fully distinguish whether the association between stimulation and production 
metrics and BNP levels among HFrEF subjects was definitively an inverted U-shaped 
association or a linear exposure-effect association because of the overlapping 
confidence intervals. However, better characterizing the associations between 
environmental factors and BNP by heart failure phenotypes is an interesting avenue for 
future research, and this has been the first study to evaluate these associations.  
5B5. CONCLUSIONS 
This analysis found that, although BNP levels were independently greater in 
HFrEF subjects compared to HFpEF subjects and to subjects without an assigned 
phenotype, we could not conclude that heart failure phenotype modified associations 
between UNGD activity and BNP levels  400 pg/mL. However, we did observe an 
exposure-effect relation with increasing quartiles of UNGD production activity and BNP 
levels among subjects with HFpEF. This supports a growing body of evidence that 
UNGD activity is associated with adverse health outcomes in exposed populations, and 
is the first study to evaluate environmental associations with BNP levels among subjects 
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Table 5b.1. Frequencies of laboratory orders for B-type natriuretic peptide (BNP) and 
subjects in this analysis by assigned phenotype status  
Phenotype Number of laboratory orders, n 
(%) 
Number of subjects, n (%) 
Not phenotyped 3668 (56.4) 2338 (59.4) 
HFrEF 1452 (22.3) 826 (21.0) 
HFpEF 1381 (21.2) 774 (19.7) 
Total 6501 (100) 3938 (100) 
 
 
Table 5b.2. Selected subject characteristics by phenotype status, at time of subjects’ 
first selected lab date 
Total subjects  
n = 3938 
Not phenotyped 
n = 2338 
HFrEF 
n = 826 
HFpEF 
n = 774 
 
p-value* 
Sex, n (%) 
    Male 








451 (58.3) < 0.001 
Race/ethnicity, n 
(%) 
    White 
    Black 
    Hispanic 
    Other 


















0 (0.0) 0.2 
Age at laboratory 







73.3 (10.6) < 0.001 
Community type, n 
(%) 
    Borough 
    Township 

















(CSD),** SD units, 
quartiles 
     1 
     2 
     3 





















185 (23.9) 0.7 
Patient status at 
end of study, n (%) 
   Alive 












393 (50.8) 0.008 








2433 (4054) 0.001 
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Total subjects  
n = 3938 
Not phenotyped 
n = 2338 
HFrEF 
n = 826 
HFpEF 
n = 774 
 
p-value* 


















5960 (7831) 0.06 
Smoking status at 
event, n (%) 
    Ever 












343 (44.3) 0.01 
Receipt of Medical 






76 (9.8) 0.06 
Body mass index 
(BMI) at event, 






33.0 (7.6) 0.000 
Time since first HF 







801 (1032) 0.1 
* p-value obtained from either chi
2
 tests (for categorical variables) or ANOVA F-test (for continuous 
variables), comparing selected characteristics by phenotype group (not phenotyped, heart failure with 
reduced ejection fraction [HFrEF], and heart failure with preserved ejection fraction [HFpEF]) 
** Community socioeconomic deprivation (CSD) was calculated based on US Census indicators; further 
information is detailed in the text 
*** Major & minor roads were identified from the Federal Highway Administration databases; distance from 
subject’s residential address to these roads was calculated in meters 
† 
Medical Assistance, a surrogate for family socioeconomic status, was calculated based on health 
insurance status at the time of lab date 
‡





Table 5b.3. Selected diagnoses and medication use at time of subjects’ first selected laboratory date, by heart failure phenotype 
group 
 
Total subjects n = 3938 
Not 
phenotyped 
n = 2338 
HFrEF 
n = 826 
 
HFpEF 
n = 774 
 
p-value* 
Medication use, by class, n 
(%)** 
    Antihypertensive 
    Antihyperlipidemic 

















Chronic obstructive pulmonary 




166 (20.1) 182 (23.5) 
 
0.2 
Coronary artery disease 




230 (27.9) 179 (23.1) 
 
< 0.001 
Hypertension, n (%) 1457 (62.3) 545 (66.0) 569 (73.5) < 0.001 
Myocardial infarction, n (%) 188 (8.0) 119 (14.4) 53 (6.9) < 0.001 
Valve disorder, n (%) 376 (16.1) 184 (22.3) 191 (24.7) < 0.001 
Diabetes, n (%) 883 (37.8) 327 (39.6) 367 (47.4) < 0.001 
Chronic kidney disease, n (%) 949 (40.6) 366 (44.3) 366 (47.3) < 0.001 





8.79 (3.0) 9.18 (2.6) 
 
< 0.001 
* p-value obtained from either chi
2
 tests (for categorical variables) or ANOVA F-test (for continuous variables), comparing selected characteristics by phenotype 
group: not phenotyped, heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF) 
** Relevant medication classes were identified based on the dates of physician orders 
*** A composite measure of overall morbidity; definition described in text
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Table 5b.4. Adjusted associations (odds ratio [OR], 95% confidence interval [CI]) of 
phenotype indicators with B-type natriuretic peptide (BNP) value ≥ 400 pg/mL (vs. 
lower), with heart failure with preserved ejection (HFpEF) fraction as the referent group 
Phenotype Indicator Indicator value 
Number of 
labs (n) OR* (95 % CI) 
HFrEF** 0 5049 Ref 
     1 1452 2.24 (1.84, 2.72) 
eMERGE applied, 






1.03 (0.83, 1.28) 





0.97 (0.80, 1.18) 
*Odds ratios obtained from generalized estimating equations (GEE) with an exchangeable correlation 
matrix. Model adjusted for: sex (female vs. male), race/ethnicity (nonwhite vs. white), smoking status (ever 
vs. never), age at time of laboratory date (centered), laboratory setting (inpatient vs. outpatient), receipt of 
Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered and centered 
squared), body mass index BMI (centered and centered squared), diagnosis of chronic kidney disease, 
antihyperlipidemic and anticoagulant medication, duration of heart failure (date of lab order – the date of first 
HF diagnosis, included as a centered and centered squared term), region, and year 
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Table 5b.5. Phenotype indicator-adjusted associations (odds ratio [OR], 95% confidence 
interval [CI]) of unconventional natural gas development (UNGD) with B-type natriuretic 
peptide (BNP) value ≥ 400 pg/mL (vs. lower) 
Metric Quartile OR* (95 % CI) 
Pad preparation 1 Ref 
 2 0.97 (0.82, 1.14) 
 3 1.11 (0.93, 1.34) 
 4 1.07 (0.88, 1.31) 
Spud 1 Ref 
 2 1.10 (0.89, 1.36) 
 3 1.02 (0.79, 1.31) 
 4 1.10 (0.83, 1.45) 
Stimulation 1 Ref 
 2 1.02 (0.86, 1.22) 
 3 1.02 (0.81, 1.28) 
 4 1.01 (0.79, 1.29) 
Production 1 Ref 
 2 1.36 (1.08, 1.73) 
 3 1.45 (1.06, 1.97) 
 4 1.54 (1.08, 2.21) 
*Odds ratios obtained from generalized estimating equations (GEE) with an exchangeable correlation 
matrix. Model adjusted for: sex (female vs. male), race/ethnicity (nonwhite vs. white), smoking status (ever 
vs. never), age at time of laboratory date (centered), laboratory setting (inpatient vs. outpatient), receipt of 
Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered and centered 
squared), body mass index BMI (centered and centered squared), diagnosis of chronic kidney disease, 
antihyperlipidemic and anticoagulant medication, duration of heart failure (date of lab order – the date of first 
heart failure diagnosis, included as a centered and centered squared term), region, year, and an indicator for 
heart failure with reduced ejection fraction (HFrEF), an indicator for having the phenotyping algorithm 
applied but not having a discernable phenotype (“eMERGE no phenotype”), and an indicator for not having 
the algorithm applied (“eMERGE not applied”). The overall phenotype reference group is heart failure with 
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Table 5b.6. Adjusted associations (odds ratio [OR], 95% confidence interval [CI]) of the 
pad preparation metric and phenotype indicators with B-type natriuretic peptide (BNP) 
value ≥ 400 pg/mL (vs. lower), with heart failure with preserved ejection (HFpEF) fraction 





value OR* (95 % CI) 
p-value for 
interaction** 
Pad preparation 1 Ref  
 2 1.19 (0.83, 1.68)  
 3 1.18 (0.84, 1.66)  
 4 1.61 (1.11, 2.35)  
HFrEF*** 0 Ref  
 1 1.10 (0.89, 1.36)  
eMERGE applied, 











1.19 (0.85, 1.66) 
 







0.72 (0.45, 1.13) 
0.83 (0.54, 1.27) 





Pad metric x 
eMERGE applied 







0.92 (0.55, 1.52) 
1.26 (0.77, 2.07) 













0.86 (0.55, 1.33) 
0.75 (0.47, 1.17) 





*Odds ratios obtained from generalized estimating equations (GEE) with an exchangeable correlation 
matrix. Model adjusted for: sex (female vs. male), race/ethnicity (nonwhite vs. white), smoking status (ever 
vs. never), age at time of laboratory date (centered), laboratory setting (inpatient vs. outpatient), receipt of 
Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered and centered 
squared), body mass index BMI (centered and centered squared), diagnosis of chronic kidney disease, 
antihyperlipidemic and anticoagulant medication, duration of heart failure (date of lab order – the date of first 
heart failure diagnosis, included as a centered and centered squared term), region, year, and cross-products 
of the pad preparation metric and each of the following: an indicator for heart failure with reduced ejection 
fraction (HFrEF), an indicator for having the phenotyping algorithm applied but not having a discernable 
phenotype (“eMERGE no phenotype”), and an indicator for not having the algorithm applied (“eMERGE not 
applied”), with heart failure with preserved ejection fraction (HFpEF) as the referent group 
**p-value for global significance of cross-product terms obtained from chi
2
 test 
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Table 5b.7. Adjusted associations (odds ratio [OR], 95% confidence interval [CI]) of the 
spud metric and phenotype indicators with B-type natriuretic peptide (BNP) value ≥ 400 






value OR (95 % CI) p-value for interaction** 
Spud 1 Ref  
 2 0.86 (0.58, 1.27)  
 3 1.42 (0.97, 2.08)  
 4 1.30 (0.87, 1.94)  
HFrEF*** 0 Ref  
 1 2.30 (1.62, 3.27)  
eMERGE 














1.08 (0.79, 1.49) 
 







1.53 (0.95, 2.46) 
0.73 (0.47, 1.13) 





Spud metric x 
eMERGE 










1.24 (0.77, 2.01) 
0.70 (0.44, 1.14) 















1.04 (0.71, 1.53) 
0.83 (0.54, 1.27) 





*Odds ratios obtained from generalized estimating equations (GEE) with an exchangeable correlation 
matrix. Model adjusted for: sex (female vs. male), race/ethnicity (nonwhite vs. white), smoking status (ever 
vs. never), age at time of laboratory date (centered), laboratory setting (inpatient vs. outpatient), receipt of 
Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered and centered 
squared), body mass index BMI (centered and centered squared), diagnosis of chronic kidney disease, 
antihyperlipidemic and anticoagulant medication, duration of heart failure (date of lab order – the date of first 
heart failure diagnosis, included as a centered and centered squared term), region, year, and cross products 
between the spud metric and each of the following: an indicator for heart failure with reduced ejection 
fraction (HFrEF), an indicator for having the phenotyping algorithm applied but not having a discernable 
phenotype (“eMERGE no phenotype”), and an indicator for not having the algorithm applied (“eMERGE not 
applied”), with heart failure with preserved ejection fraction (HFpEF) as the referent group  
**p-value for global significance of cross-product terms obtained from chi
2
 test 
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Table 5b.8. Adjusted associations (odds ratio [OR], 95% confidence interval [CI]) of the 
stimulation metric and phenotype indicators with B-type natriuretic peptide (BNP) value ≥ 






value OR* (95 % CI) 
p-value for 
interaction** 
Stim 1 Ref  
 2 0.77 (0.53, 1.10)  
 3 1.25 (0.86, 1.82)  
 4 1.25 (0.84, 1.85)  
HFrEF*** 0 Ref  
 1 2.48 (1.76, 3.50)  
eMERGE 














1.11 (0.81, 1.54) 
 







1.50 (0.96, 2.37) 
0.82 (0.53, 1.27) 

















1.41 (0.88, 2.27) 
1.01 (0.62, 1.65) 














0.99 (0.67, 1.48) 
0.67 (0.43, 1.04) 





*Odds ratios obtained from generalized estimating equations (GEE) with an exchangeable correlation 
matrix. Model adjusted for: sex (female vs. male), race/ethnicity (nonwhite vs. white), smoking status (ever 
vs. never), age at time of laboratory date (centered), laboratory setting (inpatient vs. outpatient), receipt of 
Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered and centered 
squared), body mass index BMI (centered and centered squared), diagnosis of chronic kidney disease, 
antihyperlipidemic and anticoagulant medication, duration of heart failure (date of lab order – the date of first 
heart failure diagnosis, included as a centered and centered squared term), region, year, and cross-products 
between the stim metric and each of the following: an indicator for heart failure with reduced ejection fraction 
(HFrEF), an indicator for having the phenotyping algorithm applied but not having a discernable phenotype 
(“eMERGE no phenotype”), and an indicator for not having the algorithm applied (“eMERGE not applied”), 
with heart failure with preserved ejection fraction (HFpEF) as the referent group 
**p-value for global significance of cross-product terms obtained from chi
2
 test 
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Table 5b.9. Adjusted associations (odds ratio [OR], 95% confidence interval [CI]) of the 
production metric and phenotype indicators with B-type natriuretic peptide (BNP) value ≥ 






value OR* (95 % CI) 
p-value for 
interaction** 
Prod 1 Ref  
 2 1.20 (0.82, 1.74)  
 3 2.08 (1.33, 3.26)  
 4 2.49 (1.54, 4.02)  
HFrEF*** 0 Ref  
 1 2.89 (2.03, 4.11)  
eMERGE 














1.10 (0.79, 1.53) 
 







1.18 (0.76, 1.82) 
0.72 (0.45, 1.13) 

















1.24 (0.77, 1.99) 
0.63 (0.38, 1.07) 














0.94 (0.62, 1.41) 
0.92 (0.58, 1.45) 





*Odds ratios obtained from generalized estimating equations (GEE) with an exchangeable correlation 
matrix. Model adjusted for: sex (female vs. male), race/ethnicity (nonwhite vs. white), smoking status (ever 
vs. never), age at time of laboratory date (centered), laboratory setting (inpatient vs. outpatient), receipt of 
Medical Assistance (ever vs. never prior to laboratory date), Charlson index (centered and centered 
squared), body mass index BMI (centered and centered squared), diagnosis of chronic kidney disease, 
antihyperlipidemic and anticoagulant medication, duration of heart failure (date of lab order – the date of first 
heart failure diagnosis, included as a centered and centered squared term), region, year, and cross-products 
between the production metric and each of the following: an indicator for heart failure with reduced ejection 
fraction (HFrEF), an indicator for having the phenotyping algorithm applied but not having a discernable 
phenotype (“eMERGE no phenotype”), and an indicator for not having the algorithm applied (“eMERGE not 
applied”), with heart failure with preserved ejection fraction (HFpEF) as the referent group 
** p-value for global significance of cross-product terms obtained from chi
2
 test 
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Figure 5b.1. Associations (OR and 95% CI) of quartiles of UNGD pad activity 
metric with BNP  400 pg/mL in heart failure phenotype strata. The reference 
group is the HFpEF subjects in the 1st quartile of the pad metric.  
Figure 5b.2. Associations (OR and 95% CI) of quartiles of UNGD spud activity 
metric with BNP  400 pg/mL in heart failure phenotype strata. The reference 
group is the HFpEF subjects in the 1st quartile of the spud metric.  
Figure 5b.3. Associations (OR and 95% CI) of quartiles of UNGD stimulation 
activity metric with BNP  400 pg/mL in heart failure phenotype strata. The 
reference group is the HFpEF subjects in the 1st quartile of the stimulation metric.  
Figure 5b.4. Associations (OR and 95% CI) of quartiles of UNGD production 
activity metric with BNP  400 pg/mL in heart failure phenotype strata. The 
reference group is the HFpEF subjects in the 1st quartile of the production metric.  
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Chapter 6: Miscellaneous results 
 
This chapter is used for to present results pertinent to the analyses in Chapters 3 and 4. 
Only information that is not presented elsewhere is summarized herein. The analyses 
are presented in brief form organized by the respective chapters to which they pertain. 
6.1 MISCELLANEOUS RESULTS PERTAINING TO CHAPTER 3 
 We wanted to know if control subjects who only had one ICD-9 code, or who did 
not receive any medications for heart failure, could be biasing the results of the 
case-control study. 
 We identified 1106 people were never a case (only served as control) and had no 
heart failure medication. Of these, 622 subjects had only one icd-9 code for 
428.x. 
 Descriptive statistics for these 622 individuals are below in Table 6.1. 
 
Table 6.1 Descriptive characteristics of control subjects with only one heart failure 
diagnosis code 
Variable 
n (%) of 
622 
Sex, n (%) 
    Male 




Race/ethnicity, n (%) 
    White 
    Black 
    Hispanic 






Chronic obstructive pulmonary disease, n 
(%) 144 (23.2) 
Coronary artery disease, n (%) 159 (29.6) 
Hypertension, n (%) 506 (81.4) 
Myocardial infarction, n (%) 70 (11.3) 
Valve disorder, n (%) 109 (17.5) 
Diabetes, n (%) 260 (41.8) 
Chronic kidney disease, n (%) 178 (28.6) 
 
 




FIGURE 6.4. HISTOGRAM OF AGE AT FIRST HEART FAILURE DIAGNOSIS FOR 622 CONTROLS WITH ONLY ONE 
HEART FAILURE ICD-9 CODE 
 Within the 622 individuals who only had one ICD-9 code for heart failure, we 
wanted to determine if those without any comorbidities (i.e., hypertension, 
myocardial infarction, valve disease, coronary artery disease, chronic obstructive 
pulmonary disease, diabetes) or medications for heart failure (i.e., 
antihypertensive, antihyperlipidemic, and anticoagulant medications), could be 
influencing the results in Chapter 3. 
 We excluded 52 individuals (8.4% of the 622) who had no comorbidities. The age 
distribution of these individuals is below (Figure 6.2). 
 We conducted a sensitivity analysis excluding the 52 individuals with no 
comorbidities, leaving us with 9002 subjects with 11,604 observations. 
 Results of this sensitivity analysis (odds ratios and 95% CIs) for odds of 
hospitalization by quartile of each UNGD metric are displayed in Table 6.2. 
 We concluded that these 52 individuals were not providing undue influence in our 
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FIGURE 6.5. AGE AT HEART FAILURE DIAGNOSIS FOR THE 52 SUBJECTS WITH ONLY 1 HEART FAILURE 
DIAGNOSIS, AND NO COMORBIDITIES OR MEDICATIONS 
Table 6.2. Adjusted associations of UNGD metrics and odds of hospitalizations 
 
UNGD activity 
metric OR (95 % CI)* 
Pad metric 
    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
1.19 (1.01, 1.40) 
1.67 (1.37, 2.00) 
1.71 (1.36, 2.15) 
Spud metric 
    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
1.01 (0.82, 1.25)  
1.07 (0.84, 1.34) 
0.96 (0.74, 1.25) 
Stim metric 
    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
1.01 (0.80, 1.29) 
1.54 (1.17, 2.01) 
1.78 (1.33, 2.38) 
Prod metric 
    Quartile 1 
    Quartile 2 
    Quartile 3 
    Quartile 4 
 
Reference 
0.87 (0.64, 1.19) 
1.11 (0.76, 1.62) 
1.63 (1.07, 2.46) 
*Obtained from multi-level logistic regression models, adjusting for: sex (male vs. female), race/ethnicity (white vs. 
nonwhite), receipt of Medical Assistance, smoking status (ever vs. never), body mass index (BMI, centered), age 
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6.2 MISCELLANEOUS RESULTS PERTAINING TO CHAPTER 4 
 Initially, we wanted to evaluate changes in BNP levels over time in relation to 
environmental factors. To understand how an individual’s trajectory changed over 
time, we divided the 3938 subjects into 10 groups based on the decile of their 
first BNP laboratory value. Within each decile, we randomly selected 30 
individuals and plotted their BNP measurements over time (Figures 6.3-6.12). 
 Many subjects only had two BNP values and there was great heterogeneity on 
how values changed from the first to the second measurement. Most of these 
values were below typical cutoffs for concern (e.g., 400 pg/mL). The results 
suggested that regression towards the mean may have been one primary 
determinant of change, in that low values tended to increase and high values 
tended to decline. 
 Given the limitations of two values for longitudinal analysis and the observation 
above, we concluded there was little that was likely to be learned by subjecting 
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FIGURE 6.7. RANDOM 30 SUBJECTS' BNP VALUES OVER TIME (DECILE 2) 
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FIGURE 6.9. RANDOM 30 SUBJECTS' BNP VALUES OVER TIME (DECILE 4) 
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FIGURE 6.11. RANDOM 30 SUBJECTS' BNP VALUES OVER TIME (DECILE 6) 
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Chapter 7: Discussion 
7.1 SUMMARY OF FINDINGS 
 
 This research examined associations between metrics of unconventional natural 
gas development (UNGD) activity and heart failure outcomes in Pennsylvania. First, we 
found that among 9054 subjects with a diagnosis of heart failure, 30-day UNGD metrics 
for the pad preparation, stimulation, and production metrics were associated with greater 
odds of hospitalization. Second, we found that among 3938 subjects with a diagnosis of 
heart failure and laboratory measures of B-type natriuretic peptide (BNP), quartiles of the 
UNGD production activity metric were associated with greater odds of a BNP level  400 
pg/mL. Third, we found no evidence consistent with our a priori hypothesis that 
associations of UNGD with hospitalization (and an exploratory analysis of the same 
effect modification for BNP) were stronger in HFpEF (vs. HFrEF). Fourth, in a post hoc 
analysis, we found that subjects who were phenotyped as HFpEF or HFrEF (vs. no 
phenotype), which we interpreted as a surrogate for more severe heart failure, had 
stronger associations of UNGD pad preparation, spud, and production metrics with 
hospitalization (although the global test of the three cross-products was of borderline 
significance for production). Lastly, in our analysis to evaluate effect modification by 
heart failure phenotypes on relations of UNGD metrics with BNP levels divided at  400 
pg/mL, we found significant or borderline significant global tests for both UNGD pad 
preparation and production metrics comparing HFrEF to HFpEF, but the UNGD 
associations were difficult to interpret given the non-monotonic associations of UNGD 
pad and production with BNP levels among those with HFrEF.  phenotype (vs.HFpEF 
subjects). 
 
    
 
234 
 All of these findings are the first of their kind in both the literature on the 
environmental epidemiology of UNGD as well as in the literature on the environmental 
epidemiology of heart failure, its biomarkers, and its phenotypes. Below I discuss the 
importance and implications of these findings. 
 
7.1.2 DESCRIPTION OF GOALS OF THIS DISSERTATION 
 
The goals of this dissertation research were to: 
SA1. Evaluate associations between metrics of UNGD activity and odds of 
hospitalization in a case-control study. 
SA2. Evaluate associations between metrics of UNGD activity and odds of BNP 
levels   400 pg/mL. 
SA3. Evaluate whether HFpEF or HFrEF phenotypes modified the associations in 
SA1 or SA2 above. 
Additionally, we broadened our analysis in SA2 to also evaluate environmental and 
community variables that we hypothesized could be related to BNP levels in heart failure 
patients, including community greenness (measured by the normalized difference 
vegetation index [NDVI]) and community socioeconomic deprivation (CSD). Finally, in 
post hoc analysis, we argued that the ability of the Electronic Medical Records and 
Genomics (eMERGE) algorithm to categorize the HFpEF and HFrEF phenotypes was 
based on patient factors indicative of more severe heart failure, so we repeated the 
analyses in SA3 relevant to SA1 to evaluate whether heart failure severity modified 
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7.1.3 SUMMARY OF HOSPITALIZATION STUDY (CHAPTER 3) 
 
 The results of our case control study of heart failure hospitalizations illustrated 
that 30-day metrics of UNGD activity, in various phases, were associated with increased 
odds of hospitalization among 9054 heart failure subjects with a total of 11,678 
hospitalizations and frequency-matched control encounters. We estimated that, 
comparing the 4th to the 1st quartiles of UNGD activity, the pad preparation, stimulation, 
and production phases were associated with increased odds of hospitalization (OR [95% 
CI]: 1.70 [1.35 – 2.13], 1.80 [1.35 – 2.40], and 1.62 [1.07 – 2.45], respectively). We 
observed exposure-effect relations for the pad preparation metric (OR [95% CI]: 1.19 
[1.01 – 1.40], 1.63 [1.35 – 1.97], and 1.70 [1.35 – 2.13], for the 2nd, 3rd and 4th quartiles 
compared to the 1st, respectively) and for the stimulation metric (OR [95 % CI]: 1.03 
[0.81 – 1.31], 1.56 [1.19 – 2.04], and 1.80 [1.35 – 2.40], for the 2nd, 3rd and 4th quartiles 
compared to the 1st, respectively). These results were robust to increasing covariate 
control and a number of sensitivity analyses. 
 
7.1.4 SUMMARY OF BNP STUDY (CHAPTER 4) 
 
 The results of the study of BNP revealed that 30-day metrics of UNGD activity 
production were associated with increased odds of a BNP laboratory measure being 
greater than or equal to 400 pg/mL. We observed exposure-effect relations for the 
production metric (OR [95% CI]: 1.19 [1.01 – 1.40], 1.63 [1.35 – 1.97], and 1.70 [1.35 – 
2.13], for the 2nd, 3rd and 4th quartiles compared to the 1st, respectively). These results 
were robust to increasing covariate control and a number of sensitivity analyses. We did 
not observe significant associations between the other environmental factors (e.g., 
NDVI, proximity to major and minor roads, and CSD) that we evaluated with respect to 
elevated BNP levels. 
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7.1.5 Summary of Chapter 5a  
 
 We used categorizations of heart failure phenotype provided by Geisinger’s 
eMERGE investigators as HFrEF, HFpEF, and not phenotyped groups (eMERGE not 
applied and eMERGE no phenotype). We then evaluated effect modification by 
phenotype on relations of UNGD activity metrics with hospitalization. We observed that 
HFrEF and HFpEF subjects in our study had a distribution of comorbidities that were 
biologically plausible and consistent with the heart failure descriptive epidemiologic 
literature (e.g., HFrEF subjects had a higher prevalence of coronary artery disease and 
previous myocardial infarction; HFpEF subjects had a higher prevalence of chronic 
obstructive pulmonary disease, chronic kidney disease, diabetes). This supported the 
validity of the eMERGE phenotyping algorithm and gave us confidence that phenotypes 
were accurately identified within the hospitalization study population. We found that 
HFrEF subjects had higher odds of hospitalization than HFpEF subjects, independent of 
UNGD activity. We also found that the not phenotyped groups had reduced odds of 
hospitalization compared to the HFpEF subjects, independent of UNGD activity. After 
adjusting for phenotype indicators, we evaluated UNGD activity with odds of 
hospitalization, and we found that phenotype could have partially confounded 
associations presented in Chapter 3, as associations of UNGD activity with 
hospitalization were slightly attenuated but still present for the pad preparation, 
stimulation, and production metrics. After evaluating cross-products between each 
phenotype and each respective UNGD metric in our adjusted models, we found no 
evidence consistent with our a priori hypothesis that the associations of UNGD metrics 
with hospitalization were stronger among those with HFpEF (vs HFrEF). We did, 
however, find that HFrEF phenotype, compared to HFpEF phenotype, modified 
associations between pad preparation metric and hospitalization. Our post hoc analysis 
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evaluated effect modification of the associations between UNGD activity metrics and 
hospitalization by an indicator of severity, which we generated as a binary indicator for 
being a HFpEF or HFrEF subject. We generated this indicator because we observed that 
HFpEF and HFrEF subjects in the hospitalization analysis had a shorter duration of 
disease, higher proportion of deceased subjects at the end of the study period, and a 
greater number of comorbidities. In this post hoc analysis, we observed that after 
including an indicator for severity and cross-products between this indicator and 
respective UNGD metric quartiles, this severity indicator modified associations between 
the pad preparation and spud metrics and hospitalization.  
 
7.1.6 Summary of Chapter 5b 
  
 Similar to the results of Chapter 5a, we used eMERGE assignments to 
categorize subjects in our BNP study (Chapter 4) by phenotype category (i.e., HFrEF, 
HFpEF, and not phenotyped [including eMERGE not applied and eMERGE no 
phenotype groups]). Descriptive differences between phenotype groups were similar in 
the BNP study population as they were within the case-control study population, 
although we found that the duration of heart failure did not differ between the phenotype 
groups, as it did for subjects in Chapter 5a. We found that HFrEF subjects had higher 
odds of BNP greater than or equal to 400 pg/mL, independent of UNGD activity. 
However, after adjusting for indicators of phenotype groups in the models of BNP, we 
observed exposure-effect relations among HFpEF subjects with the production metric 
(OR [95% CI]: 1.36 [1.08 – 1.73], 1.45 [1.06 – 1.97], and 1.54 [1.08 – 2.21], for the 2nd, 
3rd and 4th quartiles compared to the 1st, respectively). Unlike in Chapter 5a, we did not 
have an a priori hypothesis regarding which phenotype group would have stronger 
associations with UNGD activity and BNP levels. We found some evidence of effect 
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modification by HFrEF vs. HFpEF phenotype groups, but the associations between 
UNGD activity metrics and BNP among the HFrEF subjects were non-monotonic. 
Therefore, we did not want to over-interpret these results. Additional studies should 
explore differences in associations between environmental factors and BNP by 
phenotype. 
 
7.1.7 Overall summary of dissertation findings 
 
Because we evaluated associations of UNGD activity metrics with two heart 
failure outcomes (hospitalization and BNP), and we evaluated effect modification by 
eMERGE-designated heart failure phenotypes of these two primary associations (in both 
a priori and post hoc combinations of phenotypes), we summarized the associations 
observed in Chapters 3, 4, 5a, and 5b in Table 7.1. In the primary evaluations of UNGD 
activity metrics with hospitalization (Chapter 3) and BNP levels (Chapter 4), we 
hypothesized that we would observe exposure-effect associations with increasing 
quartiles of UNGD activity and increasing odds of the respective outcome. In Chapter 
5a, we observed that HFrEF subjects had higher odds of hospitalization compared to 
HFpEF subjects, independent of UNGD activity. Our post hoc analysis evaluated an 
indicator of heart failure severity (i.e., having either HFpEF or HFrEF phenotype vs. no 
phenotype) and found that heart failure severity modified the association of UNGD 
activity metrics and hospitalization. In Chapter 5b, we observed a stronger independent 
association of the HFrEF phenotype indicator with odds of BNP  400 pg/mL. Although 
we observed globally significant cross-products between UNGD activity metrics and 
HFrEF phenotype indicators, we could not make any conclusion regarding effect 
modification by HFrEF phenotype on the association of UGND activity and BNP because 
exposure-effect associations between UNGD activity metrics and BNP among the 
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HFrEF subjects appeared to be non-monotonic, and therefore difficult to interpret. 
Because we observed differential associations between UNGD activity and BNP levels 
by HFrEF and HFpEF phenotypes, we did not evaluate effect modification of this 
association by an indicator of severity, as we did in post hoc analysis in Chapter 5a.  
 
In Chapters 3 & 4, in our evaluation of the associations between UNGD activity 
metrics and heart failure hospitalization and BNP levels, we observed evidence that 
supported our a priori hypotheses that metrics of UNGD activity would be associated 
with increased odds of hospitalization and increased odds of BNP levels  400 pg/mL. 
However, as Table 7.1 summarizes, these associations were not observed for all 
metrics of UNGD activity. In the hospitalization analysis (Chapter 3), we observed 
exposure-effect associations with the pad preparation, stimulation, and production 
metrics and increased odds of hospitalization. Associations with quartiles of the spud 
metric and hospitalization were null. In the BNP analysis (Chapter 4), we observed null 
associations for the pad preparation, spud, and stimulation metrics with odds of a BNP 
level  400 pg/mL; however, we observed exposure-effect associations with increasing 
quartiles of UNGD production. Our a priori hypothesis in Chapter 5a, which evaluated 
effect modification by heart failure phenotypes on the associations between UNGD 
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Abbreviations:  BNP = B-type natriuretic peptide; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart 
failure with reduced ejection fraction; Q = quartile; prod = production metric; stim = stimulation metric. 
* Shape of these associations should be interpreted with caution due to overlapping confidence intervals 
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activity and hospitalization, was that we would observe stronger associations with UNGD 
activity among HFpEF (vs. HFrEF) subjects. Our rationale for this hypothesis was due to 
evidence that HFpEF subjects often have a higher prevalence of comorbidities (e.g., 
hypertension, obesity, diabetes) that are affected by environmental conditions compared 
to HFrEF subjects [1]. We did not find evidence to support this hypothesis. Instead, we 
observed similar odds of hospitalization for heart failure in relation to UNGD activity 
metrics for HFpEF and HFrEF subjects. Given these findings and our observations 
regarding the distribution of comorbidities and medications across HFpEF, HFrEF, and 
not phenotyped subjects, we evaluated, in post hoc analyses, effect modification of the 
associations between UNGD activity metrics and hospitalization by an indicator of 
severity. We did observe that this indicator of severity modified associations between the 
pad preparation and spud metrics and hospitalization, and after accounting for cross-
products between this indicator and UNGD activity, we observed a 4th quartile 
association with the spud metric, which was not observed in Chapter 3.  Lastly, in 
Chapter 5b, we did not have a priori hypotheses regarding effect modification by 
phenotype group on relations of UNGD with BNP because there were no prior studies 
that were relevant to this question, so these analyses were largely exploratory. As Table 
7.1 outlines, we did observe associations between UNGD activity and BNP among 
HFpEF subjects for the production metric, and, in contrast to what we observed in 
Chapter 4, also for the 4th quartile of the pad preparation metric. Associations between 
UNGD metrics and BNP among HFrEF subjects, who had greater odds of BNP  400 
pg/mL independent of UNGD activity, evidenced no clear exposure-effect association 
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7.2 COMPARISONS ACROSS STUDY POPULATIONS  
 
 Because samples of persons with the relevant data were different in the different 
chapters, we evaluated the degree to which bias could have accounted for differential 
findings across chapters. Figure 2.1 outlines the selection process, and subsequent 
tables in Chapter 2 (Tables 2.11- 2.15) illustrate that subjects who had the eMERGE 
algorithm applied had, in general, greater usage of medications and had a higher 
prevalence of comorbidities. We are confident that the results of Chapters 3 and 4 are 
not biased by these differences, however, as we modeled the probability of being 
selected into either of these studies (from the 13,183 subjects eligible for selection) and 
then we included sensitivity analyses that accounted for inverse probability weights in 
both Chapters 3 and 4. The results of inverse probability weighted sensitivity analyses 
indicated that neither associations nor inferences substantially differed in the unweighted 
and weighted analyses.  
One notable difference across study populations, however, is that subjects in 
Chapters 4 and 5b appeared to have more severe disease than those included in 
Chapters 3 and 5a. For example, a greater proportion of subjects in Chapters 4 and 5b 
were deceased by the end of the study period compared to the proportion of subjects 
who were deceased by the end of the study period in Chapters 3 and 5a (48.8% vs. 
33.7%). Although the two samples did not differ greatly in terms of the duration of heart 
failure, sex, age, race/ethnicity, or community type, the mean (SD) number of medication 
orders for heart failure among subjects in the BNP analysis was 62.8 (131) over the 
duration of the study period compared to a mean of 38.6 (96.1) for heart failure among 
subjects in the hospitalization analysis (Chapter 2, Table 2.12). This is reasonable 
considering that monitoring and measurement of BNP would be more common among 
more severe heart failure subjects.  
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7.3 UNGD AND HEART FAILURE: CONTRIBUTION TO THE EPIDEMIOLOGIC LITERATURE 
 
 Heart failure is a common, severe disease that primarily affects older adults, with 
approximately 5.7 million persons living with heart failure in the United States [2, 3]. 
Heart failure is the most common diagnosis among hospitalizations for elderly individuals 
[4], and these hospitalizations carry a substantial monetary cost [5]. Given the 
prevalence and public health burden of this disease, it was important to understand the 
environmental contributions to heart failure, which has been shown to be exacerbated by 
environmental conditions [6]. A growing number of epidemiologic studies have 
documented associations between UNGD activity and low birth weight and small for 
gestational age [7, 8]; preterm birth [9-11]; congenital defects [12]; three types of asthma 
exacerbations [13, 14]; migraine, fatigue, and nasal and sinus symptoms [15]; and 
depression symptoms [16]. However, no studies, to date have evaluated associations 
between UNGD activity and any disease that primarily affects older individuals. This 
dissertation research has been the first to evaluate associations between UNGD activity 
and heart failure outcomes. 
Further, this is the first study to evaluate UNGD activity in relation to any 
biological marker. This is an important contribution to both the epidemiologic literature on 
UNGD associations with health outcomes, as well as to the environmental epidemiologic 
literature of BNP, which has only been studied in relation to environmental factors in very 
small sample sizes with mixed results [17-19]. The findings of associations between 
UNGD production activity with BNP (Chapter 4) are biologically plausible given how we 
hypothesized air pollution and stress (i.e., the two main pathways through which UNGD 
impacts cardiac health) would be associated with heart failure outcomes. These findings 
have critical public health relevance, since BNP levels have been associated with 
mortality in several epidemiologic studies [20-22].  
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Lastly, this study is the first to have evaluated any environmental associations 
with heart failure subjects phenotyped by the eMERGE heart failure phenotyping 
algorithm [23, 24] and the first to our knowledge to evaluate effect modification by 
important disease categories of relations of UNGD with any health outcome. This is a 
novel contribution to heart failure epidemiology, as studies of heart failure outcomes 
have been limited by the inability to systematically differentiate heart failure diagnoses 
obtained from electronic health records by phenotype groups [25, 26]. Although we did 
not observe differences in associations between UNGD activity and hospitalizations by 
subjects with HFrEF or HFpEF, we did find that severity of disease modified the 
associations we observed in Chapter 3, which supports the validity of our primary 
findings and suggests that more severe subjects had stronger associations between 
UNGD activity metrics and the likelihood of hospitalization, which is a biologically 
plausible finding. 
 
7.4 CAUSAL INFERENCES BASED ON CURRENT BODY OF EVIDENCE 
 
What is clear regarding the exposure scenario of UNGD is that, although we 
have not implicated a specific agent or pathway in the observed associations between 
UNGD activity and heart failure outcomes, there is enough consistent evidence now to 
conclude that UNGD is associated with negative impacts on population health [7, 9, 11, 
13, 15, 16, 27-30]. Epidemiologic studies have found associations between UNGD 
activity metrics and several health outcomes. The main advantage of using UNGD 
activity metrics to quantify potential exposures is that these can be assessed 
retrospectively; the main disadvantage of this approach is that studies of UNGD activity 
metrics and health outcomes are vulnerable to spatial and temporal confounding. In this 
study and in several studies of UNGD activity and health outcomes within the Geisinger 
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population, the extent to which unmeasured spatial and temporal confounding influenced 
results was assessed. In our Chapter 3 analysis, we conducted a negative exposure 
control analysis, assigning UNGD activity metrics from 2014 and 2015 to hospitalizations 
and matched control dates in 2008 and 2009, and we found null associations with 
hospitalization. The production metric had an elevated, but not statistically significant, 
association with hospitalization, but the production metric was also highly correlated over 
time. Other studies in this population have performed negative outcome control analyses 
(i.e., evaluating UNGD activity in relation to a biologically implausible outcome), and all 
have found null associations, for diarrheal illness [13], skin and soft tissue infections [11], 
and cold/flu, ear pain, or bad breath symptoms [15]. These sensitivity analyses were 
constructed to test if causal assumptions [31, 32], particularly temporality (negative 
exposure control) and biologic plausibility (negative exposure control analyses), were 
violated in assessment of UNGD activity and health outcomes, and they were not. The 
epidemiologic evidence of associations between UNGD activity and adverse health 
outcomes is also growing, and findings have been consistent across studies in Colorado 
[28], Texas [9, 33], and Pennsylvania [7, 11, 27], adding to the support for causal 
inference. 
 
7.5 POLICY IMPLICATIONS 
Due to environmental and health concerns of UNGD, some states with 
undeveloped shale reserves have banned their development. These bans have been in 
place since 2012 in Vermont, 2014 in New York state, and since 2017 in Maryland. 
Rationale for these bans cite risks of negative impacts to the environment and to health 
[34]. Interestingly, epidemiologic evidence of negative health impacts associated with 
UNGD has been generated by studies in Pennsylvania. However, Pennsylvania has not 
banned hydraulic fracturing and development of shale gas resources. This is likely 
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because there are substantial short-term economic benefits to UNGD, and Pennsylvania 
is the second-largest natural gas producer in the United States (after Texas) [35]. 
However, economic benefits must be viewed through a holistic lens that internalizes the 
costs for hospitalizations and overall disease burdens likely attributable to UNGD.  
Perhaps most concerning is that UNGD is a relatively recent phenomenon, and 
what we know about the population health impacts is limited to associations between 
UNGD activity and short-term health impacts (i.e., hospitalizations, birth outcomes, acute 
symptoms). Given the short-term impacts that have been observed, it is possible that 
long-term health impacts will be realized in the future. We also do not know the 
cumulative impact on population health, which is especially worrisome because UNGD 
production is projected to increase over the next 30 years [36]. 
The probable health effects associated with UNGD activity should be considered 
not just from an environmental standpoint (i.e., regarding policies that allow for shale gas 
development), but also from a health services and health policy standpoint, since it is 
clear that environmental factors contribute to the burden of cardiovascular disease [37-
40]. This has been evident well before this dissertation research linked UNGD activity to 
hospitalizations for heart failure and to increased levels of BNP. Health care systems, 
insurers, and clinicians should therefore be more vocal about environmental activities 
that contribute to the burden of cardiovascular disease, especially regarding 
hospitalizations for heart failure, which are costly [41]. This research has demonstrated 
that UNGD activity was associated with two different heart failure outcomes, one of 
which was a mechanistically important biomarker that itself predicts life expectancy, and 
these associations were modified by heart failure phenotypes in biologically plausible 
ways. These findings would seem to strengthen the causal evidence in our view. 
7.5 FINAL REMARKS 
 




Heart failure is a prevalent disease with a high mortality rate and public health 
burden. Patients living with heart failure are limited in terms of mobility and activity, and 
they are at risk for frequent hospitalization. We observed biologically plausible and 
robust associations with metrics of UNGD activity and hospitalization and with greater 
odds of an elevated BNP level, a biological indicator of diagnosis and prognosis, among 
heart failure patients. We also observed that heart failure severity modified the 
associations between UNGD activity and hospitalization for heart failure, suggesting that 
UNGD activity in Pennsylvania has contributed to the public health burden of heart 
failure in this population. 
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Appendix A. Heart failure algorithm 
Heart Failure 
With Differentiation between Reduced and Preserved Ejection Fraction 
Phenotype Algorithm Pseudo Code 
Mayo Clinic 
Version:  March 4, 2014 
 
Contacts: 
Suzette J. Bielinski (Bielinski.suzette@mayo.edu, 507-538-4914) 
Jyotishman Pathak (Pathak.jyotishman@mayo.edu, 507-538-8384) 
 
Updates: 
 March 4, 2014:   
o Updated pseudo code to include instructions for categorizing free test 
ejection fraction results. 
o Data Dictionary was altered to include optional reporting of free text EF 
results when numeric EF measurements are unavailable.   
o Height and weight units were changed to cm and kg in the data dictionary to 
correspond to eMERGE standard practice.   
 
Introduction: 
Heart failure (HF) is a complex syndrome characterized by the inability of the heart to 
supply sufficient blood flow to the body.  HF is diagnosed clinically and further 
dichotomized by left ventricular ejection fraction (i.e. reduced or preserved).  In 2010, 
HF affected 6.6 million Americans at a cost of 34.4 billion [279, 280].  However, the 
syndromic nature of HF presents challenges in identification of HF cases and controls 
from EHR data for research given that the diagnosis is clinical.  The Electronic Medical 
Records and Genomics (eMERGE) Network[281] consortium has demonstrated the 
applicability and portability of EHR derived phenotype algorithms using different types 
and modalities of clinical data for algorithm execution including billing and diagnoses 
codes, natural language processing (NLP), laboratory measurements, patient procedure 
encounters, and medication data.   
 
Development:   
Using a gold standard cohort of 706 manually abstracted HF cases defined according to 
Framingham Heart Failure Criteria[282] from the Heart Failure in the Community 
Cohort (R01 HL72435), structured EHR data were combined with analyses of the clinical 
note (unstructured) to identify the set of parameters needed to reidentify all the cases.  
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HF terms were identified using natural language processing (NLP) (i.e. dictionary 
lookup, negation/probable identification with ConText[283-285]) to identify positive hits 
of HF from the major and secondary problem lists of the clinical note.   
Algorithm and Covariates: 
This algorithm requires the following types of information: 
 Patient demographics 
 Encounter history 
 ICD diagnosis codes 
 Structured problem list or unstructured problem list  (processed using NLP) 
 Echocardiography measurements 
 Medications 
Some covariates are repeated measurements requiring associated dates and others are a 
single measure.   
 
Collection of Covariates 
Detailed definitions of all covariates are included in the data dictionary.  Note that some 
covariates are captured as repeated measures and include ejection fraction, myocardial 
infarction, BMI, and medication use.  Medication history includes the following list of 
drugs.  A complete list of drug names is included in the data dictionary.   
 Angiotensin Converting Enzyme Inhibitors (ACE) 
 Angiotensin II Receptor Blockers (ARB) 
 Beta Blockers (BB) 
 Calcium Channel Blockers (CCB) 
 
Implementation Notes:   
 Appendix A Mayo Clinic Implementation:  provides a description of how the 
algorithm was implementation a CDA formatted document structured EMR with 
structured echo data. 
 Appendix B Group Health Implementation:  provides a description of how the 
algorithm was implementation a non-CDA formatted EMR with unstructured 
echo data.   
 Appendix C Alternative Case Definition:  provides a description of an optional 
NLP only case definition.  Consider at institutions with highly transient patient 
populations.  
 
For Mayo and Group Health, the NLP component of the HF algorithm was implemented 
using MedTagger-IE, a pattern-based information extraction framework, which will be 
available open source under Open Health Natural Language Processing (OHNLP) 
consortium (Liu H, Bielinski SJ, Sohn S, Murphy S, Wagholikar KB, Jonnalagadda SR, 
Ravikumar KE, Wu ST, Kullo IJ, Chute CG.  An information extraction framework for 
cohort identification using electronic health records. AMIA Summits Transl Sci Proc.  
2013;2013:149-153.  PMCID: PMC3845757).   
 
 





Step 1:  Identifying Heart Failure Case Definition (both conditions must be met) 
 
Presence of ICD9-CM Diagnosis Codes for HF 




Positive mention of HF in the problem list through either NLP or structured problem list 
 Unstructured problem list (NLP) – at least one positive mention of a HF term in 
diagnosis-related sections. Positive mention is defined using ConText for 
assigning statuses to each NLP result – positive, probable, and negative 
(Chapman, Chu et al. 2007; Harkema, Dowling et al. 2009; Chapman, Lee et al. 
2011). Thus a positive hit for this requirement equates to a non-negative and non-
probable result.   Mapping of terms is insensitive to upper/lower case.   
 multi-organ failure or multiorgan failure 
 cardiac failure 
 CHF 
 heart failure 
 ventricular failure 
 Structured problem list – The descendant traversal of SNOMEDCT code 
84114007 (heart failure).  
 
Step 2:  Date of First Documented Heart Failure 
 
Data Processing for Problem List  
 Unstructured problem list (NLP) - assign the earliest note date among those 
notes with non-negative and non-probable HF terms detected in diagnosis-
related sections. 
 Structured problem list - assign the earliest date among the corresponding 
HF codes appearing in the problem list. 
 
Case Date Assignment  
 If the earliest problem list date and earliest ICD9 date fall within 1 year of 
each other assign the patient the earlier of the two dates.   
 If the earliest problem list date and earliest ICD9 date are assigned > 1 year 
apart then do as follows  
 Use the first two dates that occur within a rolling year between any 
combination of problem list dates and ICD9 dates.  If two dates found 
within a rolling year, use the earlier one.   
 Exclude cases where a date could not be assigned because they did 
not have any ICD9 nor problem list dates within a rolling year of each 
 
    
 
253 
other (Note:  If the same date appeared twice within the problem list 
dates, this was ignored).   
 
Step 3:  Classifying Heart Failure in terms of Ejection Fraction 
Classify the type of HF using the priority metric below. Some patients may have 
multiple echo measurements within a given time window – use the lowest EF recorded 
in the time window.   
 
Numeric EF Results - Priority Metric  
1. Lowest EF measured 0-182 days (approximately a 6 month period) after the HF 
date.  If missing, go to number 2. 
2. Lowest EF measured 0-182 days (approximately a 6 month period) prior to the 
HF date.  If missing go to number 3. 
3. Lowest EF measured 183-365 days after the HF date.  If missing go to number 4. 
4. Lowest EF measured 183-365 days prior to HF date.  If missing, set HF type to 
none (HF Type = 0).   
 
Coding Rules to Assign Heart Failure Type:   
 HF with reduced EF = ejection fraction < 50% (HF Type = 1) 
 HF with preserved EF = ejection fraction ≥ 50% (HF Type = 2) 
 No qualifying EF measurements within any of the time frames 
considered(HF Type = 0) 
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Free Text Ejection Fraction Results - Priority Metric  
(Optional – Use only if numeric EF measurements are not available)  
EF Result Categories Free Text Variations 
Preserved normal, supernormal, low-normal, moderate 
Reduced abnormal, reduced, low, severe, decreased 
1. EF Result 0-182 days after the HF date 
a. If EF preserved then HF Type = 2 
b. If EF reduced then HF Type = 1 
c. If missing, go to number 2. 
2. EF Result 0-182 days prior the HF date 
a. If EF preserved then HF Type = 2 
b. If EF reduced then HF Type = 1 
c. If missing, go to number 3. 
3. EF Result 183-365 days after the HF date 
a. If EF preserved then HF Type = 2 
b. If EF reduced then HF Type = 1 
c. If missing, go to number 4. 
4. EF Result 183-365 days prior the HF date 
a. If EF preserved then HF Type = 2 
b. If EF reduced then HF Type = 1 
c. If missing, set HF type to none (HF Type = 0). 
 
Step 4:  Identifying Heart Failure Controls (all conditions must be met):   
 




 Absence of positive heart failure terms in the EMR via NLP at any section or absence 




 EF ≥ 50% if measured or patient does not have echocardiographic measurements  
 
AND 
    Has ≥5 years of continuous enrollment/contact since age 35. 
Note: This is the same definition used in the Zoster algorithm.  “Continuous 
enrollment/contact” is implemented in an integrated group practice (HMO) 
setting as a period of continuous enrollment ignoring gaps of up to 90 days 
(which tend to reflect administrative data lags rather than actual interruptions 
in access to care).  In fee-for-service or non-integrated care settings, continuous 
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enrollment is implemented as consecutive 5-year periods with at least one 
encounter per period. At Mayo Clinic we used ICD9 and CPT dates to define 
encounters.  Encounters may be rolled up to the calendar date for purposes of 
establishing encounters during a period. 
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Heart Failure Algorithm Flow Chart
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Appendix A:  Mayo Clinic Implementation: 
 
NLP Specific Details:  The NLP component of the case definition was implemented by 
searching the Major and Secondary problem list section of the clinical note for at least 
one positive mention of one of the heart failure terms.  Positive mention is defined using 
ConText for assigning statuses to each NLP result – positive, probable, and negative 
[283-285]. Thus a positive hit for this requirement equates to a non-negative and non-
probable result.   Mapping of terms is insensitive to upper/lower case.  All NLP dates 
associated with probable heart failure as defined by ConText were excluded.  Among 
the remaining dates, we assigned the earliest NLP date among those associated with the 
major problem list and in the case where there was no note date associated with the 
major problem list; the earliest NLP date among those associated with the secondary 
problem list was used.     
 
Echocardiography Results:  Mayo Clinic echo data is stored in a structured database.  
Variable corresponding to ejection fraction (EF) measurements were identified.  It is 
common for several EF measurements to be taken during a single exam thus the average 
of all available EF measurements from a single exam was used.   
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Appendix B:  Group Health Implementation: 
 
 
NLP Specific Details:   The clinical notes are in non-CDA formatted documents, thus 
SecTag was used to detect Diagnosis and other sections (i.e. Chief Complaints or 
Impressions as the Secondary Problem List section).   
 
Echocardiography Results:  Group Health echo data is unstructured thus NLP was 
deployed to search the radiology reports for EF measurements.  The following list of 
*regular expressions for reporting EF was used.   
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 Calculated EF ##% 
 Calculated LVEF ##% 
 Calculated LV ejection fraction ##% 
 Calculated Left Ventricular ejection fraction ##% 
 Calculated Ejection Fraction ##% 
 Calculated Ejection Fraction ##%. Visual estimate ##%-##% 
 Estimated EF ##% 
 Estimated EF = ##% 
 Estimated EF ##%-##% 
 Estimated Ejection Fraction ##% 
 Estimated Ejection Fraction ##%-##% 
 Estimated Left Ventricular Ejection Fraction ##% 
 Estimated Left Ventricular Ejection Fraction ##%-##% 
 Estimated Left Ventricular Ejection Fraction range ##%-##% 
 EF ##% 
 Ejection Fraction ##% 
 LVEF ##% 
 LVEF ~  ## - ##%Left Ventricular Ejection Fraction ##% 
 Visual Estimate of LVEF ##% 
 Visual estimate of Left Ventricular Ejection Fraction ##% 
 Visual Estimate of EF ##% 
 Visual Estimate of Ejection Fraction ##% 
 
*The regular expression list above includes the variations identified at Mayo Clinic and 
Group Health and thus is not an exhaustive list of every possible combination of the use 
of characters such as “=” or “~”.  
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Appendix C:  Alternative Case Definition: 
 
As part of the algorithm development, an alternative case definition using NLP evidence 
in the absence of an ICD9 diagnosis HF code (i.e. 428.X) was tested.  This alternative case 
definition at Mayo Clinic required a positive NLP hit for HF terms 1 time in the Major 
problem list AND ≥ 5 times in Secondary problem list.  HF date assignment considered 
only the NLP dates and those patients without two dates in a rolling year are excluded.  
Despite good overall performance), the yield of cases was minimal (n = 13 at Mayo 
Clinic).  Abstraction of these cases revealed that all of the 13 patients identified by this 
definition were true cases and all were transient/referral patients.  Therefore the NLP 
only case definition was not included in the final algorithm.  However, for sites with a 
large referral or transient population, the alternative case definition should be 
considered as it may result in higher yield as compared to the stable population at Mayo 
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